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A major hurdle facing current hepatocyte transplantation practice is the marginal quality of 
isolated hepatocytes. Previous studies showed that mesenchymal stem cells (MSCs) could maintain 
morphology and improve liver-specific metabolism of co-cultured hepatocytes. The present work 
aimed to optimise the MSCs co-culture system by testing adipose tissue (AT), bone marrow, and 
umbilical cord-derived MSCs at predefined seeding ratios. Liver-specific metabolism and apoptosis 
assays were performed to investigate hepatotrophic and antiapoptotic effects of MSCs co-culture. 
Indirect co-culture was established to investigate the role of paracrine factors in hepatotrophic effect 
of MSCs co-culture. Hypoxia-preconditioned (HPc) MSCs were co-cultured with hepatocytes to 
investigate potentiative effect of HPc induction. Intracellular reactive oxygen species (ROS) activity 
quantitation and antagonisation experiments were performed to investigate whether HPc potentiated 
MSCs co-culture by an intracellular ROS-dependent mechanism. Tumour necrosis factor alpha 
(TNF-α), transforming growth factor beta1 (TGF-β1), extracellular collagen, and apoptosis-
associated caspase and BAX/BCL-2 signalling pathways were analysed to investigate the 
contribution of soluble factors, extracellular collagen, and gene signalling to the hepatotrophic 
effects of MSCs co-culture and potentiative effect of HPc induction. All the three types of MSCs 
exhibited a similar hepatotrophic effect, with a comparable effect even in low-density AT-MSCs co-
culture. Hepatotrophic and antiapoptotic effects of MSCs showed a cell contact dependent manner, 
and HPc potentiated MSCs co-culture by a cell-contact intracellular ROS-dependent mechanism. 
Decreased hepatocyte autocrine TNF-α, increased MSC autocrine TGF-β1, and enhanced MSCs 
deposition of extracellular collagen contributed to the hepatotrophic effects of MSCs co-culture and 
potentiative effect of HPc induction, with downregulated expression of proapoptotic CASP9, BAX, 
and BID and upregulated expression of antiapoptotic BCL-2. It is concluded that synergistic effects 
of cell contact, intracellular ROS-dependent soluble factors, extracellular matrix, and apoptosis-
associated signalling in MSCs co-culture contribute to hepatotrophic effect and HPc-induced 
potentiative effect. Co-transplantation with MSCs should improve therapeutic effects of HCT by 
enhancing survival and metabolism of co-transplanted hepatocytes.  
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CHAPTER 1 GENERAL INTRODCUTION 
1.1 Overview of Hepatocyte Transplantation 
Orthotopic liver transplantation (OLT) is the replacement of a patient’s diseased liver with a 
healthy donor’s liver allograft. OLT has been used as the curative modality in acute or chronic 
conditions, especially inborn liver-based metabolic diseases (Dhawan et al., 2006), that result in 
irreversible liver dysfunction. The operative technique of OLT has been well established over the last 
five decades, and patient survival following OLT has been continuously improved due to refinements 
in surgical care and better knowledge of transplantation immunology (Desai et al., 2008; Beinhardt 
et al., 2013). The primary limitation of OLT in current transplantation practice is that the number of 
donor livers available is unfortunately far less than that of recipients on the waiting list (Lo et al., 
2004). The operative procedure is also subject to some surgical morbidities and mortalities for both 
donors in case of living donors and recipients (Ammori et al., 2008). Additionally, patients receiving 
OLT normally require a life-long immunosuppressive regimen, which impairs patients’ quality of life 
physiologically and psychologically, and places a huge burden on public healthcare system 
(Schoening et al., 2013). 
Hepatocyte transplantation (HCT) has been emerging as a promising alternative treatment 
modality to OLT for patients who have no access to donor liver or cannot tolerate OLT (Dhawan et 
al., 2010). The concept of HCT comes from the fact that only a very small portion (approximately 5–
10%) of hepatocytes can perform a series of metabolic functions to sufficiently maintain a human 
subject (Kawashita et al., 2005) In this therapeutic technique, hepatocytes are isolated and purified 
from donor liver segments that are unused or rejected for OLT mostly due to underlying steatosis 
(Sagias et al., 2010), using an enzyme perfusion and digestion system. The quality of isolated 
hepatocytes is subsequently assessed in vitro with regards to cell yield, viability, and microbiological 
safety (Lehec et al., 2009). The preferred recipient site is the liver, into which hepatocytes are 
delivered through an intra-portal vein catheter (Figure 1.1; Hughes et al., 2012), whilst some 
alternative sites are also available, including the spleen, pancreas, peritoneal cavity, and subrenal 
capsule (Hughes et al., 2012). Preclinical studies of HCT on liver disease animal models showed a 
favourable outcome and led to the clinical use of HCT (Mazaris et al., 2005; Fisher and Strom, 
2006). 
HCT has been showing a series of clinical benefits in current practice (Table 1.1). The primary 
advantage of HCT is the minimal invasiveness as compared to OLT (Meyburg et al., 2009). For 
HCT, isolated hepatocytes are delivered into the liver or other ectopic sites through a catheter using 
an interventional radiology technique or Doppler ultrasonographic monitoring. This minimally 
invasive access, thus, minimizes the procedural risks, and offers patients, who cannot tolerate OLT 
due to poor liver function reserve or pre-existing comorbidities, an additional therapeutic 




Figure 1.1 Routes of cell administration for hepatocyte transplantation: through portal, inferior 
mesenteric and umbilical veins (Hughes et al., Transplantation, 2012). 
Table 1.1 Clinical benefits of HCT as compared to OLT 
HCT OLT 
 Minimally invasive  Excessively invasive 
 Technically simple  Technically complicated 
 Repeatable if required  Not repeatable in most cases 
 Low medical cost   Huge financial burden 
 One donor liver can be shared by multiple 
adult or pediatric recipients 
 One donor liver can be given to a single 
recipient only, or an adult and a paediatric 
recipient 
 Preservable and can be used in case of 
emergency 
 Not preservable, and usually not available 
for emergency use 
 Native liver preserved as backup  Native liver lost for ever 
 Not requiring immunosuppression for the 
treatment of acute liver failure 
 Normally requiring life-long 
immunosuppression 
of day surgery. HCT can be repeated within a relative short period if required (Sauer et al., 2012), 
and the medical costs of HCT is much lower than that of OLT. Hepatocytes isolated from a single 
donor can be transplanted into multiple recipients, especially in paediatric patients (Mitry et al., 
2004). Hepatocytes also can be cryopreserved in cell banks, allowing the immediate accessibility of 
hepatocytes for emergency transplantation (Fuller et al., 2013). Moreover, the native liver is 
preserved in place in patients undergoing HCT, which offers a possibility of gene therapy if this 
becomes clinically feasible in the future. Autologous hepatocytes could be isolated and genetically 
modified ex vivo and back-transplanted to correct metabolic liver disorders (Nguyen et al., 2009). 
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The use of cell autografts avoids the requirement for a life-long immunosuppressive regimen 
following HCT, although hepatocytes are presumed to be less immunogenic than the whole liver 
(Bumgardner  et al., 1998). All the aforementioned advantages have been encouraging a wider use of 
HCT worldwide (Hughes et al., 2012). 
1.1.1 HCT for inborn liver-based metabolic errors 
HCT was initially used for the treatment of inborn liver-based metabolic errors in urea cycle 
defects, severe unconjugated hyperbilirubinemia (Crigler–Najjar syndrome type 1), factor VII 
deficiency (haemophilia A), and familial hypercholesterolemia (Dhawan et al., 2006). The outcomes 
of HCT were most encouraging in patients with inborn liver-based metabolic disorders, as HCT 
could offer these patients a definite therapeutic benefit (Ribes-Koninckx et al., 2012). In these cases, 
only a relatively small number of transplanted hepatocytes may be required to compensate for the 
inherited deficiency of a single liver enzyme, especially in children. In our centre, over ten paediatric 
patients underwent HCT due to liver-based metabolic disorders, the majority of whom exhibited a 
clinical improvement without any procedural complications (Dhawan et al., 2005). 
1.1.2 HCT for acute liver failure 
The indication of HCT was further extended to acute liver failure (ALF) as an auxiliary 
treatment regimen. ALF occurs in severe liver injury with the loss of 80–90% of liver cells within a 
short period. The prognosis of ALF is highly variable, depending mainly on the underlying etiology. 
The mortality rate of ALF was up to 80%, but it has been decreasing due to improvements in 
multidisciplinary intensive care and the advent of emergency liver transplantation (Karvellas et al., 
2009). The clinical use of HCT in ALF aims to bridge patients to subsequent OLT, or extend the 
survival long enough for the native liver to recover and regenerate (Bilir et al., 2000). As the 
transplanted cells are expected to compensate for the entire liver, the number of hepatocytes required 
for ALF is normally higher than that for liver-based metabolic disorders, and the infusion of 
hepatocytes needs to be repeated. Moreover, toxic substances accumulating in ALF patients may be 
potentially cytotoxic to the transplanted hepatocytes (Mitry et al., 2009). A previous clinical study 
demonstrated that HCT improved liver function measures in ALF patients, but the overall survival 
outcome was highly variable (Baccarani et al., 2005). Up to now, it is not possible to draw any 
conclusion on the overall efficacy of HCT in ALF patients as no controlled trials have been 
performed. 
1.1.3 HCT for acute-on-chronic liver failure 
HCT has also been attempted in patients with decompensated liver cirrhosis, namely, acute-on-
chronic liver failure (ACLF), and aims to prolong a patient’s survival and improve one’s quality of 
life, with the hope that OLT will become available at a later time (Kobayashi et al., Transplant Proc, 
2000). HCT can improve liver function and overall survival in animal models with chemically-
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induced liver cirrhosis (Kobayashi et al., 2000). However, the treatment outcomes from published 
clinical studies were even more variable for cirrhotic patients (Pareja et al., 2010; Pareja et al., 2013), 
probably due to the presence of underlying liver fibrosis. The fibrotic lobules prevent the 
transplanted hepatocytes from passing through the sinusoidal barrier and engrafting into the liver 
(Gandillet et al., 2005). 
1.2 Limitations and Modifications of Hepatocyte Transplantation 
It is inevitable that HCT is subject to some technical limitations in terms of accessibility, 
effectiveness, and safety (Hughes et al., 2012). As compared to OLT, HCT even has a more limited 
supply of donor liver as hepatocytes used for cell replacement therapy are usually isolated from liver 
segments unused or rejected for OLT. Another drawback for HCT is the marginal quality of 
hepatocytes isolated from donor livers unsuitable for OLT mainly due to underlying liver steatosis 
(Sagias et al., 2010). Steatotic hepatocytes are vulnerable to enzymatic digestion, and processing of 
fatty liver tissue normally shows a low cell yield and a poor cell viability rate. Therefore, a larger 
number of hepatocytes of marginal quality are required to maintain normal liver function. Moreover, 
adult-derived hepatocytes cannot divide or survive long in vitro and have a weak repopulation 
potential, unless the cells are stimulated by appropriate growth factors (Amano et al., 2011). 
Hepatocytes become dedifferentiated following isolation, and dedifferentiated hepatocytes have an 
impaired metabolic function (Ambrosino et al., 2005). Hepatocyte transplants are likely to be 
eliminated by the innate and adaptive immune systems within 7 to 10 days (Han et al., 2009). In 
animal studies, up to 70% of hepatocytes are primarily cleared by Kupffer cells within the first 24 
hours of transplantation, irrespective of synergic or allogeneic grafting (Krohn et al., 2009). Post-
transplantation cell loss necessitates the transplantation of a larger number of hepatocytes, in a 
paradox with the shortage of hepatocyte supply. 
1.2.1 Alternative HCT cell graft sources 
New cell sources have been emerging in recent studies to overcome the primary technical 
hurdle of HCT, namely, the shortage of donor liver for hepatocyte isolation (Figure 1.2; Fitzpatrick, 
et al., 2009). Juvenile hepatocytes exhibit a potent repopulation potential as compared to adult cells, 
but juvenile liver donors are only occasionally available in clinical practice (Walldorf et al., 2004). 
Hepatocyte xeno-transplantation has been investigated in some animal models showing favorable 
survival and functional outcomes (Yamamoto et al., 2010); however, this technique is at a high risk 
of transmitting zoonotic diseases and raises some ethical concerns. Genetically modified or 
immortalized hepatocytes are reported to have a longer survival by increasing cell replication and 
reducing cell apoptosis (Tsuruga et al., 2008). The technique of gene manipulation is not clinically 
available yet and subject to a tumourigenic risk (Trejo-Becerril et al., 2012). Among the newly 
emerging cell sources, stem cells/progenitor cells are expected to exhibit the most promising 
outcomes as these cells have been widely investigated for cell replacement therapy. Transplantation 




Figure 1.2 Potential alternative sources of hepatocyte for transplantation: ES cells, iPS cells, 
haematopoietic stem cells, foetal progenitor cells, liver progenitor cells, and MSCs (Fitzpatrick et al., J 
Intern Med, 2009). 
reconstruction of a patient’s haematopoietic system. These stem cells can be driven to differentiate 
into metabolically functional hepatocyte-like cells under specific conditions in vitro (Takayama et al., 
2012) and promote liver repair and regeneration in vivo (Li et al., 2013). The sources of stem cells 
that have been investigated for HCT include embryonic stem (ES) cells, foetal liver cells, adult-
derived hepatic progenitor cells, induced pluripotent stem (iPS) cells, and more popular 
mesenchymal stem cells (MSCs). 
1.2.1.1 ES cells 
ES cells are stem cells derived from the inner cell mass of the blastocyst, an early-stage embryo, 
4–5 days post-fertilisation in humans. ES cells are believed to be pluripotent rather than totipoent in 
terms of cell potency (Denker, 2008), and offer a rich source for cell replacement therapy including 
HCT.  ES cells have been successfully induced to differentiate into hepatocytes by way of embryoid 
body formation in two- or three-dimensional culture in vitro (Touboul et al., 2010; Subramanian et 
al., 2013). Hepatocytic commitment requires the presence of retinoic acid, hepatocyte growth factor 
(HGF), and β-nerve growth factor (Kuai et al., 2003). These chemically-defined conditions are 
thought to recapitulate liver development in embryogenesis (Touboul et al., 2010). The 
immunophenotype and functional activities of ES cells-derived hepatocytes were reported to be 
identical to those of freshly isolated primary hepatocytes following orthotopic transplantation into 
the liver or ectopic transplantation into the spleen in animals (Rosen et al., 2003). However, the 
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harvest of ES cells raises ethical issues as it results in the destruction of fertilised human embryos 
(de Wert G et al., 2003). The risk of neoplastic transformation in undifferentiated ES cells may be 
underestimated in current studies, which report an inconsistent presence of teratomas (Choo et al., 
2008). Therefore, undifferentiated ES cells should be eliminated prior to transplantation, which is 
technically difficult in clinical practice. 
1.2.1.2 Foetal liver cells 
Foetal liver cells are believed to be enriched with hepatoblasts, the progenitor of hepatocytes 
and cholangiocytes (Masson et al., 2006). These progenitor cells decline rapidly in number after 
birth and become almost undetectable in adult livers (Schmelzer et al., 2006). Pilot studies on in 
utero transplantation of foetal livers showed a favourable outcome, with advantages in immune 
tolerance and optimal environment for donor cells in host foetuses (Rosen et al., 2003). The isolation 
and characterisation of hepatoblasts vary among studies, mainly using liver-specific markers, such as 
alpha-foetoprotein (AFP), and epithelial cell markers, such as cytokeratins (CK)-18 and -19 (Dan et 
al., 2006). A number of studies have documented the effectiveness and safety of foetal liver cells in 
repopulating normal or experimentally injured livers as these cells are destined to mature primarily 
into hepatocytes (Machimoto et al., 2007). The use of foetal liver cells is also limited by the shortage 
of donor foetuses and significant ethical concerns (Mychaliska et al., 1998). Moreover, in contrast to 
expectations, a rodent transplantation study showed that foetal liver cells had a poor liver 
engraftment and lower repopulation capacity than adult-derived hepatocytes (Haridass et al., 2009). 
1.2.1.3 Liver progenitor cells 
Liver is well known for its regeneration capacity in response to detrimental factors. As little as 
one quarter of liver remnant can generate a whole liver de novo in healthy subjects (Ju et al., 2012). 
Liver regeneration has been well described since the age of the original Prometheus myth. This 
phenomenon is predominately attributed to the quiescent G0-phase hepatocytes that re-enter the cell 
cycle, bypass the G0/G1 checkpoint, and finally complete mitosis (Satyanarayana et al., 2004). It is a 
compensatory growth rather than true regeneration of the liver. However, there is some evidence that 
damaged hepatocytes can be replaced by some liver progenitor cells in adults (Pintilie et al., 2010). 
These cells are termed as hepatic oval cells in rodents and hepatic progenitor cells in humans. These 
progenitor cells reside in the canals of Hering, which are located in the periportal region and account 
for a very small percentage (0.3–0.7%) of liver mass. Adult hepatic progenitor cells are reported to 
resemble foetal hepatoblasts in terms of phenotype and biopotency (Nava et al., 2005). The 
identification of oval cells in rats involves multiple immunomarkers, such as oval antigen 6, CK-7, 
CK-19, and albumin (Terrace et al., 2007). Oval cells can be effectively propagated in vitro and 
directed to the commitment of hepatocytes (Yasui et al., 1997). In animal models of liver injury, oval 
cells can expand to compensate for the increased turnover of damaged mature hepatocytes when 
normal G0-phase hepatocyte mitosis is blocked or in replicative senescence (Yang et al., 2004). 
However, oval cells are also less accessible for clinical use, and the large-scale expansion of oval 
cells in vitro proves to be technically challenging and subject to loss of potency. 
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1.2.1.4 iPS cells 
iPS cells are a type of artificially programmed pluripotent stem cells that are derived from 
somatic cells by inducing a forced expression of transcriptional factors. iPS cells were first produced 
from mouse-derived fibroblasts in 2006 (Takahashi et al., 2006) and from human fibroblasts in 2007 
(Takahashi et al., 2007). Theoretically, iPS cells can be reprogrammed to differentiate into any 
mature cells of ectodermal, mesodermal, and endodermal origin. This technique avoids ethically 
controversial use of embryos for harvest of ES cells, and also allows production of iPS cells from a 
patient’s own somatic cells, which require no conventional immunosuppression like that following 
allogeneic transplantation. Functional hepatocytes have been produced from mouse iPS cells that are 
sequentially subjected to inducing factors (Figure 1.3; Li et al., 2010). These iPS cell-derived 
hepatocytes share identical morphological and metabolic identities with those derived from ES cells. 
Human liver disease-specific iPS cells have been available, and these cells can express hepatocyte-
specific markers and exhibit a comparable metabolic functionality (Ghodsizadeh et al., 2010). The 
therapeutic potential of iPS cell-derived hepatocyte-like cells has been justified in a mouse model of 
carbon tetrachloride (CCl4)-induced liver injury (Asgari et al., 2011). Primary hepatocytes can also 
be reprogrammed to iPS cells (Liu et al., 2010). It is interesting that these iPS cells can be directed to 
differentiate into hepatic progenitor cells as well as mature hepatocytes. 
  
Figure 1.3 Hepatocyte-like cells differentiated from human iPS cells on albumin 
immunofluorescence microscopy (left panel) and periodic acid-Schiff staining (right panel) (Li et al., 
J Cell Physiol, 2010). 
The use of iPS cells for HCT is faced with some technical challenges with respect to 
effectiveness and safety. Firstly, the reprogramming of iPS cells shows a very low efficiency; less 
than 1% of somatic cells can be induced into iPS cells in vitro. These techniques usually require 
precise but clinically less feasible laboratory manipulation. Genomic insertion of transcription 
factors impairs the safety of iPS cells for cellular therapy as oncogenes are used as reprogramming 
factors to genomically disintegrate iPS cells and lead to tumourigenesis, a primary safety concern of 
using iPS cells. Therefore, it is critical to purify differentiated cells by eliminating undifferentiated 
iPS cells prior to clinical transplantation. Fluorescence activated cell sorting is the preferred method; 
however, hepatocytes are known to have a complex immunophenotypic profile, and cell sorting may 
miss a large number of less differentiated progenitor cells with a huge potential of hepatic 
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regeneration. It remains controversial whether iPS cells are functionally equivalent to ES cells (Bilic 
and Izpisua, 2012; Puri and Nagy, 2012). It has been reported that iPS cells have a lower efficiency 
than ES cells in terms of hepatocytic differentiation (Li et al., 2010; Jozefczuk et al., 2011). 
Moreover, iPS cell-derived hepatocytes were reported to express high-level AFP but low-level 
albumin, urea, and CYP450, as compared to primary human hepatocytes (Yu et al., 2012). This 
finding suggests that iPS cell-derived hepatocytes are not completely mature with respect to 
genotype and phenotype. 
1.2.1.5 Haematopoietic stem cells 
Haematopoietic stem cells (HSCs) are multipotent progenitor cells that differentiate into 
myeloid and lymphoid lineages. HSCs transplantation has been well established in the last four 
decades for treating haematological and autoimmune disorders. HSCs share a stem cell marker Thy-
1 with hepatic oval cells, the liver progenitor cells in rats (Petersen et al., 1998). An in vitro study 
confirmed that CD45+ HSCs could be driven into hepatogenesis in the presence of HGF (Zhao et al., 
2003). However, it remains controversial whether HSCs can differentiate into hepatocyte-like cells 
or become fused with hepatocytes in vivo. Sex-mismatched peripheral blood HSCs transplantation 
studies showed that hematopoietic donor chimera cells expressing hepatocyte markers were present 
in the liver as early as two weeks after transplantation, suggesting the possible differentiation of 
circulating HSCs into mature hepatocytes (Körbling et al., 2002; Mirzania et al., 2010). Camargo et 
al. (2004) reported that functional hepatocytes derived from HSCs were primarily mature 
myelomonocytic cells spontaneously fusing with host hepatocytes. It is a technical challenge to 
induce hepatocytic differentiation of HSCs which requires manipulation in culture over a long period 
(Miyazaki et al., 2004), although using a combination of multiple growth factors may facilitate 
HSCs differentiation into hepatocytes (Sellamuthu et al., 2011). The therapeutic role of HSCs in 
liver disease needs to be critically reassessed. Cantz et al. (2004) reported that genetically-labelled 
HSC transplants could not be detected in the liver or other visceral organs of mice undergoing 
extended major hepatectomy or chemical injury, although these cells were mobilised by granulocyte 
colony-stimulating factor.  
1.2.1.6 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are mesoderm-derived multipotent stem cells that normally 
differentiate into a variety of mesenchymal-type cells, including osteoblasts, chondrocytes, and 
adipocytes. Typical human MSCs manifest a fibroblast-like appearance in a vortex shape. No single 
cell surface marker can differentiate MSCs from other cell lines; however, undifferentiated MSCs 
are shown to highly express mesenchymal cell markers, such as CD73, CD105, and CD 106, rather 
than HSC markers, namely, CD34 and CD45. Novel markers have been emerging and are 
commercially available for the detection and isolation of MSCs from human or animals, such as 
bone morphogenetic protein (BMP), stem cell factor receptor, and Stro-1 (Ning et al., 2011). 
Substantial variability exists in the markers defining MSC population among reports, probably due 
to the intrinsic heterogeneity of MSCs. As with other multipotent stem cells, MSCs have a 
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substantial capacity for self-renewal while maintaining their multipotency. MSCs have been 
artificially driven to differentiate into various cell lines, including epidermal cells (Chun-mao et al., 
2007), epithelial cells (Liu et al., 2013; Wu et al., 2013), endothelial cells (Katikireddy et al., 2013), 
islet cells (Gopurappilly et al., 2013; Marappagounder et al., 2013; Zanini et al., 2011), myocytes 
(Khani et al., 2013), and specific-type neurons (Yang et al., 2013). For hepatic differentiation, three 
sources of MSCs have been investigated: BM (Soleimani and Nadri, 2009), umbilical cord (UC) 
blood (Laitinen and Laine, 2007) or matrix (Wang et al., 2004), and adipose tissue (AT; Neupane et 
al., Tissue Eng Part A, 2008). A number of studies have examined metabolic functions of MSCs-
derived hepatocytes and shown a promising therapeutic prospect (Kang et al., 2005; Sgodda et al., 
2007; Ishii et al., 2008; Aurich et al., 2009; Piryaei et al., 2011; Liang et al., 2012; Brückner et al., 
2013). 
BM-derived MSCs MSCs were first reported to be present in BM, namely, BM-derived MSCs, 
which co-exist with another stem cell line, namely, HSCs. When supplemented with fibroblast 
growth factor (FGF)-4 and HGF, a large percentage of rat BM-derived MSCs are induced to exhibit 
a hepatocyte-like morphology in vitro (Kang et al., 2005). These hepatocyte-like cells are capable of 
secreting albumin, synthesising urea, and storing glycogen. The differentiation media have been 
optimised in multiple in vitro studies, but remain FGF-4- and/or HGF-based. The supplementary 
growth factors and cytokines that favour directed hepatocytic differentiation consist of insulin-like 
growth factor 1 (IGF-1; Ayatollahi et al., 2011), β-nerve growth factor (Feng et al., 2011), 
hepatocyte nuclear factor (NF) 4α (Chen et al., 2010), and oncostatin M (Lee et al., 2004). Other 
gene products, such as AFP (Ishii et al., 2008), alkaline phosphatase (Kosmacheva et al., 2011), and 
CK-18 (Kang et al., 2005; Lange et al., 2005a; Lange et al., 2005b; Lange et al., 2006) have also 
been used to characterise MSCs-derived hepatocytes under specific inductive circumstances. 
UC-derived MSCs UC-derived MSCs are concomitantly present in cord blood and matrix 
(Wharton’s jelly). This type of MSCs has been successfully transdifferentiated into hepatocytes 
using a protocol similar to that for BM-derived MSCs, although with a lower efficiency (Hong et al., 
2005). Human UC-derived MSCs were reported to repopulate and engraft into the liver of a cirrhotic 
rat model (Jung et al., 2009). However, a xenotransplantation experiment showed that regenerated 
hepatocytes were actually chimera of donor MSCs and recipient hepatocytes; UC-derived MSCs 
expressed human albumin and Hep par 1, but murine CK-18, following transplantation into the liver 
of immunodeficient mice (Sharma et al., 2005). It was reported in the same rodent model that human 
UC-derived MSCs could differentiate into mature hepatocytes in the absence of cell fusion 
(Newsome et al., 2003). Interestingly, following transplantation into CCl4-induced fibrotic rat liver, 
UC-derived MSCs restored liver function by secreting bioactive cytokines and promoting hepatocyte 
regeneration rather than differentiating into hepatocytes in vivo (Tsai et al., 2009). This contradiction 
may be attributed to intrinsic variations in UC-derived MSCs. 
AT-derived MSCs A newly emerging source of MSCs, AT-derived MSCs are readily available 
and ethically less controversial (Figure 1.4; Banas et al., 2007). Zuk et al. (2001) isolated 




Figure 1.4 Primary human MSCs isolated from AT (left panel) and albumin-immunopositive 
hepatocyte-like cells (right panel) differentiated from AT-derived MSCs transplanted into CCl4 
liver injury model (Banas et al., Hepatology, 2007). 
specimens in 2001. The immunophenotypes of AT-derived MSCs are basically similar to those of 
other sources of MSCs, although almost all AT-derived MSCs express CD49f and CD54, which are 
rarely expressed in BM-derived MSCs (Zuk et al., 2001). The primary advantages of AT-derived 
MSCs are extensive source from body adipose, easy harvest by lipoaspiration, and possibility of 
autologous transplantation. Additionally, AT-derived MSCs are found to be more readily 
reprogrammed into iPS cells than BM-derived MSCs probably due to the variation in the 
microenvironment of origin (Mosna et al., 2010). AT-derived MSCs have been driven to differentiate 
into hepatocyte-like cells with hepatocyte metabolism and hepatocyte-specific transcripts (Ohnishi et 
al., 2011). Compared to undifferentiated cells, pre-differentiated AT-derived MSCs exhibit a more 
efficient engraftment into recipient liver (Okura et al., 2010). The therapeutic benefits of AT-derived 
MSCs have been demonstrated in animal models of inherited liver disease (Okura et al., 2011). 
Liver tissue-derived MSCs MSCs can also be isolated from foetal liver tissue (Heidari et al., 
2013), with a trilineage differentiation potential identical to BM- and AT-derived MSCs and a 
proliferative capacity similar to BM-derived MSCs. Human foetal liver-derived MSCs share 
identical MSCs immunophenotype and potential of multilineage differentiation, and inhibit mitogen-
induced lymphocyte proliferation in vitro (Götherström et al., 2003). Foetal liver-derived MSCs 
were reported to be immunosuppressive on T-lymphocytes (Giuliani et al., 2011). These liver-
derived MSCs have also been isolated from human adults, basically same to BM-derived MSCs in 
terms of genome-wide gene expression (Pan et al., 2011). These mesenchymal-like cells co-express 
hepatic and mesenchymal markers, including albumin, cytochrome P3A4, vimentin, and alpha-  
smooth muscle actin (Najimi et al., 2007). These cells are preferentially determined to differentiate 
into hepatocyte-like cells. Following intrahepatic transplantation, the offspring cells are 
immunopositive for albumin, pre-albumin, and AFP, and show a favourable engraftment potential. A 
subset of engrafted MSCs survived over the long term in vivo and maintained stem cell 
characteristics (Najimi et al., 2007). 
Limitations There are some unavoidable limitations in using MSCs as cellular source for HCT. 
Harvest of MSCs is not always possible from the patients themselves for autologous transplantation 
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or from the donors for allogeneic transplantation. Aspiration of bone marrow is invasive for the 
donors, and the amount of bone marrow collected from an individual donor is very limited even in a 
healthy subject. In a diseased or ageing subject, the propagation potential of BM-derived MSCs 
becomes compromised (Katsara et al., 2011). Use of UC-MSCs requires a long-time preservation, 
whilst the potency of long-preserved UC-MSCs remains questionable. Whereas AT is enriched with 
highly proliferative MSCs, it is essential to purify the heterogeneous AT-derived cell population 
(Zhang et al., 2011). As AT-derived MSCs emerged in the last decade, it was less known whether AT-
derived MSCs could differentiated into hepatocytes as effectively as BM-derived and UC-derived 
counterparts, although a previous study reported a similar hepatogenic differentiation potential and 
efficiency between AT- and BM-derived MSCs (Taléns-Visconti  et al., 2006). It usually takes two to 
three weeks to drive MSCs differentiation into functional hepatocytes in vitro; therefore, it makes 
MSCs-based HCT less suitable for emergency cases, such as for ALF patients. Functional patterns of 
differentiated hepatocytes are mainly characterised with albumin secretion, urea synthesis, and 
glycogen storage as well as CYP450 activity, often at low levels, whereas hepatocytes have complex 
biochemical activities. It remains  an open question whether MSCs can differentiate into other cell 
lineages other than hepatocytes even in directed conditions. These side products may be detrimental 
for transplanted hepatocyte or even the recipient. MSCs may be a double-edged sword in liver 
regeneration due to their pro-fibrogenic potential especially in chronic liver injury (di Bonzo et al., 
2008). As with other stem cells, the tumourigenic risk of MSCs cannot be underestimated for HCT. 
It has been recently discovered that MSCs can promote mammary tumourigenesis and progression 
by enhancing  vascularisation in the microenvironment (Ke et al., 2013) although the role of MSCs 
in breast cancer remains controversial (Usha et al., 2013). 
1.2.2 Preconditioning of hepatocytes 
1.2.2.1 Supportive factors of hepatocytes in vivo 
In a native liver, hepatocytes are supported by hepatocytes themselves, extracellular matrix 
(ECM), and nonparenchymal cells (NPCs). Hepatocyte-to-hepatocyte contact is believed to be 
crucial for the maintenance of hepatocyte polarity, morphology, and functionality. Calcium-
dependent, epithelial-type cadherin (E-cadherin), a major component of intercellular tight junction, 
maintains hepatocyte spheroid formation and prevents primary hepatocytes from apoptosis by a 
caspase-independent mechanism (Luebke-Wheeler et al., 2009). E-cadherin expression is modulated 
by HGF/MET signalling pathway in multiple carcinoma cell lines, including breast cancer, gastric 
cancer (Han et al., 2005), pancreatic cancer (Paciucci et al., 1998), bladder cancer, prostate cancer, 
ovarian cancer, melanoma, hypopharyngeal cancer, and nasopharyngeal cancer. 
In tissue engineering and regenerative medicine research, seed cells can be preconditioned and 
modified by supplementing extrinsic growth factors, trophic cytokines, and ECM, or by 
manipulating intrinsic gene expression prior to transplantation to improve survival, engraftment, and 
functionality of transplanted cells (Li et al., 2013). These modifications aim to improve proliferation, 
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survival, committed differentiation, and biological function of seed cells in vitro and in vivo. Stem 
cells are preferred target cells to be modified as these pluripotent cells are capable of self-renewal 
and maintaining the modified effect in the long-term (Navarro-Alvarez et al., 2009). Among these 
modifications, HGF modification is frequently used to potentiate the regenerative potential of MSCs 
for the purpose of cellular replacement therapy (Ido and Tsubouchi, 2009; Ishikawa et al., 2011; 
Ishikawa et al., 2012; Sun et al., Int J Mol Sci, 2013). Bian et al. (2009) reported that HGF-modified 
MSCs exhibited a greater viability as compared to non-modified counterparts and improved skin 
graft survival. Chen et al. (2011) successfully transplanted HGF-modified UC-derived MSCs to 
ameliorate ischaemia/reperfusion-induced acute kidney injury via anti-apoptotic and anti-
inflammatory mechanisms. Alternatively, HGF can also be loaded onto collagen- and fibrin-based 
biomaterials as artificial ECM to recruit MSCs and promote wound healing (van de Kamp et al., 
2013). The concept of modifying the niche rather than the seed cells is of great clinical significance 
as this technique avoids costly multi-step procedures of isolating, culturing, and transplanting 
allogeneic stem cells. 
1.2.2.2 Growth factors and cytokines 
Hepatocytes are a terminally differentiated, mature cell population with a series of highly 
complex biochemical and metabolic functions (Clayton et al., 2005). Therefore, it is less feasible and 
more challenging to modify hepatocytes in vitro. A large number of growth factors and cytokines, 
including HGF at the first place (Nakamura et al., 2011; Li et al., 2013; Xu et al., 2013), vascular 
endothelial growth factor (VEGF; Sturm et al., 2004; Bockhorn et al., 2007), epidermal growth 
factor (EGF; Natarajan et al., 2007; Liu et al., 2013), insulin-like growth factor (IGF; Sobrevals et 
al., 2010; Zaouali et al., 2010), transforming growth factor (TGF; Meindl-Beinker et al., 2012), 
basic fibroblast growth factor (bFGF; Ma et al., 1999), tumour necrosis factor (TNF; Sudo et al., 
2008; McMahan et al., 2013), and interleukin (IL) 6 (Sudo et al., 2008; Tiberio et al., 2008), are 
known to exhibit a marked in vitro and in vivo hepatocytotrophic effect with respect to hepatocyte 
survival and regeneration in animals and humans. Microprinted array is a more efficient technique 
for delivering growth factors to hepatocyte culture on the standard collagen monolayer. Printed 
arrays of HGF and BMP-7 exhibit antifibrotic and antiapoptotic effects on primary rate hepatocytes 
(Jones et al., 2010). However, it is not cost-effective to supplement hepatocytotrophic growth factors 
or cytokines directly into culture medium or surface of hepatocytes as trophic effect of soluble 
factors can only remain for several days. Additionally, hepatocytotrophic factor supplementation 
cannot be repeated once hepatocytes have been transplanted. 
1.2.2.3 Gene transfection 
Gene transfection seems to be a more effective technique for hepatocyte modification. This 
technique allows the delivery of target genes into donor hepatocytes to overexpress therapeutically 
efficacious proteins even though the donor cells may be of marginal quality. Additionally, autologous 
recipient hepatocytes can also be treated as donor cells using the gene fusion or transfection 
technique to compensate or even correct underlying liver diseases, especially for metabolism-based 
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disorders. Gene therapy has been experimentally attempted at the levels of both hepatic progenitor 
cells and mature hepatocytes. Li et al. (2012) simultaneously transplanted HGF-modified hepatic 
oval cells together with orthotopic liver transplantation, and this modification decreased liver 
allograft rejection and prolonged graft survival in rat recipients. Ajioka et al. (2001) co-transplanted 
hepatocytes transfected with multiple hepatotrophic genes, including HGF, TNF, and VEGF, to 
establish a heterotropic liver tissue mass with a favourable access to the blood circulation. More 
encouragingly, Wu et al. (2010) transfected human coagulation factor IX into mouse hepatocytes and 
transplanted gene-modified cells intrasplenically into factor IX knockout mice, a haemophilia B 
model. Genetically engineered hepatocytes exhibited a significantly higher plasma factor IX clotting 
activity than the wild-type counterpart with a similar engraftment and factor IX production efficiency. 
However, the use of genetically modified hepatocytes is inevitably subject to technical limitations 
and safety concerns although all the experimental studies had shown promising results. It usually 
takes a few days to complete conventional hepatocyte gene transfection in primary culture. Such a 
delay prior to HCT is not suitable for clinical use as patients, especially those suffering from ALF, 
are in urgent need of HCT. Kuge et al. (2006) successfully reduced infection time down to only one 
hour using an adenoviral vector-based transfection system but at the risk of uncontrollable viral 
infection in the recipient. Viral vector transduced hepatocytes also require the host immune tolerance 
to maintain long-term transgene expression (Puppi et al., 2004), although mature hepatocytes are 
known to be relatively less immunogenic in vivo (Bumgardner et al., 1998). Moreover, 
overexpression of hepatocyte proliferation-associated genes, such as HGF, may lead to 
carcinogenesis and dissemination in the recipient. Upregulated HGF signalling is historically known 
to drive the occurrence (Yamagamim et al., 2002), progression (Jia et al., 2013), metastasis (Chau et 
al.,2008), recurrence (Mizuguchi et al., 2009), metastasis (Ogunwobi et al., 2013) and 
chemoresistance (Lasagna et al., 2006; Yu et al., 2013) of hepatocellular carcinoma, as well as liver-
metastatic colorectal cancer (Min et al., 2012).  
1.2.2.4 ECM 
ECM supportive effect is known to be essential for maintaining physiological hepatocyte 
morphology, survival, proliferation, differentiation, and liver-specific function, especially in the 
sense of the long-term in vitro culture. ECM modulates hepatocyte survival (Giri et al., 2003; Pinkse 
et al., 2004; Ohashi et al., 2005; Zavan et al., 2005), viability, morphology (Zavan et al., 2005), 
phenotype (Page et al., 2007; Woodrow et al., 2009), proliferation (Hammond et al., 2011), 
differentiation (Sidhu et al., 2004; Kimata et al., 2006; Kimata et al., 2006), maturation (Brill et al., 
2002), metabolism (Depreter et al., 2000; Sellaro et al., 2010), repair (Ma et al., 1999), and 
regeneration (Hammond et al., 2011), via paracrine factors, such as  HGF (Schuppan et al., 1998), 
hepatocyte NF 4 (Oda et al., 1995), bFGF (Ma et al., 1999), and cell adhesion molecules, such as 
integrin (Pinkse et al., 2004). 
Multiple novel tissue engineering biomaterials, namely, scaffolds, have been investigated to 
construct the optimal residential environment for hepatocytes in vitro. The scaffolds are usually 
composed of naturally hyrdrogels, such as chitosan (Elçin et al., 1998) and alginate (Elkayam et al., 
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2006), or artificially synthesised high-molecule glycopolymers, such as polyethylene glycol 
(Underhill et al., 2007) and polycaprolactone/polylactic-co-glycolic acid (Shim et al., 2013). ECM 
modification is even more beneficial for maintaining long-term hepatocyte culture in vitro for the 
purpose of drug hepatotoxicity screening (De Bruyn et al., 2013), bioartificial liver support 
(Kinasiewicz et al., 2008; Giri et al., 2013), and anti-hepatitis virus agent experiments (Molina-
Jimenez et al., 2012). These scaffolds can be further surface-modified with major components of 
ECM, such as collagen (Hou et al., 2011), fibrin (Gwak et al., 2004), laminin (Tai et al., 2010), and 
fibronectin (Mehta et al., 2010). Common growth factors, such as HGF  (Seo et al., 2006; Nelson et 
al., 2011), VEGF (Kedem et al., 2005; Hou et al., 2011), EGF (Koyama et al., 2009), and IGF 
(Nelson et al., 2011) can also be incorporated into surface-modified bioscaffolds using the nano-
material technology to augment survival and functionality of seeded hepatocytes. The emergence of 
an injectable bioscaffold allows hepatocyte-scaffold transplants to be delivered using minimal 
invasive access techniques, especially for cirrhotic patients. Navarro-Alvarez et al. (2010) 
constructed a peptide nanofiber-based, three-dimensional scaffold, loaded with growth factors and 
seeded with immortalised human hepatocytes, into a tissue-engineered liver graft that could be 
injected intramuscularly. This engineered liver graft could maintain liver-specific gene expression 
and functionality in vitro to correct acute or chronic liver failure in animal models.  
1.2.2.5 Bioscaffold 
A potential additive benefit of using growth factor surfaced bioscaffold is that controlled release 
of growth factors may improve engraftment and survival of hepatocytes by promoting angiogenesis 
other than offering attachment alone in the long term (Hou et al., 2011). Kedem et al. (2005) 
delivered sustained VEGF to enhance scaffold vascularisation and improved hepatocyte transplant 
engraftment in the host liver lobe by 4.6 fold up to 12 days following transplantation. However, 
Smith et al. (2006) augmented hepatocyte transplant short- rather than long-term survival by 
delivering EGF and HGF using a VEGF-designated porous polymer scaffold. These findings suggest 
that hepatocyte transplant engraftment requires simultaneous delivery of multiple signals. Therefore, 
a designated scaffold that can deliver multiple growth factors is required for the clinical use of 
hepatocyte-scaffold transplantation. A decellularised whole liver is supposed to be the ideal scaffold 
to reconstruct a ‘‘new’’ liver de novo (Baptista et al., 2011; Soto-Gutierrez et al., 2011; Zhou et al., 
2011; Shirakigawa et al., 2012; Yagi et al., 2013). Wang et al. (2013) reported that decellularised 
liver matrix effectively supported proliferation and differentiation of murine foetal liver progenitors 
for up to 2 weeks. However, the question from preclinical, experimental studies is how to acquire an 
ideal decellularised liver scaffold: the use of a healthy donor liver has to sacrifice billions of healthy 
hepatocytes, while that of a diseased, such as fibrotic, donor liver carries a high risk of fibrogenesis 
and carcinogenesis due to the unfavourable environmental factors. Combination of human-derived 
hepatocytes and swine-derived acellular liver scaffold may be a good solution. Barakat et al. (2012) 
established an acellular porcine liver scaffold while preserving the native architecture and most ECM 
components, which facilitated maturation of human foetal hepatocytes co-cultured with foetal 
stellate cells into differentiated hepatocytes with respect to immunohistochemistry and biochemical 
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metabolism. Again using animal-derived material is subject to ethical challenge and risk of zoonosis. 
1.3 Heterotypic Interactions of Hepatocytes with Non-hepatocytic cells  
Once isolated and cultivated in vitro, hepatocytes are deprived of hepatocyte-to-hepatocyte 
contact, ECM support, and hepatocyte-to-non-hepatocytic cell communication. Hepatocyte mono-
culture, if not chemically defined, normally exhibits a marked reduction in phenotype and metabolic 
functionality, such as a rapid decrease in albumin secretion and AFP expression (Bhatia et al., 1998). 
This phenotypic and functional regression is attributable to the in vitro dedifferentiation of 
hepatocytes resulting from a complex, wide-ranging change in proteomics and depending on the 
culture condition (Rowe et al., 2010). Co-cultivation of multiple non-hepatocytic cells, mainly of 
mesenchymal origin, is reported to maximise hepatocyte function in vitro. NIH/3T3 cells, a 
fibroblast cell line obtained from mouse embryos, are most frequently used as feeder cells in 
hepatocyte co-culture (Lu et al., 2005). This cell line is known to regulate HGF and MET (HGF 
receptor) expression, and secrete adhesion molecules (Halverson et al., 1999). Co-culture with 
NIH/3T3 cells significantly improved albumin secretion (Nishikawa et al., 2008) and CYP450 
activity (Chia et al., 2005) in hepatocytes as compared to mono-cultured counterparts in the short 
term. TGF-β1 was thought to mediate this enhanced liver-specific metabolism as extracellular 
activation of latent TGF-β1 was upregulated in the co-culture and TGF-β1 neutralisation diminished 
this functional enhancement (Chia et al., 2005). Moreover, three-dimensional heterotypic co-culture 
with NIH/3T3 cells can even maintain a high level of albumin secretion and CYP450 activity for 
almost two weeks, while hepatocyte homo-culture becomes metabolically inactive after the first 
week (Lu et al., 2005). 
Co-culture with NIH/3T3 cells is, however, subject to a high variability in hepatocyte metabolic 
enhancement, with respect to albumin secretion, urea synthesis, and CYP450 activity (Gregory et al., 
2001). This variation can be attributed to oxygen uptake among co-culture systems varying in 
seeding density (Cho et al., 2007). Moreover, the use of fibroblasts may risk promoting liver fibrosis 
in vivo, if transplanted with hepatocytes, although it has not been reported in current literature 
regarding HCT. It was reported that TGF-β1-expressing NIH/3T3 cells, if injected intracavernously, 
could result in rat penile fibrosis (Ryu et al., 2005). Therefore, this technique is more suitable for 
developing bioartificial liver support systems (Washizu et al., 2001; Seo et al., 2006).  
1.3.1.1 Co-culture of hepatocytes with non-parenchymal liver cells 
A native liver is composed of parenchymal cells – hepatocytes accounting for 80%, and NPCs, 
also called stromal cells, for 6.5% of the total liver volume (Kmieć, 2001). Liver NPCs consist of 
Kupffer cells, sinusoidal endothelial cells, and stellate cells. These cells play a regulatory role in 
hepatocyte maintenance, proliferation, apoptosis, and maturation (Melgert et al., 2000; Zinchenko et 
al., 2006; Zhang et al., 2009). Activation of NPCs is critical for hepatocyte regeneration in the well-
established 70% partial hepatectomy model (Sakuda et al., 2002). This proliferative subpopulation 
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of hepatic cells also carries the potential for differentiation into metabolically functional hepatocyte-
like cells in the presence of HGF and EGF or FGF-4 (Duret et al., 2007). Co-culture with liver 
sinusoidal endothelial cells can help maturation of foetal and neonatal hepatocytes and maintain 
albumin secretion in rats (Morin et al., 1986). Co-culture with NPCs, including sinusoidal 
endothelial cells, hepatic stellate cells, and partially activated Kupffer cells, can even maintain and 
enhance liver-specific gene expressions of non-serum-fed hepatocytes in the presence of EGF, bFGF, 
and hepatocyte conditioned medium (CM; Ries et al., 2000). This in vitro co-culture system is 
expected to sustain the metabolic function of hepatocytes in the long term (Shulman and Nahmias, 
2013). In addition to serving as a nourishing feeder for mature hepatocytes, multiple NPCs are 
reported to direct hepatogenic differentiation of ES cells and MSCs. NPCs co-culture drives mouse 
ES cells to differentiate into hepatocyte-like cells, at a rate of approximately 70% with respect to 
albumin production, ammonia metabolism, and drug detoxification, in the presence of HGF and 
dexamethasone (Soto-Gutiérrez et al., 2007). Hepatic stellate cells are also reported to contribute to 
hepatocytic differentiation of BM-derived MSCs (Deng et al., 2008). Hepatic stellate cells activated 
by Kupffer cells exert a modulatory effect on MSCs hepatic differentiation mediated by IL-6 and -10 
(Parekkadan  et al., 2007). 
NPCs exert both positive and negative effects on neighbouring hepatocytes in paracrine, cell-
matrix, and cell-cell manners. Activated hepatic stellate cells help co-cultured hepatocytes to 
aggregate rapidly into well-defined viable spheroids (Thomas et al., 2005) and regulate hepatocyte 
proliferation in vitro (Uyama et al., 2002); these spheroids show a complex ECM support and 
hepatic ultrastructure (Thomas et al., 2005). Upregulated HGF expression underlies hepatocyte co-
culture with hepatic stellate cells, suggesting that the co-culture undergoes a post-traumatic 
regenerative process (Thomas et al., 2005). Aberrant activities of NPCs are also attributed to liver 
fibrosis through releasing inflammatory mediators and reactive oxygen species (ROS; Cohen and 
Nagy, 2011). NPCs are also involved in liver allograft rejection as this cell population is readily 
targeted by cytotoxic antibodies and complement (Astarcioglu et al., 1995). This beneficial 
technique has been investigated for bioartificial liver support systems (Nedredal et al., 2007; Soto-
Gutierrez et al., 2010) and in vitro drug toxicity screening systems (Kostadinova et al., 2013). The 
application of hepatocytes and NPCs co-culture in HCT is limited by a fact that highly variable 
NPCs themselves may inevitably result in a variation in co-culture hepatocytotrophic effect. NPCs 
supportive effect on co-cultured hepatocytes can be present for no more than 7 days in the absence of 
specific growth factors, such as HGF,  EGF (Kan et al., 2004), VEGF, and IL-6 (Kang et al., 2004). 
Moreover, it is a safety concern that NPCs are historically known to be the major source of collagen 
production if profibrotic factors are present. 
1.3.1.2 Co-culture of hepatocytes with MSCs 
Specific interactions between epithelial cells and mesenchymal-derived cells are known to be 
required for liver morphogenesis (Tanimizu et al., 2007). Heterotypic co-culture with MSCs shows a 
significantly higher metabolic activity, including albumin secretion, urea synthesis, and CYP450 
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activity, than homotypical mono-culture, especially after one week of cultivation (Gu et al., 2009a; 
Gu et al., 2009b; Gu et al., 2009c). BM-derived MSCs are stromal supporting scaffolds for HSC by 
secreting a series of crucial cytokines and growth factors (Pontikoglou et al., 2011). Hepatocyte 
multiplication can be stimulated by multiple soluble factors in vitro, including IL-6, bFGF, and TGF-
α. Similar to NPCs, BM-derived MSCs assist primary hepatocytes in the formation of spheroids in 
co-culture (Gu et al., 2009c). Scanning electron microscopy shows the establishment of cell-matrix 
and cell-cell contacts of hepatocytes on top of MSCs monolayer, with a well-organised three-
dimensional tomography (Figure 1.5; Gu et al., 2009c). 
Figure 1.5 Hepatocytes co-cultured with BM-derived MSCs (left panel) exhibit a three-
dimensional tomography on scanning electron microscopy (right panel) (Gu et al., J Cell Physiol, 
2008). 
Co-cultured hepatocytes exhibit a lower G0/G1-phase fraction, but a higher G2/S-phase fraction 
on cell cycle analysis, suggesting the activation of quiescent hepatocytes by BM-derived MSCs in 
co-culture (Gu et al., 2009b). The insertion of a semi-permeable porous membrane between MSCs 
culture and hepatocyte culture eliminates the cell-cell contact but still increases the hepatocyte 
function (Gu et al., 2009c). This suggests that trophic effect of MSCs co-culture results from soluble 
cytokines and growth factors released from MSCs. The potential trophic soluble factors consist of 
HGF, IL-6, and TNF-α as shown by the neutralisation experiments (Gu et al., 2009a). Moreover, 
ECM, such as fibronectin, laminin, and collagen type I/III/V, deposited by MSCs may also 
contribute to enhanced hepatocyte function in co-culture, as validated in ECM gene knockdown 
experiments (Gu et al., 2009c).  
In addition to maintenance and modification of hepatocytes, MSCs co-culture also facilitates 
hepatic differentiation of stem cells or progenitor cells in vitro (Lange et al., 2005b; Lange et al., 
2006; Qihao et al., 2007). Co-culture with foetal liver-derived MSCs helps hepatic maturation of 
hepatic progenitor cells and hepatic differentiation of ES cells (Ishii et al., 2010). ES cells-derived 
hepatocytes are immunocytologically characteristic of mature hepatocytes with a higher metabolic 
activity (Ishii et al., 2010). 
As MSCs are known to be potentially hepatogenic both in vitro and in vivo (Ji et al., 2012; 
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Wang et al., 2012) and immunomodulatory (Yi et al., 2012; Zhang et al., 2012), MSCs-based 
hepatocyte co-culture appears to be an effective modality for improving current HCT practice. It was 
reported that co-culture with BM-derived stromal cells augmented hepatocyte-specific metabolic 
functionality up to one month (Mohajerani et al., 2010). Foetal liver-derived MSCs improve 
engraftment of transplanted hepatocytes (Joshi et al., 2012); hepatocytes detached from BM stromal 
cell co-cultures also have a better engraftment following the transplantation into the spleen as 
compared to those detached from fibroblast cell co-cultures (Mohajerani et al., 2010). MSCs co-
culture can improve the marginal quality of hepatocytes isolated in current practice and minimise the 
number of hepatocyte transplants required for a favourable therapeutic outcome, without requiring 
delicate, costly laboratory manipulation. This technique has been successfully used to modify 
bioartificial liver system for treating ALF (Yagi et al., 2009; Yang et al., 2013), and it is also 
potentially promising to improve HCT in the treatment of ALF and liver-based metabolic disorders. 
1.3.1.3 Possible Contribution of MSCs to HCT 
Co-transplantation of MSCs with islet cells has been reported for the treatment of experimental 
diabetes mellitus (Sakata et al., 2011). MSCs co-transplants can improve islet graft survival and 
function in vitro, as well as engraftment revascularisation in vivo (Ito et al., 2010; Rackham et al., 
2011; Kerby et al., 2013). The incorporation of MSCs is also expected to bring some additional 
benefits to current HCT practice. This technique is likely to help overcome the major hurdles of 
current HCT practice, namely, shortage of hepatocytes available for transplantation and marginal 
quality of isolated hepatocytes. 
Firstly, MSCs can modify hepatocyte morphology and functionality (Gu et al., 2009a; Gu et al., 
2009b; Gu et al., 2009c). It is possible that MSCs co-culture decreases the number of hepatocytes 
required for a given recipient and gives a similar or even better therapeutic outcome. It has been 
proposed that co-transplantation of iPS cells-derived hepatocytes and MSCs should be an effective 
treatment alternative to orthotopic liver transplantation for treating end-stage liver disease (Liu et al., 
2009). 
Secondly, co-transplanted MSCs can transdifferentiate into hepatocytes following the 
engraftment. BM-derived MSCs co-cultured with foetal liver cells exhibit a high-efficiency 
hepatocytic differentiation, similar to cells sequentially subjected to stem cell factor, HGF, EGF, and 
FGF-4 (Lange et al., 2006). Human UC-derived MSCs differentiated into hepatocyte-like cells, 
without accelerating capillarisation and venularisation of liver sinusoids, in CCl4-induced liver 
fibrosis model (Ren et al., 2010). Shi and his colleagues (2009) used co-encapsulated hepatocytes 
and MSCs transplantation to successfully increase liver function and survival rate of an ALF rat 
model, and observed in vivo transdifferentiation of MSCs into hepatocyte-like cells with respect to 
albumin expression.  
Thirdly, MSCs are known to be immunomodulatory (Lin et al., 2011), and MSCs-derived 
hepatocytes are reported to less immunogenic (Al Jumah and Abumaree, 2012; Chen et al., 2013; 
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Hou et al., 2013). The immunomodulatory effect of MSCs has been applied in the therapeutics of 
some autoimmune and inflammatory diseases (Fiorina et al., 2009; Ohshima et al., 2012), including 
graft-versus-host disease (Chen et al., 2012; Gregoire-Gauthier et al., 2012; Xia et al., 2012) and 
liver transplantation (Wan et al., 2008; Popp et al., 2009; Zhang et al., 2012), although it remains 
controversial (Zhang et al., 2009). Hepatocyte-like cells, which derive from UC-derived MSCs in 
the presence of HGF and bFGF, neither express major histocompatibility complex II antigen nor 
induce lymphocyte proliferation in vitro (Zhao et al., 2009). The immunomodulatory property of 
MSCs co-transplanted with hepatocytes may result in less requirement of immunosuppressive agents, 
as compared to that in conventional HCT, if used for the treatment of inborn liver-based metabolic 
disorders (Burlina, 2004). 
Lastly, trophic factors of MSCs are also expected to be protective for hepatocytes subjected to a 
detrimental environment, such as in ACLF (Shi et al., 2011), chemically-induced liver injury (Jung 
et al., 2013; Salomone et al., 2013; Shao et al., 2013; Xagorari et al., 2013), and liver ischaemia-
reperfusion injury (Pan et al., 2012; Jin et al., 2013). Culture with ACLF serum, which contained 
high-level TNF-α but minimal EGF and VEGF, caused a high cell detachment rate, low viability, and 
reduced liver-specific function in human hepatocyte mono-culture; however, MSCs protected co-
cultured hepatocytes from ACLF-induced cytotoxicity (Shi et al., 2011). MSCs-conditioned medium 
can attenuate CCl4-induced early apoptosis of hepatocytes by IL-6 and fibroblast-like protein 1 
signalling (Xagorari et al., 2013). Moreover, MSCs transplantation can ameliorate ROS-induced rat 
liver ischaemia-reperfusion injury by downregulating mitogen-activated protein kinase/extracellular-
signal-regulated kinase (MAPK/ERK) signalling pathway (Pan et al., 2012). However, a randomised, 
controlled study demonstrated that autologous bone marrow MSC transplantation had no therapeutic 
benefit for patients with decompensated cirrhosis with respect to absolute changes in Child-Pugh 
classification, the Model for End-Stage Liver Disease (MELD) score, serum albumin, international 
normalised ratio, serum transaminases, and liver volume (Mohamadnejad et al., 2013). Moreover, 
the profibrotic effect of co-transplanted MSCs cannot be ignored as it remains controversial whether 
MSCs are antifibrotic or profibrotic following intraportal transplantation (Rabani et al., 2010; di 
Bonzo et al., 2008). 
In summary, HCT is an effective treatment alternative to OLT for ALF and inborn liver-based 
metabolic disorders. However, current HCT practice is subject to two major hurdles, namely, 
shortage of donor livers and marginal quality of isolated hepatocytes. Alternative cellular sources, 
including ES cells, foetal liver cells, adult-derived hepatic progenitor cells, iPS cells, and MSCs, 
have been investigated for the preclinical use in HCT. Differentiation of stem/progenitor cells into 
hepatocyte-like cells requires delicate, costly laboratory manipulation and risks carcinogenesis of 
undifferentiated cells. Heterotypic interaction with NPCs plays a regulatory role in hepatocyte 
maintenance, proliferation, apoptosis, and maturation. MSCs co-culture is expected to have multiple 
contributions to current HCT practice. MSCs can modify hepatocyte phenotype and metabolism; 
hepatocyte-committed transdifferentiation of MSCs may reduce liver mass required for HCT; 
immunomodulatory MSCs co-transplants may result in less requirement of immunosuppressive 
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agents following HCT; and MSCs can also protect co-transplanted hepatocytes from cytotoxicity 
induced by inflammatory factors or other unfavourable chemical factors, especially in patients with 
ALF and ACLF. Modification of MSCs and hepatocytes co-culture system is expected to further 
augment hepatocyte functionality for the clinical use of HCT. Molecular mechanisms underlying 
MSCs and hepatocytes co-culture are also yet to be delineated for improving current HCT practice. 
1.4 Objectives and Hypotheses of PhD Project 
MSCs co-culture shows favourable hepatotrophic effect with respect to morphology, cell 
survival, and liver-specific metabolic functions, as documented in current literature. The present 
work aimed to modify conventional hepatocyte co-culture with MSCs and further potentiate in vitro 
hepatotrophic effect of MSCs co-culture. Furthermore, it is a primary objective of this project to 
investigate the molecular mechanisms underlying hepatotrophic and potentiated effects of MSCs co-
culture. 
1.4.1 Optimisation of human hepatocyte and mesenchymal stem cell co-culture 
system in vitro 
Multiple sources of MSCs are available for co-culture with hepatocytes. The first objective of 
this project is to determine which source of MSCs, namely, AT-, BM-, and UC-MSCs, is the optimal 
MSCs for hepatocyte co-culture in vitro.  Additionally, it is investigated in this part of the project 
whether MSCs co-culture can suppress spontaneous and chemically-induced apoptosis of 
hepatocytes in vitro. 
1.4.2 Hypoxic preconditioning potentiates MSCs co-culture hepatotrophic effect 
As MSCs normally reside in a low-oxygen niche, hypoxic precondition (HPc) is frequently 
used to optimise MSCs for cellular transplantation use. The second objective of this project is to 
verify the hypothesis that HPc can potentiate hepatotrophic effect of MSCs. It is also investigated in 
this part of the project whether HPc-induced potentiative effect depends on intra-MSCs activity of 
ROS, a pivotal signalling factor in cellular response to oxidative stress. 
1.4.3 Mechanisms underlying hepatotrophic and HPc-induced potentiative effects 
of MSCs co-culture 
Hepatotrophic effect of MSCs is believed to result from paracrine factors and ECM deposition 
of MSCs, as well as hepatocyte-to-MSC interaction. The third objective of this project is to 
investigate whether secretion of TGF-β1 from MSCs and TNF-α from hepatocytes, deposition of 
extracellular collagen from MSCs, and hepatocyte apoptosis and survival associated signalling 
pathways are implicated in MSCs co-culture hepatotrophic effect. It is also investigated in this part 
of the project whether modulatory effects of HPc on soluble factors, ECM, and gene signalling 
pathways of hepatocytes co-cultured with MSCs depend on intra-MSCs ROS activity. 
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CHAPTER 2 GENERAL MATERIALS AND METHODS 
2.1 Sources of MSCs 
Primary human AT-MSCs, which were originally extracted from a single human donor’s 
lipoaspirate tissue through mechanical and enzymatic digestion, were purchased from Invitrogen Ltd, 
Paisley, UK. Primary cultures had been expanded for one passage before cryopreservation. The cell 
line was immunophenotyped by the supplier as positive for CD29, CD44, CD73, CD90, CD105, and 
CD166 (>99%), and negative for CD14, CD31, CD45, and Lin1 (< 1%) on flow cytometry. 
Primary human BM-MSCs, which were originally extracted from a single human donor’s bone 
marrow through enzymatic digestion, were purchased from Lonza Group, Ltd., Basel, Switzerland. 
Primary cultures had been expanded for one passage before cryopreservation. The cell line was 
immunophenotyped by the supplier as positive for CD105, CD166, CD29, and CD44 (>99%), and 
negative for CD14, CD34, and CD45 (<1%) on flow cytometry. 
Primary human UC-MSCs were originally extracted by Dr Yue Wu (Institute of Liver Studies, 
King’s College Hospital NHS Foundation Trust, London, UK) from a single human donor’s 
umbilical cord matrix (Wharton’s jelly) through digestion in 1-mg/mL collagenase type I (Sigma-
Aldrich, St Louis, MO, USA) as previously reported (Campard et al., Gastroenterology, 2008). The 
cell line was immunophenotyped as positive for CD13, CD73, CD105, CD90, and CD44 (>99%), 
but negative for CD31, CD34 and HLR-DR (<1%) on flow cytometry.  
The differential potentials of MSCs towards adipocytes, osteoblasts, and chondrocytes, were 
characterised in vitro by the suppliers using specialised differentiation media. 
2.2 Subculture of MSCs 
The MSC expansion culture media consisted of phenol red-free, low-glucose Dulbecco's 
modified Eagle medium (DMEM; Invitrogen, Paisley, UK), 10% foetal calf serum (FCS; Invitrogen, 
Paisley, UK), 2-mM L-glutamine (Sigma-Aldrich, St Louis, MO, USA), and 100-U/mL penicillin 
plus 100-μg/mL streptomycin (Invitrogen, Paisley, UK). Cryopreserved cells (approximately 1 
million cells per mL and per vial) were quickly swirled and thawed in a 37°C water bath (Grant 
Instruments, Ltd, Cambridge, UK) for 1 min. The cell suspension was immediately transferred into a 
50-mL sterile Falcon® polypropylene conical tube (BD Biosciences, Durham, NC, USA) containing 
10-mL pre-warmed culture media and centrifuged at 1,500 rpm (Heraeus Instruments, Newport 
Pagnell, UK) for 5 min. The cell pellet was subsequently resuspended in pre-warmed culture media, 
and plated onto a 75-cm2 tissue culture flask (NUNC A/S, Roskilde, Denmark) at a density of 5,000 
cells per cm2 and at a volume of 10 mL per T75 flask, in a humidified incubator (Heraeus 
Instruments, Newport Pagnell, UK), in an atmosphere of 95% O2 and 5% CO2 and at 37°C. The 
culture medium was refreshed every 3–4 d.  
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On day 7 of culture (approximately at 80% confluency), cell cultures were rinsed with 
phosphate buffered saline (PBS; Invitrogen, Paisley, UK) and detached by adding 2.5-mL 0.25% 
trypsin/PBS (Invitrogen, Paisley, UK) at 37°C for 5–10 min, and the cell dissociation was stopped 
by adding 10% FCS/DMEM. The cell suspension was replated and subcultured at a ratio of 1:5 
using the same cell culture protocol. The cells were cryopreserved in the culture medium 
supplemented with 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA) as 
multiple aliquots (1 mL per vial) using a freezing container (Thermo Fisher Scientific, Ltd, 
Loughborough, UK) in a −80°C freezer (New Brunswick Scientific, Cambridge, UK), and the stocks 
were stored in a −140°C freezer (New Brunswick Scientific, Cambridge, UK). The 6th–8th passages 
(P6–8) of MSCs were used for experiments. The total number and viability of MSCs for each 
passage were determined using a Neubauer improved bright-line hematocytometer (Weber Scientific 
International, Ltd, Hamilton, NJ, USA) and the trypan blue (0.2%; Sigma-Aldrich, St Louis, MO, 
USA) exclusion technique with a standard inverted light microscope (Leica Microsystems, Milton 
Keynes, UK) equipped with a digital single lens reflex (SLR) camera (Cannon, Tokyo, Japan). 
2.3 Primary Harvest of Human Hepatocytes 
The use of human liver tissues was approved by the Research Ethics Committee at King’s 
College Hospital NHS Foundation Trust, London, UK, and conformed the guidelines set out in 
accordance with the Human Tissues Act of 2004. All donors or their legal representatives volunteered 
to give informed consent in writing for research use. 
Primary human hepatocytes were isolated from donor liver tissues unused or rejected for 
orthotopic liver transplantation using a standard collagenase perfusion technique (Figure 2.1), as 
previously reported by Mitry (2009). Briefly, the liver tissue was maintained in ice-cold Eagle’s 
minimum essential media (EMEM; Lonza Group, Ltd., Basel, Switzerland) during pre-processing. 
One or two major patent vessels were cannulated with 16−22G intravenous catheters (Smiths 
Medical International Ltd., Rossendale, UK) and secured in place using nylon sutures (Tyco 
Healthcare Group LP, Norwalk, CT, USA). Other minor vascular and biliary vessels on the cut 
surface were ligated using silk sutures (Ethicon, Inc., Somerville, NJ, USA). The liver tissue was 
perfused using a MasterFlex® L/S® digital standard drive (Cole-Parmer Instrument Company, 
London, UK) at a flow rate of 60–80 mL/min. The perfusates contained calcium-free Hank’s 
balanced salt solution (HBSS; Lonza Group, Ltd., Basel, Switzerland), 1-M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES; Sigma-Aldrich, St Louis, MO, USA), and 0.5-mM ethylene 
glycol tetraacetic acid (EGTA; Sigma-Aldrich, St Louis, MO, USA), a calcium chelant to disrupt the 
desmosomal junctions of neighboring hepatocytes. The first perfusion solution was replaced by a 
second perfusion solution consisting of plain calcium-free HBSS. The post-perfused liver specimens 
were digested using a third EMEM-based perfusion solution containing 0.05% Clostridium 
histolyticum derived collagenase P (Roche Diagnostics Ltd., West Sussex, UK). The volume of 
collagenase solution used for the digestion varied with the weight of liver tissue, roughly 250 mL for 
every 200-gram liver tissue. The collagenase P solution was re-circulated for no more than three  
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Figure 2.1 Collagenase perfusion system (left panel) and cannulated donor liver segments 
(right panel) being digested for hepatocyte isolation. 
cycles until the specimen was appropriately digested. The buffer solutions were maintained at 37°C 
using a heating stirrer (GallenKamp Thermo, Cheshire, UK) and oxygenated with 95% O2 and 5% 
CO2 medical gas mixture (BOC Gases Medical, Surrey, UK), at a flow rate of 8 L/min, throughout 
the perfusion. 
The digested liver tissue was maintained in iced-cold EMEM and scissor-minced following the 
removal of the cannulae and sutures. The released cell suspension was filtered through 2-ply cotton 
swabs (Shermond, Brighton, UK) and subsequently through a 200−μm nylon cell strainer (BD 
Biosciences, Durham, NC, USA). Hepatocytes were washed in ice-cold EMEM containing 10% FCS 
using a low-speed centrifuge (Heraeus Instruments, Newport Pagnell, UK) at 50×g and 4°C for 5 
min, and the centrifugation was triplicated at 4°C. The total number and viability of fresh 
hepatocytes were determined using a haematocytometer and the trypan blue exclusion technique 
with a standard upright light microscope (Leitz, Wetzlar, Germany). Red blood cells in hepatocyte 
pellet were lysed, if required, using sterile water for injection (Fannin Ltd., Dublin, Ireland) for 1 
min at room temperature followed by centrifugation. The batch of hepatocytes with a viability of 
over 60% on trypan blue exclusion was used for experiments. 
2.4 Hepatocyte Mono-culture and Co-culture  
Culture vessels were pre-coated using aseptic techniques with 0.1-mg/mL rat tail collagen type 
I (Sigma-Aldrich, St Louis, MO, USA) in 1% acetic acid (Sigma-Aldrich, St Louis, MO, USA) at 
37°C for 2 h, followed by PBS rinse at 4°C for 24 h.  
Fresh hepatocytes were plated onto collagen-coated, flat-bottom microplates at a density of 
50,000 viable cells per cm2 (hepatocyte mono-culture). The culture media consisted of phenol red-
free William’s E medium (WEM; Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% FCS, 
10-mM HEPES, 2-mM L-glutamine, 0.1-μM dexamethasone (Sigma-Aldrich, St Louis, MO, USA), 
0.1-μM human recombinant insulin (Sigma-Aldrich, St Louis, MO, USA), and 100-U/mL penicillin 
plus 100-μg/mL streptomycin. The cell morphology of hepatocyte mono-culture was examined using 
a standard inverted light microscope equipped with a digital SLR camera. 
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P6–8 MSCs were resuspended in hepatocyte culture medium and incubated on collagen-coated 
microplates at the predefined densities for 24 h. Fresh hepatocytes were seeded on top of MSCs 
monolayer at a constant density of 50,000 viable cells per cm2 (hepatocyte co-culture). Hepatocyte 
mono-culture was used as control (control group), and MSCs mono-culture was used as blank 
control. The culture medium was refreshed on days 1, 3, 5, and 7, respectively. The cell morphology 
was examined using a standard inverted light microscope equipped with a digital SLR camera. 
Culture supernatants were collected into sterile 1.5-mL centrifuge tubes (Eppendorf, Hamburg, 
Germany) and cryopreserved at −80°C for further experiments. Cell cultures were rinsed with one 
wash of PBS at room temperature for further experiments. 
2.5 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Colorimetric 
Assay  
Hepatocyte mono-culture and co-culture were performed on collagen-coated, flat-bottom 96-
well Falcon® microplates (BD Biosciences, Durham, NC, USA) as described above for measuring 
mitochondrial succinic dehydrogenase activity representing hepatocyte overall viability. The cell 
cultures were rinsed with PBS, and incubated with plain WEM containing 0.5-mg/mL 3-(4,5-
dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, St Louis, MO, USA) 
solution, 200 μL per well, at 37°C for 4 h. The MTT solution was removed and replaced by 100% 
DMSO, 200 μL per well, to dissolve formazan produced by viable cells, and the microplate was 
vigorously shaken using a microplate shaker (Heidolph Instruments, Essex, UK) at 1,500 rpm for 1-
2 min. The optical density (OD) was measured at 550 nm using an MRX microplate reader equipped 
with Revelation version 4.06 incorporating Core DLL version 4.06 and Statistics DLL version 4.06 
(Dynex Technologies, Guernsey, UK). The reading of background MSCs mono-culture (blank 
control) was subtracted from that of hepatocyte co-culture to obtain the colorimetric OD of 
hepatocytes per se in co-culture (Mohajerani et al., Cell Medicine, Part B of Cell Transplantation, 
2010). The experiments were performed in quadruplicate and repeated in triplicate independently. 
2.6 Sulforhodamine B Colorimetric Assay 
Hepatocyte mono-culture and co-culture were performed on collagen-coated, flat-bottom 96-
well Falcon® microplates as described above for measuring sulphorhodamine B (SRB) binding to 
basic amino acid residues on cell membrane surfaces representing overall cell attachment. The cell 
cultures were rinsed with PBS, and fixed in 50% ice-cold trichloroacetic acid (Sigma-Aldrich, St 
Louis, MO, USA), 50 μL per well, layering on top of plain WEM, 200 μL per well, at 4°C for 1 h. 
The microplates were rinsed with tap water, and the fixed cells were stained with 0.4% SRB solution 
(Sigma-Aldrich, St Louis, MO, USA) in 1% acetic acid (Sigma-Aldrich, St Louis, MO, USA) at 
room temperature for 10 min. The wells were rinsed with 1% acetic acid and air-dried at room 
temperature. The SRB dye was solubilised in 20-mM unbuffered 2-amino-2-hydroxymethyl-
propane-1,3-diol (Tris-base) buffer  (Sigma-Aldrich, St Louis, MO, USA), 200 μL per well, and 
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shaken on a microplate shaker (Heidolph Instruments, Essex, UK) at 1,500 rpm for 15 min. The OD 
was measured at 564 nm using the microplate reader. The reading of background MSCs mono-
culture (blank control) was subtracted from that of hepatocyte co-culture to obtain the colorimetric 
OD of hepatocytes per se in co-culture (Mohajerani et al., Cell Medicine, Part B of Cell 
Transplantation, 2010). The experiments were performed in quadruplicate and repeated in triplicate 
independently. 
2.7 Albumin Enzyme-linked Immunoabsorbent Assay 
Hepatocyte mono-culture and co-culture were performed on collagen-coated, flat-bottom 24-
well Falcon® microplates (BD Biosciences, Durham, NC, USA) as described above, and cell culture 
supernatants were collected for measuring free albumin secretion representing protein synthesis of 
hepatocytes. A human albumin enzyme-linked immunosorbent assay (ELISA) quantitation kit 
(Bethyl Laboratories, Inc., Montgomery, TX, USA) with the solid-phase sandwich enzyme 
immunoassay technique was used to quantitate free albumin level. Nunc-Immuno 96 MicroWell 
solid plates (NUNC A/S, Roskilde, Denmark) were pre-coated with 1:100 affinity purified human 
albumin coating antibody, 100 μL per well, at room temperature for 60 min. The antibody solution 
was removed, and the wells were rinsed with five washes of detergent buffer. The nonspecific 
antibody binding sites were blocked with the blocking solution, 100 μL per well, at room 
temperature for 30 min. The blocking solution was removed, and the wells were rinsed with five 
washes of detergent buffer. Human reference serum albumin, at an initial concentration of 10,000 
ng/mL, was serially diluted with sample/conjugate diluents to give the standards 6.25, 12.5, 25, 50, 
100, 200, and 400 ng/mL, whilst the sample/conjugate diluent was used as the zero standard (blank) 
for the albumin standard curve. Culture supernatants were centrifuged (Eppendorf, Hamburg, 
Germany) at 1,500 rpm for 1 min to pellet any cell debris, and the samples were appropriately 
diluted (generally 20 folds) and incubated in the assigned wells, 100 μL per well, at room 
temperature for 60 min. The wells were rinsed with five washes of detergent buffer. The bound 
albumin was detected by 1:150,000 horseradish peroxide (HRP) detection antibody, 100 μL per well, 
at room temperature for 60 min. The HRP detection antibody was removed, and the wells were 
washed with were rinsed with five washes of detergent buffer. HRP chromogenic substrate 3,3’,5,5’-
tetramethylbenzidine (TMB), 100 μL per well, was added, and the plate was incubated in the dark 
and at room temperature for 15 min. The enzymatic colour reaction was stopped by adding 0.18-M 
sulphuric acid (Sigma-Aldrich, St Louis, MO, USA), 100 μL per well. The OD was measured at 450 
nm using the microplate reader. The albumin concentration (ng/mL) in each sample was determined 
using the albumin standard curve, and albumin secretion of hepatocytes in mono- and co-culture was 
normalised to one million seeded viable hepatocytes. The experiments were performed in duplicate 
and repeated in triplicate independently.  
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2.8 Urea Colorimetric Assay 
Hepatocyte mono-culture and co-culture were performed on collagen-coated, flat-bottom 24-
well microplates as described above, and cell culture supernatants were collected for measuring urea 
synthesis representing nitrogen detoxification of hepatocytes. QuantiChrom™ urea assay kit 
(BioAssay Systems, Hayward, CA, USA) was used to quantitate urea level. Culture supernatants 
were centrifuged at 1,500 rpm for 1 min to pellet any cell debris, and the samples were appropriately 
diluted (generally 50 folds) and transferred into a clear flat-bottom 96-well plate, 5 μL per well. 
Freshly prepared urea assay working solution was added, 200 μL per well, and the plate was 
incubated at room temperature for 20 min. Human reference serum urea, at an initial concentration 
of 50 mg/dL, was serially diluted with distilled water to give the standards 3.125, 6.25, 12.5, 25, and 
50 mg/dL, whilst distilled water was used as the zero standard (blank) for the urea standard curve. 
Distilled water (blank control), urea standard, and fresh hepatocyte culture media (control) were 
assayed using the same protocol. The OD was measured at 520 nm using the microplate reader. The 
corrected urea concentration (mg/dL) in each sample was calculated using the urea standard curve, 
and urea synthesis of hepatocytes in mono- and co-culture was normalised to one million seeded 
viable hepatocytes. The experiments were performed in duplicate and repeated in triplicate 
independently. 
2.9 Caspase-cleaved CK18 Assay 
Hepatocyte mono-culture and co-culture were performed on collagen-coated, flat-bottom 24-
well microplates as described above, and cell culture supernatants were collected for measuring 
apoptosis-associated K18Asp396 (M30) neo-epitope of soluble caspase-cleaved CK18 (CCK18) 
representing caspase-mediated apoptosis of hepatocytes. M30 CytoDeath™ ELISA kit (PEVIVA AB, 
Bromma, Sweden) was used to quantitate soluble CCK18 level (Figure 2.2, left panel). Human 
reference CCK18 solutions, prepared at 250, 1,000, 3,000 U/L, were used as standards, whilst the 
sample/conjugate diluent was used as the zero standard (blank) for the CCK18 standard curve. 
Culture supernatants were centrifuged at 1,500 rpm for 1 min to pellet any cell debris, and the 
samples were appropriately diluted (generally 20 folds) and incubated in the assigned wells, 25 μL 
per well, with HRP conjugate, 75 μL per well, on a microplate shaker, 600 rpm, at room temperature 
for 4 h. The HRP detection antibody was removed, and the wells were rinsed with five washes of 
detergent buffer. Chromogenic substrate TMB, 200 μL per well, was added, and the plate was 
incubated in the dark and at room temperature for 20 min. The enzymatic colour reaction was 
stopped by adding 0.18-M sulphuric acid, 50 μL per well. The OD was measured at 450 nm using 
the microplate reader. The CCK18 concentration (U/L) in each sample was calculated using the 
CCK18 standard curve, and soluble CCK18 release of hepatocytes in mono- and co-culture was 
normalised to one million seeded viable hepatocytes. The experiments were performed in duplicate 




Figure 2.2 Caspase-mediated apoptosis and total cellular death (necrosis and apoptosis) of 
hepatocytes as represented by CCK18 (left panel) and CK18 (right panel). Adapted from 
http://www.peviva.se. 
2.10 CK18 Assay 
Hepatocyte mono-culture and co-culture were performed on collagen-coated, flat-bottom 24-
well microplates as described above, and cell culture supernatants were collected for measuring 
soluble CK18 representing total cell death of hepatocytes. M65 EpiDeath® ELISA kit (PEVIVA AB, 
Bromma, Sweden) was used to quantitate soluble CK18 level (Figure 2.2, right panel). Human 
reference CK18 solutions, prepared at 200, 400, 800, 1,200, 2,000, 3,000, 5,000 U/L, were used as 
standards, whilst the sample/conjugate diluent was used as the zero standard (blank) for the CK18 
standard curve. Culture supernatants were centrifuged at 1,500 rpm for 1 min to pellet any cell debris, 
and the samples were appropriately diluted (generally 50 folds) and incubated in the assigned wells, 
25 μL per well, with HRP conjugate, 75 μL per well, on a microplate shaker, 600 rpm, at room 
temperature for 4 h. The HRP detection antibody was removed, and the wells were washed with 
were rinsed with five washes of detergent buffer. Chromogenic substrate TMB, 200 μL per well, was 
added, and the plate was incubated in the dark and at room temperature for 20 min. The enzymatic 
colour reaction was stopped by adding 0.18-M sulphuric acid, 50 μL per well. The OD was 
measured at 450 nm using the microplate reader. The CK18 concentration (U/L) in each sample was 
calculated using the CK18 standard curve, and soluble CK18 release of hepatocytes in mono- and 
co-culture was normalised to one million seeded viable hepatocytes. The experiments were 
performed in duplicate and repeated in triplicate independently. 
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Induction of apoptosis in cultured hepatocytes will result in massive release of CCK18 and 
secondary release of CK18 at a later time point, and consequently increase CCK18/CK18 ratio. In 
contrast, induction of necrosis will almost exclusively result in massive release of non-cleaved CK18, 
and consequently give rise to a low CCK18/CK18 ratio. The ratio of CCK18 to CK18 was, thus, 
calculated to determine the mode of death for hepatocytes in vitro; a ratio over 0.40 indicated that 
hepatocytes underwent apoptosis mainly, and vice versa (Kramer et al., 2004). 
2.11 Statistical Analysis 
GraphPad Prism 6 programme (GraphPad Software, Inc., La Jolla, CA, USA) was used for 
statistical analysis. All continuous data were expressed as mean ± standard deviation (SD), and the 
means were compared using the one-way repeated measures analysis of variance (ANOVA), the 
Fisher's least significant difference (LSD) test, or two independent samples student-t test unless 
specified otherwise. A two-tailed P-value less than 0.05 was considered statistically significant.
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CHAPTER 3  OPTIMISATION OF HUMAN HEPATOCYTE AND 
MESENCHYMAL STEM CELL IN VITRO CO-CULTURE SYSTEM 
3.1 Introduction 
3.1.1 Limitations of hepatocyte mono-culture 
Once isolated and cultivated in vitro, primary hepatocytes in mono-culture lose their 
proliferative potential although the liver in vivo is well known for its potent regenerative capacity as 
seen in the Prometheus myth. Hepatocytes cultured in vitro switch from the proliferative response to 
the inflammatory response, as mediated by downregulated expression of NFκB (Chaisson et al., 
2002; Fredriksson et al., 2011; Malato et al., 2012) and upregulated expression of MAPK/ERK 
(Roberts et al., 2000; Frémin et al., 2007) signalling pathways. As a result, primary hepatocytes in 
standard monolayer culture show a rapid phenotypic de-differentiation and metabolic regression 
(Mizumoto et al., 2008). 
Hepatocytes also undergo epithelial-to-mesenchymal transition (EMT) in the absence of 
specific favourable growth factors, such as HGF (Xia et al., 2006), whilst TGF-β, a potent 
profibrogenic factor, is known to be the most potent mediator of hepatocyte EMT as for other 
epithelial cell lines (Dooley et al., 2008). Hepatocyte EMT is also believed to be one of the major 
aetiologies of liver fibrosis (Breitkopf et al., 2006) aside from dysregulated proliferation of liver 
NPCs. In vitro cultured hepatocytes, if unattached, will undergo spontaneous apoptosis (Vanhaecke 
et al., 2004). This spontaneous event is controversially thought to result from the accumulation of 
pre-existing nitric oxide (Canová et al., 2008) and can also be induced by TNF or TGF-β (Roberts et 
al., 2000). 
3.1.2 Heterotypical co-culture of hepatocytes with hepatic NPCs 
Hepatic NPCs, which consist primarily of Kupffer cells, sinusoidal endothelial cells, and 
stellate cells, play a regulatory role in hepatocyte maintenance, proliferation (Harada et al., 2003), 
apoptosis (Chaisson et al., 2002), maturation (Mitaka et al., 1999; Melgert et al., 2000), and 
regeneration (Sakuda et al., 2002; Azuma et al., 2003). The regulatory effects of NPCs on 
hepatocytes are believed to be mediated by paracrine factors, such as HGF (Michalopoulos et al., 
1999), EGF (Michalopoulos et al., 1999), TGF-β (Date et al., 1998), TNF (Shinozuka et al., 1996), 
IGF, IL-1 (Boulton et al., 1997), IL-6, BMP-6, and ECM (Vrochides et al., 1996). However, co-
culture with liver-derived NPCs stimulates hepatocyte DNA synthesis, depending on cell-to-cell 
interactions rather than growth factors. NPCs co-culture can augment liver-specific metabolic 
functions of hepatocytes exposed to ALF serum (Nedredal et al., 2007). NPCs co-culture also helps 
two-dimensional sheets of hepatic progenitor cells to generate functionally differentiated three-
dimensional liver tissue (Ogawa et al., 2004). It is possible that hepatocytes and hepatic NPCs 
isolated from a single donor could be co-transplanted into a given recipient with more benefits.  
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3.1.3 Heterotypic co-culture of hepatocytes with MSCs 
Co-culture of seed cells with MSCs appears to be a promising solution to modify cellular 
replacement therapy for metabolic disorders, such as diabetes mellitus and liver-based metabolic 
diseases, as heterotypic interaction with MSCs is known to be crucial for survival and functionality 
of epithelial cells in vitro (Gómez-Aristizábal et al., 2009). Human MSCs enhance survival, 
metabolic function, and in vivo angiogenesis of isolated pancreatic islets by secreting trophic factors, 
such as VEGF (Park et al., 2010), and by depositing ECM (Hematti et al., 2013). Furthermore, Ito 
and his colleagues (2010) reported that co-transplantation with MSCs improved the morphology and 
function of islet grafts by promoting re-vascularisation in vivo. Among these exploratory studies, 
BM-MSCs are the most frequently used supportive cells as these cells are more easily expanded in 
vitro as documented in current literature (Karaoz et al., 2011; Yeung et al., 2012). 
3.1.3.1 Heterotypic co-culture of hepatocytes with BM-MSCs 
In the field of HCT, MSCs also show a favourable supportive effect on hepatocytes in long-
term co-culture in vitro (Corlu et al., 1997). BM-MSCs are still the most frequently used MSCs for 
hepatocyte co-culture. BM-MSCs maintain and improve hepatocyte morphology and metabolic 
functionality by the synergistic effects of soluble factors, cell-to-matrix, and cell-to-cell 
communications (Ijima et al., 2008; Gu et al., 2009a; Gu et al., 2009b; Gu et al., 2009c). 
Co-transplantation of hepatocytes and BM-MSCs was also attempted in preclinical studies. 
When co-encapsulated with BM-MSCs, hepatocytes could be traced up to 4 months following 
transplantation in rats (Liu and Chang, 2002). Taking all these studies together, BM-MSCs can 
improve cellular morphology, survival, and metabolic functions, such as albumin secretion, urea 
synthesis, and CYP450 activity, both in vitro and in vivo. It was, therefore, proposed that co-
transplantation of iPS derived cells and MSCs might be a novel alternative to OLT, which is limited 
by a shortage of donors and immune rejection, for treating end-stage liver disease (Liu et al., 2009).  
3.1.3.2 Heterotypic co-culture of hepatocytes with UC- and AT-MSCs 
Two other common sources of MSCs, namely, UC- and AT-derived MSCs, have also been 
investigated in the setting of preclinical study. Chao et al. (2008) reported that human UC-MSCs 
improved islet cell secretion of insulin over 3 months possibly by releasing a series of trophic factors, 
including IL-6, tissue inhibitors of metalloproteinase (MMP)-1 and -2, monocyte chemoattractant 
protein 1, growth related oncogene, HGF, IGF binding proteins 4, and IL-8. Gómez-Aristizábal and 
Davies (2012) showed that human UC perivascular cells containing UC-MSCs enhanced liver-
specific gene expressions, such as albumin, urea, and CYP450, mainly through MSC-to-hepatocyte 
contact and partially through paracrine factors.  
AT-MSCs, also called adipose stem cells, are a newer member of the MSCs family that was 
introduced in the early 21st century and less studied for co-culture with hepatocytes. Cavallari et al. 
(2012) preconditioned human AT-MSCs with a mixture of hyaluronic, butyric, and retinoic acids and 
successfully optimised co-transplantation of rat islet cells with MSCs in a diabetic rat model, in 
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which multiple growth factor signalling pathways, such as VEGF, kinase insert domain receptor 
transcript, and HGF, were activated. The soluble factors mediating the immunomodulatory effect of 
AT-MSCs also include TGF-β, chemokine (C-C motif) ligand (CCL) 2, CCL5, tissue inhibitor of 
MMP-1/2, and cyclooxygenase-2 (Kang et al., 2008). 
3.1.3.3 Optimal source of MSCs for hepatocyte co-culture 
BM-, UC-, and AT-MSCs have their own advantages and disadvantages in the scenario of 
clinical transplantation practice (Table 3.1). It remains unknown in the current literature which 
source of MSCs, namely, BM, UC, or AT, is the optimal candidate for the purpose of hepatocyte co-
culture, although BM-MSCs are most frequently used in co-culture experiments. 
Generally, these three types of MSCs have similar morphology and immunophenotype. BM and 
AT have a significantly higher success rate of MSCs isolation as compared to UC (100% vs. 100% vs. 
63%); AT has the highest colony frequency, but UC has the lowest; and UC has the highest 
proliferative capacity, but BM has the lowest (Kern et al., 2006). The low success rate of UC-MSCs 
isolation can be improved by selecting cord blood unit with a volume of more than 90 mL and a 
harvest time within 2 hours after the donor’s birth (Zhang et al., 2011). It is also confirmed that BM-
MSCs are more likely to become senescent through passages in vitro, as compared to UC- and AT-
MSCs (Vidal et al., 2012). 
All MSCs share some consistent and reproducible gene expression profiles involved in ECM 
formation, such as fibronectin, ECM2, glypican 4, DNA-binding protein inhibitor 1, neurofibromin 
1b, and homeobox (HOX) A5 and B6, but also exhibit some differential gene expression profiles 
(Wagner et al., 2005). Human adult BM-, UC-, and AT-MSCs also exhibit similar 
immunomodulatory effects in vitro. A study in a canine model reported that AT-MSCs had a 
significantly higher proliferative potential and BM-MSCs secreted the highest level of VEGF; AT- 
and UC-MSCs exhibited a greater in vitro osteogenic capacity as compared to BM-MSCs (Kang et 
al., 2012). Another in vitro study comparing human BM-, UC-, and AT-MSCs, with respect to 
surface antigen expression, differentiation potential, proliferative capacity, clonality, tolerance for 
ageing, and paracrine activity, showed that UC-MSCs had the highest rate of cell proliferation and 
clonality and a significantly lower level of senescence marker expression; human UC-MSCs reduced 
expression of proinflammatory cytokines, such as IL-1α, -6, and -8, in co-cultured, LPS-challenged 
rat alveolar macrophages (Jin et al., 2013). 
Interestingly, these three types of MSCs have a similar potential of hepatogenic differentiation 
and proliferation, while placenta-derived MSCs have the reportedly greatest potential (Lee et al., 
2012). Moreover, it has been reported that human UC-MSCs are more effective for improving 
ureagenesis while BM-MSCs is more supportive for CYP450 activity in co-cultured hepatocytes 
(Gómez-Aristizábal et al., 2012).   
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Table 3.1 Overview of BM-, UC, and AT-MSCs 
BM UC blood/matrix AT 
 Invasive harvest  Non-invasive  Non-invasive as side 
product of liposuction 
 Propagatable but reduced 
in aged donors 
 Highly propagatable  Highly propagatable 
 Less homogenous stem cell 
population 
 Homogenous stem cell 
population 
 Heterogeneous cell 
population 
 Limited source  Limited source  Relatively unlimited 
source 
 Readily available  Not readily available  Readily available 
 Most extensively studied, 
showing  high-efficiency 
differentiation 
 Extensively studied, 
showing less efficient 
differentiation 
 Less studied, and not well 
documented 
3.1.4 Compromised functionality of steatotic hepatocytes and cryopreserved human 
hepatocytes  
3.1.4.1 Steatotic hepatocytes 
Liver steatosis, also called fatty liver disease (FLD), refers to a pathological accumulation of 
lipid, mainly triglyceride acid, in liver cells. FLD is further classified as alcoholic and non-alcoholic 
subtypes. Early-stage FLD is usually reversible in most cases and thought to result primarily from 
imbalanced fatty acid metabolism secondary to abusive alcohol consumption, obesity (Fabbrini et al., 
2010), metabolic disorder, such as insulin resistance, and use of hormonal or cytotoxic agents. FLD 
patients are usually asymptomatic and exhibit no symptom or sign of liver injury if the liver remains 
well compensated. However, severe FLD has accompanying hepatocyte necrosis and inflammatory 
response, namely, steatohepatitis. This pathological condition can trigger the activation of stellate 
cells and lead to liver fibrosis (Dixon et al., 2001). 
The prevalence of non-alcoholic FLD is very high and variable in the general population, 
ranging from 14% to 34% (Browning et al., 2004; Bedogni et al., 2005). This figure is much higher 
in the Western population even without a history of alcohol abuse (Angulo, 2002). FLD is the most 
common cause of liver function test abnormality in European and North American populations. As 
FLD remains silent until the time of liver imaging or biopsy, fatty donor livers with a poor graft 
survival and functionality are frequently (estimated to be 25%) encountered in OLT practice 
(Marsman et al., 1996). Donor livers assigned to HCT use are often rejected for OLT mainly due to 
the presence of serious liver steatosis (Baccarani et al., 2003). Alexandrova et al. (2005) reported 
severe liver steatosis rather than long cold ischaemia time or older donor age was the primary risk 
factor of a low hepatocyte isolation efficiency. Moderate to severe steatosis (>10% steatotic 
hepatocytes) was reported to be associated with a low hepatocyte isolation yield from liver resection 
specimens (Alexandre et al., 2002) although mild steatosis (≤10% steatotic hepatocytes) did not 
result in a poor harvest of hepatocytes (Alexandre et al., 2002; Richert et al., 2004). Bonora-
Centelles et al. (2010) reaffirmed that donor livers with a cold ischaemia time over 15 hours or with 
underlying serious steatosis should not be accepted for HCT as these donor livers offered poor-
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quality hepatocytes in terms of cellular viability, attachment efficiency, and metabolic functionality. 
Severely steatotic hepatocytes cannot tolerate cryopreservation and subsequent thawing, and are 
consequently subject to a further cell loss and metabolic impairment (Terry et al., 2005). 
Sagias et al. (2010) added N-acetylcysteine (NAC), a widely used antioxidant for treating 
paracetamol-induced liver toxicity, into the perfusion solution of hepatocyte isolation and improved 
the viability of severely steatotic hepatocytes. The hepatoprotective effect of NAC is thought to 
result from the elimination of excessive production of ROS during ischaemia-reperfusion (Kohli et 
al., 2007). Omega-3 polyunsaturated fatty acid was reported to reverse mitochondrial injury of 
steatotic hepatocytes by upregulating mitofusin 2 gene encoding mitochondrial membrane protein 
(Zhang et al., 2011). Glucagon-like peptide-1 analogue can reduce hepatocyte steatosis and improve 
cell survival by enhancing unfolded protein response and promoting macroautophagy (Sharma et al., 
2011). However, it remains yet to be investigated how to improve the morphology and metabolic 
function of steatotic hepatocytes in the long term, especially after transplantation. 
3.1.4.2 Cryopreserved hepatocytes 
Hepatocytes can be cryopreserved and stored in a ‘‘cell bank’’ for several days, months, or even 
years following isolation, and cryopreserved hepatocytes can be subsequently thawed, allowing 
repeated or emergency transplantation on demand (Terry et al., 2010). A major limitation of 
cryopreservation for standard hepatocyte monolayer culture is that post-cryopreserved hepatocytes 
exhibit a poor cell attachment and consequent metabolic impairment on thawing. Intracellular ice 
formation and exposure to hyperosmotic solutions are two major causes for hepatocyte injury 
following cryopreservation and subsequent thawing. These injuries can damage hepatocyte 
cytoplasmic membrane and result in massive loss of cytosolic proteins. Therefore, 
cryopreserved/thawed hepatocytes have a significant reduction in albumin secretion, urea synthesis, 
and CYP450 activity as compared to the pre-freezing baseline. Severity of hepatocyte 
cryopreservation/thawing injury depends on the condition of the donor liver tissue, such as age and 
well-being of the donor, concomitant liver condition (e.g., liver steatosis), and time lengths of cold 
and warm ischaemia (Terry et al., 2005). 
A large number of studies reported optimisation of hepatocyte cryopreservation protocols, 
aiming to improve post-freezing/thawing hepatocyte viability and metabolic function. These 
modified strategies include pre-culture of liver cell suspension, pre-incubation with antioxidants 
(Terry et al., 2006), standardisation of hepatocyte concentration and cryovial use, and optimisation 
of cryoprotectants (e.g., long-chain oligosaccharide; Miyamoto et al., 2006) and cooling/thawing 
procedures. As hepatocytes become apoptotic following detachment from ECM, cryopreservation of 
hepatocytes in artificial ECM, such as collagen and high molecular weight polymer, has also been 
investigated. Canaple et al. (2001) reported that cryopreservation of hepatocytes encapsulated in 
multicomponent capsules, composed of a polyelectrolyte complexation of sodium alginate, cellulose 
sulphate and poly(methylene-co-guanidine) hydrochloride, maintained liver-specific metabolic 
function of frozen hepatocytes for up to 4 months as compared to unfrozen cells. Interestingly, it has 
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been reported that co-encapsulation of hepatocytes with MSCs can improve cell graft survival and 
liver-specific metabolic function both in vitro (Liu and Chang, 2003) and in vivo (Shi et al., 2009). 
Therefore, it is possible that co-encapsulated MSCs should protect hepatocytes from freezing/ 
thawing injury. However, it remains unknown whether these protective effects can be maintained in 
the longer term, especially after thawing. 
3.1.5 Antiapoptotic effect of MSCs co-culture on hepatocytes in vitro 
MSCs co-culture has a significant modulatory effect on the cell cycle of hepatocytes. Gu et al. 
(2009b; 2009c) reported that a larger percentage of hepatocytes co-cultured with BM-MSCs were 
accumulated in the G2/S phase, with a smaller percentage in the G0/G1 phase, as compared to mono-
cultured hepatocytes. It suggests that MSCs co-culture facilitates the bypass of G1/S checkpoint (Pok 
et al., 2013). This checkpoint is known to be regulated by protein 53 (p53), a tumour suppressor. p53 
can arrest cell growth by holding the cell cycle at the G1/S checkpoint, which allows sufficient time 
for the cell to recognise and repair DNA damage; if the damage is irreparable, p53 will initiate cell 
apoptosis (Jensen et al., 1998).  
MSCs transplantation has been investigated in preclinical and clinical studies to ameliorate liver 
ischaemia/reperfusion injury (Pan et al., 2012; Sun et al., 2012) and chemically-induced liver 
fibrosis (Manuelpillai et al., 2010). Potential contribution of MSCs may result from two aspects, 
including transdifferentiation into hepatocytes in vivo and promoting liver regeneration by paracrine 
mechanisms. Yan et al. (2009) reported that transplantation of human UC-MSCs could reduce serum 
aminotransferase level and hepatocyte denaturation by inhibiting hepatocyte apoptosis and 
promoting hepatocyte proliferation as evidenced by hepatocyte tracing and proliferating marker 
labelling. Antiapoptotic and antifibrotic effects of MSCs in vivo may derive from the contribution of 
HGF signalling, which modulates activation, apoptosis, and TGF-β signalling downregulation of 
hepatic stellate cells. Therefore, it is possible that MSCs co-culture exerts trophic and protective 
effects on hepatocytes by inhibiting hepatocyte spontaneous and chemically-induced apoptosis. This 
possibility is clinically significant for the use of HCT in the setting of ALF as transplanted 
hepatocytes will be exposed to a large number of circulating and regional (pro)inflammatory factors, 
a great majority of which are also proapoptotic, such as IL-6 and TNF-α, present in ALF patients. 
3.1.6 Chapter objectives 
 Co-culture of hepatocytes and autologous liver NPCs 
To investigate whether co-culture with autologous liver NPCs can also be trophic for 
hepatocytes in vitro. 
 Optimisation of MSCs source for hepatocyte co-culture 
To compare hepatotrophic effect of BM-, UC, and AT-MSCs on co-cultured primary human 
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hepatocytes, at an optimal MSC:hepatocyte ratio, with respect to cellular viability, cell attachment, 
and liver-specific metabolism. 
  Co-culture steatotic/cryopreserved hepatocytes with MSCs 
To investigate whether MSCs can also exert trophic effects on co-cultured steatotic or 
cryopreserved hepatocytes. 
 Contribution of soluble factors to MSCs co-culture hepatotrophic effect 
To investigate whether soluble factors released from MSCs contribute to hepatotrophic effect of 
MSCs co-culture. 
 Antiapoptotic effect of MSCs co-culture 
To investigate whether MSCs can protect co-cultured hepatocytes from spontaneous and 
chemically-induced cell apoptosis.  
 54 
 
3.2 Materials and Methods 
3.2.1 Isolation of human liver-derived NPCs 
Human liver-derived NPCs were isolated using a modified protocol described by Najimi et al. 
(2007). Briefly, the donor liver tissue was processed as described in Section 2.3, Primary Harvest of 
Human Hepatocytes. Liver cell suspension was centrifuged at 50×g and 4°C for 5 min to pellet 
hepatocytes, and the supernatant was collected and further centrifuged for three cycles at 1,500 rpm 
and 4°C for 5 min. The total number and viability of liver cells in the supernatant were determined 
using trypan blue exclusion with a hematocytometer and a light microscope. Red blood cells in the 
cell pellet were lysed using sterile water for injection for 1 min at room temperature, followed by 
centrifugation. The cell suspension was resuspended in the MSCs expansion media and plated onto a 
non-tissue culture treated, 30-mm, polypropylene Petri dishes (Thermo Fisher Scientific, Ltd, 
Loughborough, UK) at a density of 60,000 cells per cm2. As hepatocytes could adhere to 
polypropylene, floating hepatocytes (90%) were eliminated when the cell culture media were 
refreshed 4 h following plating. The cell culture was rinsed with sterile PBS and used for 
experiments. 
3.2.2 Subculture of human MSCs and adult dermal fibroblasts 
Human AT-, BM-, and UC-MSCs were subcultured as described in Section 2.2, Subculture of 
MSCs. Human adult-derived dermal fibroblasts (ADFs), a common mesenchyme-derived cell line, 
were originally extracted by Life Technologies Corporation, Carlsbad, CA, United States from a 
single human donor’s foreskin through mechanical and enzymatic digestion. These cells were used 
as a random control for MSCs. Primary cultures was expanded for one passage before 
cryopreservation. Cryopreserved human ADFs (approximately 0.5 million cells per mL per vial) 
were quickly swirled and thawed in a 37°C water bath for 1 min. The cell suspension was 
immediately transferred into a 50-mL sterile polypropylene conical tube containing 20-mL pre-
warmed culture media and centrifuged at 1,500 rpm for 5 min. The cell pellet was subsequently 
resuspended in pre-warmed culture media and plated onto a 25-cm2 tissue culture flask (NUNC A/S, 
Roskilde, Denmark) at a density of 5,000 cells per cm2 in a humidified incubator, in an atmosphere 
of 95% O2 and 5% CO2 and at 37°C. The ADFs expansion culture media consisted of phenol red-
free, low-glucose DMEM, 10% FCS, 2-mM L-glutamine, and 100-U/mL penicillin plus 100-μg/mL 
streptomycin, at a volume of 5 mL per T25 flask. The culture medium was replaced with fresh 
medium every 3–4 d.  
On day 7 of culture (approximately 80% confluency), ADFs cultures were rinsed with PBS and 
detached by adding 1-mL 0.25% trypsin at 37°C for 5–10 min, and the cell dissociation was stopped 
by 10% FCS/DMEM. The cell suspension was replated and subcultured at a ratio of 1:3 using the 
same cell culture protocol. The cells were cryopreserved using a freezing container at −80°C, and 
the stocks were stored at −140°C in the culture media supplemented with 10% DMSO. The 4th–6th 
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passages (P4–6) of ADFs were used for further experiments. The total number and viability of ADFs 
for each passage were determined using the trypan blue exclusion technique with an inverted light 
microscope equipped with a digital SLR camera. 
3.2.3 Isolation of human non-steatotic and steatotic hepatocytes 
Liver steatosis was graded by an independent consultant liver histopathologist at Institute of 
Liver Studies, King’s College Hospital NHS Foundation Trust, London, UK, using the standard four-
grade semiquantitative evaluation scale (Franzén et al., 2005): grade 0, no fat deposition in 
hepatocytes; grade 1 (mild), fat deposition in less than 33% of hepatocytes; grade 2 (moderate), fat 
deposition in 33%–66% of hepatocytes; and grade 3 (severe), fat deposition in more than 66% of 
hepatocytes. Non-steatotic donor liver tissues were processed as described in Section 2.3, Primary 
Harvest of Human Hepatocytes, while moderately steatotic donor liver tissues were processed 
similarly, except for the addition of 5-mM NAC (PLIVA Pharma, Ltd., Hampshire, UK), a potent 
scavenger of ROS precursors into the first perfusion buffer (Ca2+-free HBSS) of the standard 
collagenase digestion technique as previously reported by Sagias et al. (2010). The total number and 
viability of fresh hepatocytes were determined using a hematocytometer and the trypan blue 
exclusion technique with a light microscope. Red blood cells in hepatocyte pellet were lysed using 
sterile water for injection for 1 min at room temperature, followed by centrifugation. Batches of 
hepatocytes with a viability of over 60% on trypan blue exclusion were used for experiments. 
3.2.4 Cryopreservation and thawing of human hepatocytes 
Freshly isolated hepatocytes were cryopreserved using a standard controlled-rate freezing 
protocol as previously reported by Mitry et al. (2010). Hepatocytes were resuspended in 
cryopreservation solution at a final density of 1.0×107 cells per mL. The cryopreservation solution, 
consisting of 1 part of 50% glucose (Hameln Pharmaceuticals Ltd., Gloucester, UK), 1 part of 
clinical grade 100% DMSO, and 8 parts of ViaSpan™ University of Wisconsin (UW) solution 
(Bristol-Myers Squibb Pharmaceutical Limited, Dublin, Ireland), was chilled on an ice pack. 
Hepatocyte suspension (5 mL) was transferred into a sterile 10-mL cryovial (Thermo Fisher 
Scientific) using a 10-mL syringe (BD Biosciences) chilled on an ice pack and immediately placed 
flat into the controlled-rate freezer connected to a liquid nitrogen container (Kryo 10, series III; 
Planer Products, Ltd., Middlesex, UK) at a pressure stabilised between 34.5 and 48.3 kPa. The 
cryovial holder and frame were pre-chilled at 4–8°C for 30–60 min prior to use. A modified stepwise 
controlled-rate freezer programme was started to produce a linear temperature decrease and prevent 
cell damage from latent heat of fusion during water crystallisation (Diener et al., 1993). The start 
temperature was 8°C, and the end temperature was −140°C over 60-minute freezing. Frozen 
cryovials were immediately transferred on dry ice to the −140°C cell storage tank.  
Cryopreserved hepatocytes were defrosted using a modified protocol as previously reported by 
Steinberg et al. (1999). Frozen hepatocyte suspension (5 mL per vial) was briefly and gently thawed 
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in a 37°C water bath, and immediately transferred into a 250-mL Falcon® polypropylene conical 
tube  (BD Biosciences) containing 50-mL ice-cold thawing solution at a slow rate using the aseptic 
technique. The thawing solution consisted of 1 part of 20% human serum albumin (Baxter 
Healthcare Ltd., Compton, UK) and 9 parts of EMEM. Hepatocyte suspension was pelleted at 50×g 
and at 4°C for 5 min and re-washed in 20-mL ice-cold 2% HSA/EMEM solution. The total number 
and viability of fresh hepatocytes were determined using a hematocytometer and the trypan blue 
exclusion technique with a standard upright light microscope. Batches of hepatocytes with a viability 
of over 60% on trypan blue exclusion was used for experiments. 
3.2.5 Hepatocyte co-culture protocols 
3.2.5.1 Hepatocyte co-culture with liver NPCs 
Floating hepatocytes were eliminated from the supernatant cell culture by refreshing the cell 
culture media 4 h after plating. Hepatocyte mono-culture and co-culture with liver NPCs at a ratio of 
10:1 were established as described in Section 2.4, Hepatocyte Mono-culture and Co-culture. The 
seeding density of hepatocytes was fixed at 50,000 viable cells per cm2. Hepatocyte mono-culture 
was used as control, and NPCs mono-culture was used as a blank control. 
3.2.5.2 Optimisation of MSCs source 
Fresh non-steatotic  hepatocytes were  co-cultured with P6–8 human AT-, BM-, and UC-MSCs, 
as well as P4–6 human ADFs, as described in Section 2.4, Hepatocyte Mono-culture and Co-
culture, to determine the optimal MSCs source for hepatocyte co-culture. The seeding density of 
MSCs and ADFs was 20,000 viable cells per cm2, and that of hepatocytes was 50,000 viable cells 
per cm2, at a MSC/ADF:hepatocyte ratio of 1:2.5. Hepatocyte mono-culture was used as control, 
hepatocyte co-culture with human ADFs was used as random control, and MSCs mono-culture was 
used as a blank control. 
3.2.5.3 Optimisation of MSC:hepatocyte ratio 
P6–8 optimal source-derived MSCs were co-cultured with fresh non-steatotic  hepatocytes as 
described in Section 2.4, Hepatocyte Mono-culture and Co-culture, to determine the optimal 
MSCs:hepatocytes ratio for hepatocyte co-culture. The seeding density of hepatocytes was fixed at 
50,000 viable cells per cm2, and those of the optimal source-derived MSCs were predetermined to be 
50,000, 20,000, 10,000, and 5,000 viable cells per cm2, at a ratio of 1:1, 1:2.5, 1:5, and 1:10, 
respectively. Hepatocyte mono-culture was used as control, and MSCs mono-culture was used as 
blank control.  
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3.2.5.4 Co-culture of cryopreserved/steatotic hepatocytes with MSCs 
P6–8 optimal source-derived MSCs were co-cultured with cryopreserved non-steatotic, as well 
as fresh non-, mildly, moderately, and severely steatotic hepatocytes as described in Section 2.4, 
Hepatocyte Mono-culture and Co-culture. The seeding density of hepatocytes was fixed 150,000 
viable cells per cm2, with that of the optimal source-derived MSCs at the optimal MSC:hepatocyte 
ratio. Hepatocyte mono-culture was used as control, and MSCs mono-culture was used as blank 
control. 
3.2.5.5 Indirect co-culture of hepatocytes with MSCs 
Indirect co-culture using Transwell plates Indirect co-culture of hepatocytes with the 
optimal source-derived MSCs using Transwell® Permeable Supports (Corning Incorporated, Corning, 
NY, USA) was performed to investigate the contribution of MSCs-derived soluble factors to the 
MSCs co-culture hepatotrophic effect. Hepatocytes were separated from MSCs in the Transwell® co-
culture system to exclude possible effects of ECM and direct MSC-to-hepatocyte contact on 
contribution of soluble factors. The optimal source-derived MSCs were plated onto Transwell® 
permeable culture inserts at a density equalling to that at the optimal MSC:hepatocyte ratio, and pre-
cultured with hepatocyte culture media for 24 hours. Fresh hepatocytes were mono-cultured as 
described in Section 2.4, Hepatocyte Mono-culture and Co-culture, and MSCs-plated culture 
inserts were transferred into hepatocyte mono-culture using aseptic techniques with hepatocyte 
mono-culture alone as control.  
MSCs co-culture CM Soluble trophic factors released from MSCs in co-culture are 
likely to be regulated by ECM and direct MSC-to-hepatocyte contact. Indirect co-culture of 
hepatocytes with the optimal source-derived MSCs co-culture CM was performed to investigate 
whether hepatotrophic effect of MSCs co-culture was mediated by paracrine mechanisms. The 
optimal source-derived MSCs were co-cultured with fresh hepatocytes for 24 h at the optimal 
MSC:hepatocyte ratio as described in Section 2.4, Hepatocyte Mono-culture and Co-culture. Fresh 
MSCs co-culture CM was collected to feed mono-cultured hepatocytes, with hepatocytes mono-
cultured with fresh hepatocyte culture media as control. The reading of background MSCs co-culture 
CM (blank control) was subtracted from that of hepatocytes cultured with CM to obtain the actual 
reading of hepatocytes. 
The culture media were refreshed on days 1, 3, 5, and 7, respectively. The cell morphology was 
examined using a standard inverted light microscope equipped with a digital SLR camera; 
hepatocyte co-culture with AT-MSCs was also examined using a laser capture microdissection 
system (Leica Microsystems, Wetzlar, Germany). Culture supernatants were collected into sterile 
1.5-mL centrifuge tubes and frozen at −80°C for further experiments. Cell cultures were rinsed with 
one-wash PBS at room temperature for further experiments. All experiments were performed in 
duplicate and repeated in triplicate independently. 
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3.2.6 Staurosporine cytotoxicity assay 
Staurosporine cytotoxicity assay was performed to investigate whether MSCs co-culture 
specifically inhibited hepatocyte apoptosis by targeting at caspase signalling pathway. Staurosporine 
is a prototypical ATP-competitive protein kinase inhibitor that is mainly used to induce cell apoptosis 
in biological experiments and reported to activate caspase-3 signalling (Barrachina et al., 2002). 
Fresh non-steatotic hepatocyte mono-cultures were treated with 0- (blank control), 0.5-, 1-, 2.5-, 5-, 
and 10-μM staurosporine (Sigma-Aldrich, St. Louis, MO, USA) for 24 h. Cell culture supernatants 
were collected for CCK18 and CK18 assays as described in Section 2.9, Caspase-cleaved CK18 
Assay and Section 2.10, CK18 Assay. Fresh hepatocytes were co-cultured with the optimal source-
derived MSCs at the optimal ratio in the presence of staurosporine at the least concentration that 
induced significant increases in hepatocyte apoptosis and total death, as controlled by hepatocyte 
mono-culture in the absence of staurosporine. All experiments were performed in duplicate and 
repeated in triplicate independently. 
3.2.7 General cellular activity and liver-specific metabolic function assays 
MTT assay was performed as described in Section 2.5, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide Colorimetric Assay to determine hepatocyte mitochondrial 
dehydrogenase activity. SRB assay was performed as described in Section 2.6, Sulforhodamine B 
Colorimetric Assay to determine overall hepatocyte attachment. Albumin ELISA was performed as 
described in Section 2.7, Albumin Enzyme-linked Immunoabsorbent Assay to determine protein 
synthesis of hepatocytes. Urea colorimetric assay was performed as described in Section 2.8, Urea 
Colorimetry to determine nitrogen detoxification of hepatocytes. All experiments were performed in 
duplicate and repeated in triplicate independently. 
3.2.8 Hepatocyte apoptosis and total death assays 
CCK18 assay was performed as described in Section 2.9, Caspase-cleaved CK18 Assay to 
determine caspase-mediated hepatocyte apoptosis. CK18 assay was performed as described in 
Section 2.10, CK18 Assay to determine total hepatocyte death. The ratio of CCK18 to CK18 was 
also produced to determine the death mode of hepatocytes in vitro; a ratio of over 0.40 indicated that 
hepatocytes underwent apoptosis mainly, and necrosis vice versa. All experiments were performed in 




3.3.1 Morphology of mono-cultured human liver NPCs, MSCs, and ADFs  
3.3.1.1 Human liver NPCs 
Human liver NPCs showed a viability of 60–80% on trypan blue exclusion at the time of 
primary harvest. This mixed cell population could adhere to and grow on non-tissue culture treated 
plate surfaces. These cells were variable in cell size (10–40 μm), but uniformly spindle-shaped in 
contrast to polygonal- or round-shaped hepatocytes (Figure 3.1A). From day 7 onwards, these cells 
detached from the plate and could not be passaged. 
3.3.1.2 Human AT-, BM-, and UC-MSCs 
All three sources of MSCs showed a similar spindle-shaped, fibroblast-like morphology (20–40 
μm) with double or multiple small projections after being seeded on non-tissue culture treated plate 
surface and reached 90% of confluency within 7 days of culture (Figure 3.1B–D). On confluency 
MSCs were polarised, with a small cell body and two slim projections in a homogenous manner. 
MSCs remained proliferative and attached from passages 6 to 8. Cell yield was approximately 1–
2×106 cells per T75 culture flask, equal to a multiplication rate of 200–400%. The viability on trypan 
blue exclusion was over 99.5% for each passage and remained above 99% after freezing and thawing. 
UC-MSCs appeared to have a relatively rapid proliferation, while AT-MSCs exhibited a relatively 
large cell body on low confluency. 
3.3.1.3 Human ADFs 
Human ADFs also showed a spindle-shaped morphology (10–20 μm)  with two slim projections 
after being seeded on non-tissue culture treated plate surface and reached 90% of confluency within 
7 days of culture. On confluency ADFs were polarised, with a small cell body and two relatively 
shorter projections, as compared to MSCs, in a homogenous manner (Figure 3.1E). ADFs remained 
proliferative and attached from passages 4 to 6. Cell yield was approximately 0.5×106 cells per T25 
culture flask, equal to a multiplication rate of 400%. The viability on trypan blue exclusion was over 
90% for each passage and remained above 90% after freezing and thawing.  
3.3.2 Morphology of hepatocytes in mono-, direct co-, and indirect co-cultures 
3.3.2.1 Hepatocytes in mono-culture 
Primary human hepatocytes attached to collagen-coated culture vessel surfaces within 4–6 
hours, while a large number of hepatocytes remained unattached at the time of culture media 
replacement. Adherent hepatocytes at a low seeding density exhibited a round-shaped morphology at 
a size of below 10 μm. Primary hepatocytes aggregated into a few small-sized colonies containing 






Figure 3.1 Morphology of human liver-derived NPCs (A), AT-MSCs (B), BM-MSCs (C), UC-
MSCs (D), and ADFs (E) on inverted light microscopy (200×): (A) liver-derived NPCs were variable 
in cell size (10–40 μm) but uniformly spindle-shaped; (B–D) AT-, BM-, and UC-MSCs were homogenous 
and polarised, with a small cell body and two slim projections; and (E) ADFs were homogenous and 
polarised, with a small cell body and two relatively shorter projections. 
viability of primary hepatocytes on trypan blue exclusion continued declining and neared zero on 
day 7 of in vitro culture.  
3.3.2.2 Hepatocytes in co-culture with liver NPCs 
Freshly isolated human hepatocytes attached to the liver NPCs monolayer within 4–6 hours, 
and a relatively small number of hepatocytes were detached from culture vessel surface at the time 
of culture media replacement. Adherent hepatocytes exhibited a morphology similar to those in 
mono-culture, while a greater number of hepatocytes aggregated and attached closely to liver NPCs 
over 7 days of co-culture (Figure 3.2B). The viability of primary hepatocytes co-cultured with 









Figure 3.2 Morphology of human primary hepatocyte mono-culture (A), hepatocyte co-
culture with liver-derived NPCs (B), hepatocyte co-culture with AT-MSCs (C), and hepatocytes 
indirectly co-cultured with AT-MSCs using Transwell culture system (D) on inverted light 
microscopy (200×) and hepatocyte co-culture with AT-MSCs on a laser capture microdissection 
system (E, 200×; F, 400×): (A) primary hepatocytes occasionally aggregated into a few small-sized 
colonies containing 3–5 cells; (B) a greater number of hepatocytes aggregated and attached closely to 
liver NPCs; (C) far more hepatocytes aggregated massively into larger, oval-shaped colonies and attached 
closely to MSCs; (D) a relatively greater number of attached hepatocytes aggregated into scattered, small-
sized colonies; and (E,F) laser capture microscopy showed three-dimensional  aggregation of hepatocytes 
(arrows) on top of MSCs monolayer. 
3.3.2.3 Hepatocyte in direct co-culture with MSCs 
The great majority of freshly isolated human hepatocytes attached to the MSCs monolayer 
within 2–4 hours, and only a few hepatocytes were detached from the culture vessel surface at the 
time of culture media replacement. Adherent hepatocytes exhibited a morphology similar to those in 
co-culture with liver NPCs, but far more hepatocytes aggregated into larger, oval-shaped colonies 






showed that aggregated hepatocytes were attached on top of MSCs monolayer in a three-
dimensional manner (Figure 3.2E and F). 
3.3.2.4 Hepatocytes in indirect co-culture with MSCs 
Primary hepatocytes cultured with MSCs co-culture CM or indirectly co-cultured with MSCs 
on Transwell plates exhibited a morphology generally similar to those in mono-culture. Hepatocytes 
became adherent to collagen-coated culture vessel surfaces within 4–6 hours, and a large number of 
hepatocytes were detached at the time of culture media replacement. Adherent hepatocytes exhibited 
a morphology similar to those in mono-culture, and a relatively greater number of attached 
hepatocytes appeared to be aggregated into scattered, small-sized colonies (Figure 3.2D). The 
viability of primary hepatocytes on trypan blue exclusion also continued declining and neared zero 
on day 7 of in vitro culture. 
3.3.3 Hepatotrophic effect of NPCs co-culture 
3.3.3.1 Viability 
Liver NPCs co-culture improved hepatocyte viability as compared to hepatocyte mono-culture 
throughout 7 days of culture (Figure 3.3A). On day 1, hepatocyte viability had significantly declined 
in both co- and mono-cultures as compared to the baseline (approximately 62%); however, the 
viability of hepatocytes co-cultured with liver NPCs was significantly higher than that of mono-
cultured hepatocytes (co-culture vs. mono-culture: day 1, 40.6% ± 6.4% vs. 27.8% ± 3.1%; P <0.01). 
The viability of hepatocytes co-cultured with liver NPCs decreased at a relatively slower rate as 
compared to that of mono-cultured hepatocytes until day 7 (24.3% ± 4.2% vs. 1.5% ± 0.2%; P 
<0.01). 
3.3.3.2 Mitochondrial dehydrogenase activity 
Liver NPCs co-culture exhibited a significant hepatotrophic effect, with respect to 
mitochondrial dehydrogenase activity, as compared to hepatocyte mono-culture throughout 7 days of 
culture (Figure 3.3B). Hepatocytes co-cultured with liver NPCs had a significantly higher MTT 
activity than control mono-culture from day 1 (2.35 ± 0.20 vs. 1.40 ± 0.10 OD units; P <0.01) until 
day 7 (1.53 ± 0.12 vs. 0.59 ± 0.10 OD units; P <0.01).  
3.3.3.3 Cell attachment 
Liver NPCs co-culture exhibited a significant hepatotrophic effect, with respect to hepatocyte 
attachment, as compared to control (Figure 3.3C). Hepatocytes co-cultured with liver NPCs had a 
significantly higher SRB cell attachment than control mono-culture from day 1 (2.83 ± 0.30 vs. 2.40 
± 0.22 OD units; P <0.05) until day 5 (2.39 ± 0.36 vs. 1.99 ± 0.25 OD units; P <0.05), with a similar 




Figure 3.3 Viability (A), MTT activity (B), SRB cell attachment (C), albumin secretion (D), 
and urea synthesis (E) of hepatocytes co-cultured with liver NPCs versus hepatocyte mono-culture. 
Co-culture with liver NPCs showed significant hepatotrophic effect within 7 days of culture. All data 
were expressed as mean ± SD; *P <0.05 and **P <0.01 (n = 6). 
3.3.3.4 Albumin secretion 
No albumin secretion was detected in liver NPCs mono-culture. Liver NPCs co-culture 
exhibited a significant hepatotrophic effect, with respect to albumin secretion, as compared to 
control (Figure 3.3D). Albumin secretion remained significantly higher in liver NPCs co-culture than 
that in control mono-culture from day 3 (3.1 ± 0.6 vs. 1.1 ± 0.4 μg/106 hepatocytes; P <0.01) until 






3.3.3.5 Urea synthesis  
Liver NPCs co-culture also exhibited a significant hepatotrophic effect, with respect to urea 
synthesis, as compared to control (Figure 3.3E). Urea synthesis remained constantly higher in liver 
NPCs co-culture than that in control mono-culture from day 3 (27.2 ± 6.8 vs. 17.2 ± 3.0 μg/106 
hepatocytes; P <0.01) until day 7 (37.6 ± 8.0 vs. 17.8 ± 2.6 μg/106 hepatocytes; P <0.05). 
3.3.4 Optimisation of MSCs/hepatocyte co-culture 
3.3.4.1 Optimal source of MSCs for hepatocyte co-culture 
Proliferation of MSCs Cellular proliferation was similar among AT-, BM-, and UC-MSCs 
over 7 days of culture (Table 3.2). Mitochondrial dehydrogenase activity remained similar among 
three sources of MSCs from day 1 until day 7. SRB cell attachment also remained similar among 
these three sources of MSCs from day 1 until day 7. 
Table 3.2 MTT and SRB activities (mean ± SD) of MSCs over 7 days of culture 
 MTT (OD unit) SRB (OD unit) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
AT- 1.26 ± 0.06 1.55 ± 0.12 1.92 ± 0.20 2.30 ± 0.24 1.22 ± 0.12 1.60 ± 0.23 2.14 ± 0.26 2.43 ± 0.23 
BM- 1.12 ± 0.05 1.52 ± 0.10 2.02 ± 0.21 2.23 ± 0.21 1.28 ± 0.15 1.79 ± 0.19 2.20 ± 0.23 2.60 ± 0.34 
UC- 1.14 ± 0.04 1.56 ± 0.12 1.68 ± 0.22 2.22 ± 0.19 1.18 ± 0.13 2.06 ± 0.19 2.16 ± 0.25 2.40 ± 0.27 
Mitochondrial dehydrogenase activity ADFs co-culture showed a significant 
hepatotrophic effect as compared to control mono-culture; MSCs co-culture also exhibited 
significant hepatotrophic effects, similar among three MSCs co-cultures, with respect to 
mitochondrial dehydrogenase activity, as compared to ADFs co-culture and control mono-culture 
(Figure 3.4A). Hepatocytes co-cultured with MSCs had a significantly higher MTT activity than 
those co-cultured with ADFs from day 3 (AT vs. BM vs. UC vs. ADFs vs. control, 1.62 ± 0.12 vs. 
1.65 ± 0.13 vs. 1.69 ± 0.09 vs. 1.44 ± 0.07 vs. 1.23 ± 0.12 OD units; P <0.05) and control mono-
culture from day 1 (1.65 ± 0.15 vs. 1.67 ± 0.16 vs. 1.58 ± 0.14 vs. 1.61 ± 0.17 vs. 1.39 ± 0.04 OD 
units; P <0.05) until day 7 (2.59 ± 0.25 vs. 2.49 ± 0.24 vs. 2.38 ± 0.20 vs. 1.69 ± 0.16 vs. 1.25 ± 0.15 
OD units; P <0.01), respectively. 
Cell attachment ADFs co-culture showed a limited hepatotrophic effect as compared to 
control mono-culture; MSCs co-culture exhibited significant hepatotrophic effects, similar among 
three MSCs co-cultures, with respect to cell attachment as compared to ADFs co-culture and control 
mono-culture (Figure 3.4B). Hepatocytes co-cultured with MSCs had significantly higher SRB 
activity than those co-cultured with ADFs and control mono-culture from day 1 (3.07 ± 0.15 vs. 3.29 
± 0.16 vs. 3.24 ± 0.14 vs. 2.91 ± 0.17 vs. 2.75 ± 0.14 OD units; P <0.05) until day (3.58 ± 0.42 vs. 
3.70 ± 0.30 vs. 3.63 ± 0.25 vs. 3.17 ± 0.26 vs. 3.00 ± 0.26 OD units; P <0.01). 
Albumin secretion No albumin secretion was detected in ADFs and MSCs mono-culture. 
ADFs co-culture showed a significant hepatotrophic effect as compared to control mono-culture; 
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MSCs co-cultures also exhibited significant hepatotrophic effects, similar among three MSCs co-
cultures, with respect to albumin secretion, as compared to ADFs co-culture control mono-culture 
(Figure 3.4C). Hepatocytes co-cultured with MSCs had significantly higher albumin secretion than 
those co-cultured with ADFs and control mono-culture from day 3 (2.4 ± 0.3 vs. 2.5 ± 0.3 vs. 2.5 ± 
0.3 vs. 2.0 ± 0.2 vs. 0.9 ± 0.2 μg/106 hepatocytes; P <0.05) until day 7 (4.6 ± 0.4 vs. 4.6 ± 0.3 vs. 4.3 
± 0.3 vs. 3.6 ± 0.3 vs. 1.4 ± 0.2 μg/106 hepatocytes; P <0.01). 
Urea synthesis ADFs co-culture showed a significant hepatotrophic effect as compared to 
control mono-culture; MSCs co-cultures exhibited significant hepatotrophic effects, similar among 
three MSCs co-cultures, with respect to urea synthesis, as compared to ADFs co-culture and control 
mono-culture (Figure 3.4D). Hepatocytes co-cultured with MSCs had significantly higher urea 
synthesis than those co-cultured with ADFs and control mono-culture from day 3 (23.4 ± 2.2 vs. 23.7 
± 1.9 vs. 23.0 ± 1.9 vs. 19.4 ± 2.4 vs. 15.8 ± 2.0 μg/106 hepatocytes; P <0.05) until day 7 (35.9 ± 3.0 
vs. 36.4 ± 2.6 vs. 35.3 ± 2.5 vs. 32.1 ± 2.3 vs. 17.0 ± 2.4 μg/106 hepatocytes; P <0.01). 
Overall AT-MSCs co-culture exhibited a significant hepatotrophic effect, similar to BM- and 
UC-MSCs co-cultures, as compared to ADFs co-culture and hepatocyte mono-culture. Due to the 
practical advantages of AT-MSCs in contrast to BM- and UC-MSCs, AT-MSCs were determined to 





Figure 3.4 MTT activity (A), SRB cell attachment (B), albumin secretion (C), and urea synthesis (D) of hepatocytes co-cultured with AT-, BM-, and UC-MSCs versus 
hepatocytes co-cultured with ADFs and hepatocyte mono-culture. Co-culture with MSCs showed a significant hepatotrophic effect, similar among the three co-cultures, within 7 





3.3.4.2 Optimal MSC:hepatocyte co-culture ratio 
Mitochondrial dehydrogenase activity AT-MSCs co-cultures at all MSC:hepatocyte 
ratios exhibited a significant hepatotrophic effect, with respect to mitochondrial dehydrogenase 
activity, as compared to control mono-culture (Figure 3.5A). Hepatocytes co-cultured with AT-MSCs 
had significantly higher MTT activity than control mono-culture from day 1 (1:1 vs. 1:2.5 vs. 1:5 vs. 
1:10 vs. control, 1.67 ± 0.19 vs. 1.75 ± 0.24 vs. 1.60 ± 0.20 vs. 1.65 ± 0.18 vs. 1.39 ± 0.10 OD units; 
P <0.05) until day 7 (2.65 ± 0.26 vs. 3.43 ± 0.24 vs. 2.90 ± 0.20 vs. 3.05 ± 0.25 vs. 1.25 ± 0.15 OD 
units; P <0.01). Of note, the 1:2.5 co-culture tended to have the highest hepatocyte mitochondrial 
dehydrogenase activity as compared to the other co-cultures on day 7 of culture. 
Cell attachment AT-MSCs co-cultures at all MSC:hepatocyte ratios exhibited a significant 
hepatotrophic effect, with respect to cell attachment, as compared to control mono-culture (Figure 
3.5B). Hepatocytes co-cultured with AT-MSCs had significantly higher SRB activity than control 
mono-culture from day 1 (3.34 ± 0.20 vs. 3.51 ± 0.19 vs. 3.38 ± 0.22 vs. 3.22 ± 0.15 vs. 2.75 ± 0.10 
OD units; P <0.05) until day 7 (4.68 ± 0.40 vs. 5.58 ± 0.43 vs. 5.26 ± 0.50 vs. 4.97 ± 0.37 vs. 3.00 ± 
0.30 OD units; P <0.01). Of note, all co-cultures had similar hepatocyte SRB attachment throughout 
7 days of culture. 
Albumin secretion AT-MSCs co-cultures at all MSC:hepatocyte ratios exhibited a significant 
hepatotrophic effect, with respect to albumin secretion, as compared to control mono-culture (Figure 
3.5C). Hepatocytes co-cultured with AT-MSCs had significantly higher albumin secretion than 
control mono-culture from day 3 (2.3 ± 0.3 vs. 2.5 ± 0.3 vs. 2.3 ± 0.3 vs. 2.3 ± 0.2 vs. 0.9 ± 0.2 
μg/106 hepatocytes; P <0.01) until day 7 (4.2 ± 0.4 vs. 4.7 ± 0.4 vs. 4.6 ± 0.4 vs. 4.3 ± 0.3 vs. 1.4 ± 
0.2 μg/106 hepatocytes; P <0.01). Of note, all co-cultures had similar albumin secretion throughout 7 
days of culture. 
Urea synthesis AT-MSCs co-cultures at all MSC:hepatocyte ratios exhibited a significant 
hepatotrophic effect, with respect to urea synthesis, as compared to control mono-culture (Figure 
3.5D). Hepatocytes co-cultured with MSCs had  significantly higher urea synthesis than control 
mono-culture from day 1 (21.6 ± 2.0 vs. 22.6 ± 2.3 vs. 21.8 ± 2.4 vs. 21.8 ± 1.6 vs. 18.0 ± 2.6 μg/106 
hepatocytes; P <0.05) until day 7 (35.7 ± 3.0 vs. 37.9 ± 3.0 vs.34.2 ± 2.9 vs. 36.4 ± 2.5 vs. 17.0 ± 2.4 
μg/106 hepatocytes; P <0.01). Of note, all co-cultures had similar albumin secretion throughout 7 
days of culture. 
Overall AT-MSCs co-culture at the MSC:hepatocyte ratio of 1:2.5 exhibited a significant 
hepatotrophic effect, as compared to hepatocyte mono-culture, similar to co-cultures at the ratio of 
1:1, 1:5, and 1:10. As AT-MSCs reached a 100% confluency at a density of approximately 20,000 
cells per cm2, the ratio of 1:2.5 was used in further experiments to exclude the possibility of MSCs 




Figure 3.5 MTT activity (A), SRB cell attachment (B), albumin secretion (C), and urea synthesis (D) of hepatocytes co-cultured with AT-MSCs at a predefined 
MSC:hepatocyte ratio of 1:1, 1:2.5, 1:5, and 1:10 versus hepatocyte mono-culture. Co-culture with MSCs at all predefined ratios exhibited significant hepatotrophic effect, to a 





3.3.5 Hepatotrophic effect of MSCs co-culture on cryopreserved and steatotic 
hepatocytes 
3.3.5.1 Hepatotrophic effect of AT-MSCs co-culture on steatotic hepatocytes 
Mitochondrial dehydrogenase activity AT-MSCs co-culture exhibited a significant 
trophic effect on moderately steatotic hepatocytes, with respect to mitochondrial dehydrogenase 
activity, as compared to control mono-culture (Figure 3.6A). Moderately steatotic hepatocytes co-
cultured with MSCs had significantly higher MTT activity than control mono-culture from day 1 
(co-culture vs. mono-culture, 1.35 ± 0.20 vs. 0.70 ± 0.10 OD units; P <0.01) until day 7 (1.40 ± 0.20 
vs. 0.60 ± 0.10 OD units; P <0.01). 
Cell attachment AT-MSCs co-culture exhibited a significant trophic effect on moderately 
steatotic hepatocytes, with respect to cell attachment, as compared to control mono-culture (Figure 
3.6B). Moderately steatotic hepatocytes co-cultured with MSCs had significantly higher SRB 
activity than control mono-culture from day 1 (2.25 ± 0.30 vs. 1.80 ± 0.15 OD units; P <0.01) until 
day 7 (2.40 ± 0.39 vs. 1.83 ± 0.27 OD units; P <0.01). 
Albumin secretion AT-MSCs co-culture exhibited a significant trophic effect on moderately 
steatotic hepatocytes, with respect to albumin secretion, as compared to control mono-culture 
(Figure 3.6C). Hepatocytes co-cultured with MSCs had significantly higher albumin secretion than 
control mono-culture from day 3 (1.2 ± 0.3 vs. 0.5 ± 0.1 μg/106 hepatocytes; P <0.01) from day 7 
(2.4 ± 0.2 vs. 0.9 ± 0.1 μg/106 hepatocytes; P <0.01). 
Urea synthesis AT-MSCs co-culture exhibited a significant trophic effect on moderately 
steatotic hepatocytes, with respect to urea synthesis, as compared to control mono-culture (Figure 
3.6D). Hepatocytes co-cultured with MSCs had significantly higher urea synthesis than control 
mono- culture from day 1 (17.6 ± 1.4 vs. 9.0 ± 1.0 μg/106 hepatocytes; P <0.01) until day 7 (25.4 ± 
2.3 vs. 8.5 ± 0.9 μg/106 hepatocytes; P <0.01). 
3.3.5.2 Hepatotrophic effect of AT-MSCs co-culture on cryopreserved hepatocytes 
Mitochondrial dehydrogenase activity AT-MSCs co-culture exhibited a significant 
trophic effect on cryopreserved hepatocytes, with respect to mitochondrial dehydrogenase activity, as 
compared to control mono-culture (Figure 3.7A). Moderately steatotic hepatocytes co-cultured with 
AT-MSCs had significantly higher MTT activity than control mono-culture from day 1 (co-culture vs. 
mono-culture, 1.12 ± 0.14 vs. 0.68 ± 0.10 OD units; P <0.01) until day 7 (1.44 ± 0.21 vs. 0.54 ± 0.11 
OD units; P <0.01). 
Cell attachment AT-MSCs co-culture exhibited a significant trophic effect on cryopreserved 
hepatocytes, with respect to cell attachment, as compared to control mono-culture (Figure 3.7B). 
Moderately steatotic hepatocytes co-cultured with MSCs had significantly higher SRB activity than 
control mono-culture from day  1 (2.59 ± 0.33 vs. 1.80 ± 0.19 OD units; P <0.01) until day 7 (2.75 ± 
0.41 vs. 2.24 ± 0.32 OD units; P <0.01). 
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Figure 3.6 MTT activity (A), SRB cell attachment (B), albumin secretion (C), and urea 
synthesis (D) of moderately steatotic hepatocytes co-cultured with AT-MSCs at a ratio of 2.5:1 
versus hepatocyte mono-culture. Co-culture with MSCs had significant trophic effect on steatotic 
hepatocytes within 7 days of in vitro culture. All data were expressed as mean ± SD (error bar); *P <0.05 
and **P <0.01 versus control mono-culture (n = 6). 
Albumin secretion AT-MSCs co-culture exhibited a significant trophic effect on cryopreserved 
hepatocytes, with respect to albumin secretion, as compared to control mono-culture (Figure 3.7C). 
Hepatocytes co-cultured with AT-MSCs had significantly higher albumin secretion than control 
mono-culture from day 1 (0.7 ± 0.1 vs. 0.5 ± 0.1 μg/106 hepatocytes; P <0.01) until day 7 (2.1 ± 0.3 
vs. 0.9 ± 0.1 μg/106 hepatocytes; P <0.01). 
Urea synthesis AT-MSCs co-culture exhibited a significant trophic effect on cryopreserved 
hepatocytes, with respect to urea synthesis, as compared to control mono-culture (Figure 3.7D). 
Hepatocytes co-cultured with MSCs had significantly higher urea synthesis than control mono-
culture from day 1 (13.0 ± 1.6 vs. 8.8 ± 1.3 μg/106 hepatocytes; P <0.01) until day 7 (19.9 ± 2.3 vs. 





Figure 3.7 MTT activity (A), SRB cell attachment (B), albumin secretion (C), and urea 
synthesis (D) of cryopreserved hepatocytes co-cultured with AT-MSCs at a ratio of 2.5:1 versus 
hepatocyte mono-culture. Co-culture with MSCs had significant trophic effect on cryopreserved 
hepatocytes within 7 days of in vitro culture. All data were expressed as mean ± SD (error bar); *P <0.05 
and **P <0.01 versus control mono-culture (n = 6). 
3.3.6 Contribution of soluble factors to hepatotrophic effect of MSCs co-culture 
3.3.6.1 Soluble factors alone contribute minimally to hepatotrophic effect of MSCs co-culture 
Mitochondrial dehydrogenase activity MSCs indirect co-culture using Transwell plates 
exhibited no significant hepatotrophic effect, with respect to mitochondrial dehydrogenase activity, 
as compared to control mono-culture (Table 3.3). Mitochondrial dehydrogenase activity remained 
similar between indirect co-culture and control mono-culture from day 1. 
Cell attachment MSCs indirect co-culture exhibited no significant hepatotrophic effect, 
with respect to hepatocyte attachment, as compared to control mono-culture (Table 3.3). SRB cell 
attachment remained similar between indirect co-culture and control mono-culture from day 1 until 





Table 3.3 MTT activity and SRB cell attachment (mean ± SD) of hepatocytes indirectly co-
cultured with AT-MSCs on Transwell plates versus mono-cultured hepatocytes 
 MTT (OD unit) SRB (OD unit) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
iCo- 1.60 ± 0.16 1.30 ± 0.10 1.25 ± 0.10 1.31± 0.09 2.88 ± 0.20 3.10 ± 0.20 3.01 ± 0.16 3.05 ± 0.21 
Mono- 1.59 ± 0.18 1.25 ± 0.16 1.27 ± 0.18 1.29 ± 0.09 2.80 ± 0.14 2.91 ± 0.17 2.94 ± 0.15 2.99 ± 0.14 
iCo-, indirect co-culture; Mono-, mono-culture. 
Albumin secretion MSCs indirect co-culture exhibited no significant hepatotrophic effect, 
with respect to albumin secretion, as compared to control mono-culture (Table 3.4). Albumin 
secretion was similar between indirect co-culture and control mono-culture from day 1 until day 7. 
Urea synthesis MSCs indirect co-culture exhibited no significant hepatotrophic effect, 
with respect to urea synthesis, as compared to control (Table 3.4). Urea synthesis was similar 
between indirect co-culture and control mono-culture from day 1 until day 7. 
Table 3.4 Albumin secretion and urea synthesis (mean ± SD) of hepatocytes indirectly co-
cultured with AT-MSCs on Transwell plates versus mono-cultured hepatocytes 
 Albumin (μg/106 hepatocytes) Urea (μg/106 hepatocytes) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
iCo- 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 18.6 ± 2.4 16.9 ± 2.5 17.1 ± 2.4 15.6 ± 2.0
Mono- 1.0 ± 0.1 0.9 ± 0.2 1.1 ± 0.2 1.2 ± 0.2 19.0 ± 2.3 17.5 ± 2.3 16.7 ± 2.8 17.0 ± 3.0
iCo-, indirect co-culture; Mono-, mono-culture. 
3.3.6.2 MSCs co-culture CM have minimal hepatotrophic effect 
Mitochondrial dehydrogenase activity MSCs co-culture CM exhibited a limited 
hepatotrophic effect, with respect to mitochondrial dehydrogenase activity, as compared to control 
mono-culture throughout 7 days of indirect co-culture (Table 3.5). Hepatocytes cultured with MSCs 
co-culture CM had significantly higher MTT activity than mono-cultured hepatocytes (CM culture 
vs. mono-culture, 1.58 ± 0.15 vs. 1.39 ± 0.14 OD units; P <0.01) on day 1; however, mitochondrial 
dehydrogenase activity remained similar between hepatocytes cultured with MSCs co-culture CM 
and mono-cultured hepatocytes from day 3 until day 7. 
Cell attachment MSCs co-culture CM exhibited no significant hepatotrophic effect, with 
respect to hepatocyte attachment, as compared to control mono-culture (Table 3.5). SRB cell 
attachment remained similar between hepatocyte cultured with MSCs co-culture CM and mono-
cultured hepatocytes from day 1 until day 7. 
Table 3.5 MTT activity and SRB cell attachment (mean ± SD) of hepatocytes cultured with 
AT-MSCs co-culture CM versus mono-cultured hepatocytes 
 MTT (OD unit) SRB (OD unit) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
Cond 1.58 ± 0.15** 1.21 ± 0.19 1.25 ± 0.10 1.29 ± 0.17 2.71 ± 0.26 2.91 ± 0.24 2.93 ± 0.26 2.97 ± 0.24 
Mono- 1.39 ± 0.14 1.23 ± 0.15 1.24 ± 0.16 1.25 ± 0.18 2.75 ± 0.27 2.86 ± 0.23 2.93 ± 0.25 3.00 ± 0.22 
Cond, conditioned; Mono-, mono-culture; **P< 0.01 versus mono-culture.  
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Albumin secretion No albumin secretion was detected in MSCs mono-culture. MSCs co-
culture CM exhibited no significant hepatotrophic effect, with respect to albumin secretion, as 
compared to control mono-culture (Table 3.6). Albumin secretion remained similar between 
hepatocytes cultured with MSCs co-culture CM and mono-cultured hepatocytes from day 1 until day 
7. 
Urea synthesis MSCs co-culture CM exhibited no significant hepatotrophic effect, with 
respect to urea synthesis, as compared to control mono-culture (Table 3.6). Urea synthesis was 
similar between hepatocytes cultured with MSCs co-culture CM and mono-cultured hepatocytes 
from day 1 until day 7. 
Table 3.6 Albumin secretion and urea synthesis (mean ± SD) of hepatocytes cultured with 
AT-MSCs co-culture CM versus mono-cultured hepatocytes 
 Albumin (μg/106 hepatocytes) Urea (μg/106 hepatocytes) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
Cond 1.0 ± 0.1 1.0 ± 0.3 1.1 ± 0.2 1.2 ± 0.1 19.0 ± 2.6 15.6 ± 2.6 16.4 ± 2.3 15.6 ± 2.6 
Mono- 0.9 ± 0.1 0.9 ± 0.2 1.2 ± 0.3 1.4 ± 0.2 18.0 ± 2.6 15.8 ± 2.8 15.9 ± 1.9 17.0 ± 2.0 
Cond, conditioned; Mono-, mono-culture. 
3.3.7 Anti-apoptotic effect of MSCs co-culture on hepatocytes 
3.3.7.1 MSCs co-culture suppresses caspase-mediated spontaneous hepatocyte apoptosis 
MSCs direct co-culture No CCK18 or CK18 release was detected in MSCs mono-culture. 
Direct co-culture with MSCs significantly reduced CCK18 release from hepatocytes as compared to 
control mono-culture (Figure 3.8A). Soluble CCK18 level remained significantly lower in 
hepatocytes co-cultured with MSCs than that in mono-cultured hepatocytes from day 1 (co-culture 
vs. mono-culture, 18.5 ± 1.4 vs. 23.6 ± 1.5 U/106 hepatocytes; P <0.01) until day 7 (0.3 ± 0.1 vs. 1.6 
± 0.1 U/106 hepatocytes; P <0.01). Direct co-culture with MSCs also significantly reduced CK18 
release from hepatocytes, as compared to hepatocyte mono-culture (Figure 3.8B), from day 1 (91.2 ± 
8.2 vs. 123.6 ± 16.3 U/106 hepatocytes; P<0.01) until day 7 (20.0 ± 1.9 vs. 52.0 ± 5.0 U/106 
hepatocytes; P <0.01). As is shown in Figure 3.8C, CCK18/CK18 ratio (cell death mode; Figure 
3.8C) remained similar between co-cultured hepatocytes and mono-cultured hepatocytes from day 1 
(20.2% ± 3.0% vs. 19.1% ± 2.6%; P >0.05) until day 7 (1.5% ± 0.1% vs. 3.0% ± 0.4%; P >0.05). 
MSCs indirect co-culture using Transwell plates Indirect co-culture with MSCs had no 
significant effect on hepatocyte CCK18 or CK18 release as compared to control mono-culture (Table 
3.7). Soluble CCK18 level remained similar between hepatocytes indirectly co-cultured with MSCs 
and mono-cultured hepatocytes from day 1 until day 7. Soluble CK18 level also remained similar 
between hepatocytes indirectly co-cultured with MSCs and mono-cultured hepatocytes from day 1 
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until day 7. CCK18/CK18 ratio remained similar between hepatocytes indirectly co-cultured with 
MSCs and  mono-cultured hepatocytes (Table 3.4) from day 1 until day 7. 
 MSCs co-culture CM MSCs co-culture CM had no significant effect on hepatocyte 
CCK18 or CK18 release from s as compared to control mono-culture (Table 3.8). Soluble CCK18 
level remained similar between hepatocytes cultured with MSCs co-culture CM and mono-cultured 
hepatocytes from day 1 until day 7. Soluble CK18 level also remained similar between hepatocytes 
cultured with MSCs co-culture CM and mono-cultured hepatocytes from day 1 until day 7. 
CCK18/CK18 ratio remained similar between hepatocytes cultured with MSCs co-culture CM and  






Figure 3.8 CCK18 release (A), CK18 release (B), and CCK18/CK18 ratio (C) of hepatocytes 
cultured with AT-MSCs versus mono-cultured hepatocytes. MSCs co-culture significantly reduced 
caspase-mediated apoptosis and total death of hepatocytes without altering cell death mode within 7 days 






Table 3.7  CCK18 release, CK18 release, and CCK18/CK18 ratio (mean ± SD) of hepatocytes indirectly co-cultured with MSCs versus mono-cultured hepatocytes 
 CCK18 (U/106 hepatocytes) CK18 (U/106 hepatocytes) CCK18/CK18 ratio (%) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
iCo- 20.8 ± 2.4 23.2 ± 2.3 15.9 ± 1.7 1.6 ± 0.2 108.8 ± 12.4 390.0 ± 35.0 276.0 ± 33.0 50.4 ± 4.6 19.1 ± 2.8 5.9 ± 1.1 5.8 ± 1.3 3.2 ± 0.1 
Mono- 23.6 ± 2.5 21.0 ± 2.5 15.7 ± 1.5 1.6 ± 0.2 123.6 ± 16.4 352.0 ± 39.0 259.5 ± 35.0 52.0 ± 4.0 19.1 ± 2.5 8.2 ± 1.3 6.1 ± 1.1 3.1 ± 0.3 
iCo-, indirect co-culture; Mono-, mono-culture. 
Table 3.8  CCK18 release, CK18 release, and CCK18/CK18 ratio (mean ± SD) of hepatocytes cultured with MSCs co-culture CM versus mono-cultured hepatocytes 
 CCK18 (U/106 hepatocytes) CK18 (U/106 hepatocytes) CCK18/CK18 ratio (%) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
iCo- 20.3 ± 2.1 22.5 ± 2.0 16.3 ± 1.8 2.0 ± 0.4 110.5 ± 12.5 360.0 ± 33.3 286.0 ± 31.7 54.1 ± 4.0 18.4 ± 2.0 6.3 ± 1.1 5.7 ± 1.0 3.7 ± 0.2 
Mono- 23.8 ± 2.6 21.0 ± 2.4 15.9 ± 2.0 2.1 ± 0.3 123.5 ± 14.0 358.0 ± 40.0 266.7 ± 33.0 54.1 ± 4.3 19.3 ± 2.4 5.9 ± 1.2 6.0 ± 1.1 3.9 ± 0.2 
Cond, conditioned; Mono-, mono-culture. 
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3.3.7.2 MSCs co-culture protects hepatocytes from staurosporine-induced cell apoptosis 
Effect of staurosporine on hepatocytes Addition of 0.5-μM staurosporine had no 
significant effect on CCK18 release from hepatocytes as compared to blank control; however, the 
presence of 1-, 2.5-, 5-, and 10-μM staurosporine significantly increased soluble CCK18 level as 
compared to that of 0.5-μM staurosporine (0.5 μM vs. 1 μM vs. 2.5 μM vs. 5 μM vs. 10 μM, 24.7 ± 
2.9 vs. 44.7 ± 3.6 vs. 51.2 ± 5.0 vs. 56.1 ± 5.5 vs. 70.2 ± 5.7 U/106 hepatocytes; P <0.01; Figure 3.9A) 
in a dose-dependent manner. Similarly, addition of 0.5-μM staurosporine had no significant effect on 
CK18 release from hepatocytes as compared to that of 0-μM staurosporine; however, in the presence 
of 1-, 2.5-, 5-, and 10-μM staurosporine significantly increased soluble CK18 level as compared to 
that at 0.5-μM staurosporine (136.1 ± 14.8 vs. 156.9 ± 18.9 vs.176.0 ± 20.4 vs. 187.3 ± 25.0 vs. 204.8 
± 17.9 U/106 hepatocytes, P <0.01; Figure 3.9B) in a dose-dependent manner. Moreover, addition of 
1-, 2.5-, 5-, and 10-μM staurosporine switched cell death mode of hepatocytes from necrosis (lower 
CCK18/CK18 ratio) to apoptosis (higher CCK18/CK18 ratio) as shown in Figure 3.9C. 
Effect of MSCs co-culture on staurosporine-induced hepatocyte apoptosis Hepatocytes 
co-cultured with or without MSCs were subjected to 1-μM staurosporine to investigate whether 
MSCs co-culture could protect hepatocytes from chemically-induced apoptosis. As is shown in 
Figure 3.10A, co-culture with MSCs significantly reduced staurosporine-induced hepatocyte 
apoptosis (soluble CCK18 level) as compared to hepatocyte mono-culture: co-culture vs. mono-
culture vs. blank, 26.5 ± 2.5 vs. 44.7 ± 6.3 vs. 21.2 ± 2.1 U/106 hepatocytes (P <0.01). However, 
MSCs co-culture had no significant effect on staurosporine-induced total cell death (soluble CK18 
level) of hepatocytes (Figure 3.10B): 148.0 ± 10.7 vs. 156.9 ± 18.9 vs. 111.3 ± 17.0 U/106 
hepatocytes (P <0.01). Moreover, MSCs co-culture reversed staurosporine-induced necrosis-to-
apoptosis switch of hepatocyte death mode (Figure 3.10C): CCK18/CK18 ratio, 18.0% ± 2.2% vs. 






Figure 3.9 CCK18 release (A), CK18 release (B), and CCK18/CK18 ratio (C) of hepatocytes 
subjected to 0-, 0.5-, 1-, 2.5-, 5-, 10-μM staurosporine. Addition of 0.5-μM staurosporine had no 
significant effect on apoptosis, total death, and death mode of hepatocytes, while  addition of 1-, 2.5-, 5-, 
and 10-μM staurosporine significantly increased apoptosis and total death of hepatocytes in a dose-
dependent manner and switched cell death mode of hepatocytes from necrosis to apoptosis. All data were 









Figure 3.10 CCK18 release (A), CK18 release (B), and CCK18/CK18 ratio (C) of hepatocytes 
subjected to 1-μM staurosporine and co-cultured with or without AT-MSCs versus hepatocyte 
mono-culture treated without staurosporine. Addition of staurosporine significantly increased caspase-
mediated apoptosis and total death of hepatocytes and switched death mode of hepatocytes from necrosis 
to apoptosis, while MSCs co-culture significantly reduced staurosporine-induced hepatocyte apoptosis 
and reversed death mode switch. All data were expressed as mean ± SD; **P <0.01 versus non-
staurosporine-treated, mono-cultured hepatocytes; ^^P <0.01 versus staurosporine-treated, mono-cultured 







3.4.1 Potentials of liver NPCs in HCT 
Multiple techniques have been reported to separate liver NPCs from parenchymal cells 
(hepatocytes), among which selective enzymatic digestion and unit gravity sedimentation is most 
frequently used, due to the fact that NPCs are in a relatively small size. Doolittle et al. (1987) 
identified and characterised an unfractioned population of liver NPCs by flow cytometry and 
reaffirmed that cell size was linearly correlated to the sedimentation velocity. Primary liver NPCs 
were successfully isolated in the present work using the modified protocol as previously reported 
(Najimi et al., 2007); the purity of liver NPCs was over 90% as determined on cell morphology 
following the first culture medium refreshment.  
NPCs occupy only 6.5% of the total volume of the liver but account for approximately 40% of 
the total number of liver cells. Liver NPCs themselves are highly heterogeneous, in terms of cell 
morphology, functionality, and topography, consisting of sinusoidal hepatic endothelial cells, 
Kupffer cells, and hepatic stellate cells lining the liver sinusoid, as well as ‘‘pit cells’’, namely, liver 
residing lymphocytes. Liver NPCs play an active role in regulating biological activities of 
hepatocytes in vivo, including hepatocyte survival, proliferation, maintenance, and metabolism. In 
addition, liver NPCs are also involved in inflammatory and immune responses of the liver in the 
setting of sepsis (Scott et al., 2005), malignancy, autoimmune disorder, and immune rejection (Chen 
et al., 2002).  
Liver NPCs show a significant trophic effect on hepatocytes co-cultured in vitro. Sinusoidal 
endothelial cells and Kupffer cells regulate hepatocyte secretion of albumin and alpha 1-acid 
glycoprotein by monokines (especially IL-6), dexamethasone, and inducible nitric oxide synthase 
pathway (Itoh et al., 1994). In a study regarding bioartificial liver system, co-cultivation of 
hepatocytes with NPCs significantly multiplied amino acid conversion, lactate production, nitrogen 
metabolism, drug detoxicification, and clearance of aggregated gamma-globulin as compared to 
hepatocytes alone (Nedredal et al., 2007). The present work showed that co-culture of hepatocytes 
with autologous liver NPCs even at a very low NPC:hepatocyte ratio (1:10) was still beneficial with 
respect to overall cellular viability, attachment, and liver-specific metabolic function. It suggests a 
possibility that co-transplantation of autologous liver NPCs can improve current HCT practice. An 
additional benefit of co-transplanting NPCs is to protect parenchymal cells from immune elimination. 
Yang et al. (2009) reported that hepatic stellate cells had a profound inhibitory effect on T-cells and 
effectively prevented islet allografts from acute rejection in mice. These comprehensive T-cell 
inhibitory activities included induction of apoptosis of graft-infiltrating antigen-specific effector T-
cells and marked expansion of CD4(+) Forkhead box protein 3(+) T-regulatory cells by interferon-
gamma signalling (Yang et al., 2009). 
However, the use of co-culture of hepatocytes with liver NPCs is primarily limited by the high 
intrinsic heterogeneity (Pan et al., 1996) and possible fibrogenic potential of NPCs in the presence of 
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profibrotic factors (Perepelyuk et al., 2013). These limitations result in unfavourable reproducibility 
and safety profile of NPCs co-culture. The present work showed that expansion potential of primary 
liver NPCs isolated from adult donors was very limited as the great majority of this heterogeneous 
cell population is terminally differentiated. Moreover, cellular components and constituents 
remained unevaluated among previous studies regarding co-culture of hepatocytes with liver NPCs. 
A study regarding fractioning and characterising liver NPCs by immunophenotyping is ongoing in 
our research group. 
3.4.2 Hepatotrophic effect of MSCs co-culture on human hepatocytes 
3.4.2.1 Optimisation of cellular source and ratio for MSCs co-culture 
In vitro hepatotrophic effect of MSCs co-culture has been well documented in current literature. 
Gu and his colleagues (2009a; 2009b; 2009c) isolated BM-MSCs from pigs and preserved the 
morphology and liver-specific metabolic function of porcine hepatocytes in a three-dimensional co-
culture system. Fitzpatrick et al. (Cell Transplant, Epub ahead of print) also co-cultured human 
hepatocytes with human UC matrix-derived MSCs and successfully improved viability and 
functionality of co-cultured hepatocytes. Whether AT-MSCs has comparable trophic effect on co-
cultured hepatocytes remains occasionally studied as AT-MSCs are a new family member of MSCs. 
No da et al. (2012) co-cultured human hepatocytes isolated from partial hepatectomy specimen and 
human AT-MSCs at a ratio of 1:1 to generate hepatocyte spheroids and improved albumin secretion 
and CYP450 activity of co-cultured hepatocytes over one week. Chen et al. (2012) isolated AT-
MSCs from human orbital fat and co-cultured these MSCs with rat hepatocytes; this co-culture 
protected rat hepatocytes from ALF serum by upregulating immunomodulatory IL-6. Saito et al. 
(2013) reported that AT-MSCs transplantation attenuated ischaemia/reperfusion-induced liver injury 
and promoted liver regeneration as early as 6 hours after reperfusion by upregulating VEGF 
expression. The present work demonstrated for the first time that human AT-MSCs had a significant 
trophic effect on co-cultured human hepatocytes, to an extent similar to BM- and UC-MSCs. As AT-
MSCs are more readily available and subject to less ethical controversies, AT-MSCs are determined 
to be the optimal MSCs for hepatocyte co-culture.  
The present work also showed that human MSCs co-culture improved hepatocyte cellular 
activity and liver-specific metabolic function to a greater extent than human ADFs co-culture. 
NIH/3T3 cells, a standardised fibroblast cell line, are frequently used as the ‘‘feeder cells’’ for co-
cultured hepatocytes in bioartificial liver and in vitro drug hepatotoxicity screening systems (Cho et 
al., 2007; Chan et al., 2013). Devitalised fibroblasts and fibroblast CM alone were reported to be 
minimally hepatotrophic in vitro (Bhandari et al., 2001). Hepatotrophic effect of fibroblast co-
culture is believed to synergistically result from homotypic hepatocyte-to-hepatocyte interaction, 
heterotypic hepatocyte-to-fibroblast communication, hepatocyte-to-ECM contact, and soluble factors. 
Therefore, greater hepatotrophic effect of MSCs co-culture may be derived from potentiated 
synergistic effect of these factors rather than as adherent matrix or source of paracrine factors alone. 
82 
 
Theoretically a small number of MSCs should exhibit a significant trophic effect on co-cultured 
hepatocytes in vitro as liver NPCs occupy only a small portion of liver cells. Gu et al. (2009c) 
randomly co-cultured hepatocytes and BM-MSCs and predefined MSC:hepatocyte ratio at 1:1, 1:2, 
1:5, and 1:10, respectively, with the total cell number fixed at 1 million per well; the optimal liver-
specific metabolic function was achieved in the co-culture at the ratio of 1:2, with respect to albumin 
secretion and urea synthesis, which reached the peak on day 2 of co-culture. Fitzpatrick et al. (Cell 
Transplant, Epub ahead of print) modified the co-culture protocol of hepatocytes with UC-MSCs 
(plating of hepatocytes followed by that of MSCs) and predefined MSC:hepatocyte ratio, with the 
number of hepatocytes fixed at 150,000/cm2, at 1:3, 1:6, and 1:10, respectively; UC-MSCs co-
culture exhibited a similar hepatotrophic effect, regardless of MSC:hepatocyte ratio, within 7 days of 
in vitro culture with respect to albumin secretion and urea synthesis. This similarity between low- 
and high-density UC-MSCs co-culture may be attributed to the fact that UC-MSCs are highly 
proliferative in vitro and able to reach the confluency within 7 days of culture even starting from a 
low seeding density. In contrast, the co-culture protocol was further modified in the present work, by 
seeding hepatocytes onto pre-existing AT-MSCs monolayer in a well-organised, three-dimensional 
manner, with MSC:hepatocyte ratio predefined, with the number of hepatocytes fixed at 50,000/cm2, 
at 1:1, 1:2.5, 1:5, and 1:10, respectively. The present work showed that even a very low seeding 
density of AT-MSCs (5,000/cm2) still had trophic effect on co-cultured hepatocytes generally similar 
to the high-density AT-MSCs (50,000/cm2). This similarity between low- and high-density AT-MSCs 
may result from the fact that AT-MSCs have a relatively large cell size compared to BM- and UC-
MSCs and provide adequate cellular and matrical surface even at a low seeding density. AT-MSCs 
normally reach 100% confluency at a density of 25,000/cm2; therefore, the optimal MSC:hepatocyte 
ratio was determined to be 1:2.5, equalling a 20,000/cm2 seeding density of MSCs, at which AT-
MSCs would become 100% confluent within a very short time, to exclude the possible confounding 
effect of MSCs proliferation in vitro throughout co-culture. 
3.4.2.2 Hepatotrophic effect of MSCs co-culture on steatotic hepatocytes 
A seriously steatotic donor liver rejected for the use of OLT will normally also fail isolation of 
hepatocytes. The paradox arising from availability of donor liver is that only poor-quality, usually 
steatotic, donor liver tissues will be assigned for HCT use in most cases. Furthermore, isolated 
steatotic hepatocytes normally exhibit a poor metabolic function and susceptibility to cellular injury 
in vitro, although a steatohepatitis patient usually exhibit no abnormality in liver gross morphology 
and metabolic function (Donato et al., 2006; Donato et al., 2007). Compromise of steatotic 
hepatocytes may be compensated by the huge liver function reserve and a high-level hepatocyte self-
renewal and turnover, while steatotic hepatocytes have already shown morphological distortion and 
molecular dysregulation. Compensatory hepatic progenitor cell expansion accompanies steatotic 
hepatocyte replicative arrest (Cho et al., 2010), and steatotic liver is thought to be a suitable source 
for isolation of hepatic progenitor cells (Tolosa et al., 2011). 
A comparative genomic profiling analysis in obese insulin-resistant Zucker rats with 
83 
 
spontaneous liver steatosis demonstrated that dysregulated expression of metabolic and survival 
genes, including defence/acute phase-, detoxification-, cell growth/proliferation-, and protein 
synthesis/transformation-associated genes might lead to the vulnerability of steatotic hepatocytes to 
cell injury (Buqué et al., 2010), e.g., hypoxia-reoxygenation injury, which could be reversed by 
defatting (Berthiaume et al., 2009) and mitochondrial uncoupling protein-2 blockade (Evans et al., 
2012). Activation of TGF-β signalling and production of ROS are reported to contribute to 
hepatocyte death and lipid accumulation in non-alcoholic steatohepatitis (Yang et al., 2013) and also 
sensitise  hepatocyte susceptibility to acute toxic effect of acetaminophen (Kučera et al., 2012) and 
proapoptotic effect of TNF-α (Zhang et al., 2010). 
Hayashi et al. (2007) reported an interesting rat steatotic HCT study: steatotic hepatocytes 
secreted significantly less albumin in vitro than nonsteatotic counterparts; however, intrasplenically 
transplanted steatotic hepatocytes produced a serum albumin level similar to nonsteatotic cells. It is 
possible that in vivo factors, such as growth factors and soluble cytokines, improve steatotic 
hepatocyte metabolic function by modifying and improving cellular biological and molecular 
activities. Sun et al. (2003) showed that IL-6 pretreatment prevented sinusoidal endothelial cell 
death in response to ischaemia/reperfusion injury, activated cell survival signal transducer and 
activator of transcription factor 3 in both hepatocytes and sinusoidal endothelial cells, and also 
improved steatotic liver isograft microcirculation. Hong et al. (2004) further demonstrated that 
protective effect of IL-6 treatment on steatotic hepatocytes in vivo resulted from increased 
mitochondrial β oxidation of fatty acid and export of triglyceride and cholesterol as mediated by 
peroxisome proliferator-activated receptor α and TNF-α signalling pathways. The present work 
reported for the first time that MSCs co-culture could also improve cellular activity and liver-
specific metabolic function of steatotic hepatocytes as for nonsteatotic hepatocytes. The effect size 
of MSCs co-culture was similar between steatotic hepatocytes and nonsteatotic hepatocytes as 
compared to mono-cultured counterparts, with respect to improvement in liver-specific metabolism. 
As reported by Gu and his colleagues (2009a), MSCs secreted a massive amount of IL-6 into 
hepatocyte co-culture system, and neutralization of IL-6 compromised hepatotrophic effect of MSCs 
co-culture with respect to albumin secretion and urea synthesis. The role of other in vivo factors, 
such other cytokines, ECM, and heterotypic hepatocyte-to-NPC interaction, in trophic effect of 
MSCs co-culture on steatotic hepatocytes remains to be investigated. A possible mechanism is that 
MSCs expedite ROS elimination in co-cultured hepatocytes as human BM-MSCs was reported to 
inhibit production of ROS in co-cultured macrophages in a dose-dependent manner by a paracrine 
mechanism (Tsyb et al., 2008)  
3.4.2.3 Hepatotrophic effect of MSCs co-culture on cryopreserved hepatocytes 
Cryopreservation was thought to be capable of preserving and maintaining the ultrastructural 
characteristics and metabolic, biochemical and toxicological functions of hepatocytes to some extent. 
However, cryopreserved hepatocytes are inevitably subject to loss of viability and impairment in 
metabolic function following thawing and plating. This freezing/thawing-associated injury results 
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from the underlying cellular and molecular changes. Rijntjes et al. (1986) reported that formation of 
more ‘blebs’, lipid droplets, and lysosomes were observed in cryopreserved hepatocytes after 
thawing, accompanied by increased lactate dehydrogenase release and decreased albumin secretion. 
This ultrastructural distortion was primarily attributed to the change in cytoplasmic osmolality and 
subsequent intracellular ice crystal formation. Dou et al. (1992) also recommended that at least a 38-
hour recovery time after seeding should be given for thawed human hepatocytes to stabilise cellular 
membrane integrity, protein synthesis, and drug metabolism enzymes. Interestingly, profound 
dysregulation of gene expression, invovled in liver-specific metabolism, cellular apoptosis, and 
proteasomal protein recycling, was observed in hepatocytes after plating rather than after thawing 
(Richert et al., 2006). Oxidative stress manifesting as intracellular accumulation of ROS was thought 
to partially contribute to this gene expression dysregulation (Stevenson et al., 2007). 
A major problem associated with thawing of cryopreserved adult human hepatocytes is poor 
attachment efficiency and rapid reduction in cellular survival. A lot of work has been done to 
improve viability and metabolic function of cryopreserved hepatocytes by modifying 
cryopreservation protocols and cryoprotectants. Birraux et al. (2002) reported that three-dimensional 
cryopreservation of rat hepatocytes sandwiched between two layers of collagen type I could 
adequately restore cellular and liver-specific metabolic function of hepatocytes. Lee et al. (2012) 
also reported that cryopreservation of spheroid hepatocytes was more effective in maintaining 
hepatocyte viability and liver-specific metabolic function as compared to that of single hepatocytes. 
These study findings suggested that ECM and cell-to-cell could recover cryopreserved hepatocytes 
from freezing/thawing injury to some extent. However, it is rarely reported in current literature how 
to improve culture of cryopreserved hepatocytes after thawing. Moshage et al. (1988) used 
precoating with homologous ECM to successfully reverse the deleterious effect of freezing/thawing 
on hepatocyte attachment efficiency and survival in vitro for over 4 weeks. The present work 
demonstrated for the first time that MSCs co-culture could also improve cellular activity and liver-
specific metabolic function of cryopreserved hepatocytes as for fresh hepatocytes with a similar 
effect size. Gu et al. (2009c) observed extensive deposition of ECM, such as fibronectin, laminin, 
and collagen type I, III, and V, in MSCs co-culture system, while silencing of genes encoding 
fibronectin, laminin, and collagen type I and V in MSCs could reduce albumin secretion and urea 
synthesis of co-cultured hepatocytes. It is also likely that MSCs protect the host cells from oxidative 
stress by secreting more superoxide dismutase 3 in the presence of inflammatory cytokines, such as 
TNF-α and interferon γ (Kemp et al., 2010). 
3.4.2.4 Paracrine mechanisms of MSCs co-culture hepatotrophic effect 
Hepatotrophic effect of MSCs co-culture is thought to result from three major aspects, 
including soluble cytokines secreted by MSCs, such as HGF, stem cell factor (Hu and Colletti, 2008), 
and other growth factors, ECM, and heterotypic cell-to-cell contact (Gómez-Aristizábal and Davies, 
2012). A large number of previous studies have documented contribution of soluble factors to 
trophic effect of MSCs on co-cultured cells of epithelial origin, such as islet cells (Park et al., 2010), 
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intestinal epithelial cells (Weil et al., 2009), and hepatocytes (Murakami et al., 2004), using the 
Transwell culture system. In this culture system, MSCs are separated from seed cells by the 
semipermeable culture insert to exclude the involvement of ECM and cell-to-cell contact but allow 
free transport of soluble cytokines and growth factors. 
BM-MSCs CM exhibited a potent trophic effect on rat hepatocytes with respect to albumin 
secretion and urea synthesis as compared to hepatocyte or co-culture CM although CM culture did 
not improve spheroid hepatocyte formation (Ijima et al., 2008). Gu et al. (2009a) further performed 
IL-6 neutralisation experiment and confirmed involvement of IL-6 in hepatotrophic effect of porcine 
BM-MSCs co-culture with respect to albumin secretion and urea synthesis. A recently published 
study regarding AT-MSCs co-culture with islet cells demonstrated that AT-MSCs CM improved 
porcine islet cell viability in a VEGF- rather than IL-6-dependent manner (Yamada et al., 2013). 
Mintz et al. (2014) also recently reported that CD34+ HSCs secreted 32 growth factors or cytokines 
associated with cell proliferation, survival, tissue repair, and wound healing. CD34+ stem cells CM 
also prevented chemically-induced hepatocyte death by inhibiting the caspase-3 signalling pathway. 
It remains controversial whether soluble factors released from MSCs also have a trophic effect 
on human hepatocytes. Fouraschen et al. (2012) reported that human liver-derived MSCs CM 
significantly upregulated expression levels of genes associated with protein synthesis, cell survival, 
and cell proliferation in human hepatocyte-like Huh7 cells. However, Fitzpatrick and her colleagues 
(Cell Transpl, Epub ahead of print) reported that neither MSCs indirect co-culture (MSCs separated 
from hepatocytes by a porous membrane) nor MSCs co-culture CM had minimal or insignficant 
trophic effect on human hepatocytes, in the absence of additional ECM deposition and hepatocyte-
to-MSC contact as shown in the present work. Minimal hepatotrophic effect of MSCs indirect co-
culture suggested that release of MSCs-derived trophic factors may require the extrinsic stimulation 
of heterotypic contact between MSCs and hepatocytes. Furthermore, insignficant hepatotrophic 
effect of MSCs co-culture CM implied a possibility that human hepatocytes did not respond well to 
MSCs-released trophic factors in vitro. Isolation of primary human hepatocytes is known to be 
technically more complex and time-consuming than that of animal-sourced hepatocytes. As a result, 
human hepatocytes may be in a relatively stressful status after isolation as compared to counterpart 
animal cells, and become less responsive to trophic stimuli. Taking significant hepatotrophic effect 
of MSCs direct co-culture, trophic effect of MSCs-derived soluble factors may require the 
synergistic effect of MSCs-derived ECM and hepatocyte-to-MSC interaction.  
3.4.3 Antiapoptotic effect of MSCs co-culture on hepatocytes 
Overall trophic effect of MSCs co-culture on liver-specific metabolic function of hepatocytes 
may result from two aspects, namely, increased hepatocyte survivability, potentiated metabolism of 
surviving hepatocytes, or both. It has been well documented in current literature that MSCs co-
culture significantly improved hepatocyte survival (Gu et al., 2009a; Gu et al., 2009b; Gu et al., 
2009c); however, there exists a knowledge gap whether MSCs inhibit apoptosis and/or necrosis of 
co-cultured hepatocytes. Fitzpatrick and her colleagues (Cell Transpl, Epub ahead of print) showed 
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that co-culture with UC-MSCs suppressed caspase-mediated apoptosis of hepatocytes within one 
month of culture in vitro. The present work further confirmed that AT-MSCs significantly reduced 
both spontaneous apoptotic and necrotic death of co-cultured hepatocytes without switching the 
death mode. 
Spontaneous apoptosis in mono-cultured hepatocytes is known to be a major cause of cellular 
loss of primary hepatocytes after culture in vitro. Spontaneous apoptotic death is controversially 
attributed to intracellular accumulation of nitric oxide following enzymatic digestion, which is 
invovled in the balance between proapoptotic and antiapoptotic effects on hepatocytes both in vitro 
and in vivo (Kim et al., 2000). Cleavage of CK18 by caspases is an early event in cellular apoptosis. 
Increased serum CCK18 level has been observed in patients afflicted with liver cirrhosis, primary 
graft dysfunction, ALF (Hetz et al., 2007), or non-alcoholic steatohepatitis (Yilmaz et al., 2009), 
suggesting hepatocyte apoptosis and liver degeneration in vivo. Caspase signalling is reported to be 
invovled in rat hepatocyte apoptosis induced by endotoxin as mediated by TNF-α and downstream 
TNF-α receptor 1 in Kupffer cells (Hamada et al., 1999). Cleavage of CK18 at the position detected 
by the M30 CytoDeath™ ELISA kit used in the present work was reported to be initiated by 
caspase-9 and executed by caspases-3 and -7 (Schutte et al., 2004), which could be inhibited by the 
caspase-inhibitor zVAD-fmk (Hägg et al., 2002). The present work also demonstrated that MSCs 
specifically suppressed staurosporine-induced apoptosis rather than necrosis of co-cultured 
hepatocytes, while staurosporine treatment is known to activate caspase-3 signalling independently 
of caspases-8, -9, and -12 (Feng and Kaplowitz, 2002). Thus, reduction in CCK18 release from co-
cultured hepatocytes as shown in the present work suggests that downregulation of caspase 
signalling may be implicated in antiapoptotic effect of MSCs co-culture on hepatocytes.  
MSCs inhibit apoptosis of epithelial cells via paracrine mechanisms. Human BM-MSCs CM 
enriched with IL-6, HGF, and VEGF enhances the viability and proliferation of hypoxia-injured 
human foetal intestinal epithelial cells with concomitantly downregulated caspase-3 expression 
(Weil et al., 2009). Rat islet cells co-cultured with BM-MSCs exhibited significantly upregulated 
expressions of antiapoptotic genes, such as Mapkapk-2, Tnip-1, and Bcl-3, concomitantly 
accompanied by increased IL-6 and TGF-β in the CM (Karaoz et al., 2010). Park et al. (2010) 
reported human UC-MSCs CM containing high-level IL-6 and -8, VEGF, HGF, and TGF-β had a 
significant antiapoptotic effect on mouse islet cells both in vitro and in vivo. Yeung et al. (2012) 
showed that human BM-MSCs protected human islet cells from cellular apoptosis induced by 
interferon γ, TNF-α, and IL-1β; cytoprotective factors secreted by BM-MSCs included HGF and 
matrix MMP-2 and 9. Du et al. (2013) infused concentrated rat MSCs CM into rat liver graft, which 
resulted in reduction of hepatocyte apoptosis and concomitant increase of VEGF and MMP-9. 
Xagorari et al. (2013) also reported that BM-MSCs CM containing IL-6 protected hepatocytes from 
CCl4-induced apoptosis through activation of fibroblast-like-protein signalling. However, the present 
work demonstrated paracrine factors contributed minimally to antiapoptotic effect of MSCs co-
culture. This inconsistence might be due to the possibility that isolated human primary hepatocytes 




In conclusion, the present work demonstrated that autologous liver NPCs had a significant 
trophic effect on human hepatocytes even at a very low co-culture density, although reproducibility 
and consistency of liver NPCs expansion in vitro remained debatable. Co-culture with AT-MSCs 
exhibited a significant trophic effect similar to those with BM- and UC-MSCs as compared to ADFs 
co-culture and hepatocyte mono-culture, while the effect size remained significant even at a low 
MSC:hepatocyte ratio. This suggests that hepatotrophic effect of MSCs co-culture derives from stem 
cell-specific factors, through a series of amplification effects. As optimisation of MSCs source and 
seeding density failed to further potentiate hepatotrophic effect of MSCs co-culture as shown in the 
present work, preconditioning of MSCs may be an effective alternative for optimising MSCs co-
culture system in vitro. 
Hepatotrophic effect of MSCs co-culture was also effective for steatotic and cryopreserved 
hepatocytes with a similar effect size for fresh, nonsteatotic hepatocytes. Moreover, MSCs co-culture 
significantly suppressed caspase-mediated apoptosis and necrosis of hepatocytes, and specifically 
inhibited staurosporine-induced hepatocyte apoptosis associated with caspase signalling activation. 
The absence of trophic and antiapoptotic effects on human hepatocytes as seen in MSCs indirect co-
culture and co-culture CM culture also implied a possibility that isolated human primary hepatocytes  
became unresponsive to paracrine stimuli from MSCs. Therefore, ECM and heterotypic interaction 
between MSCs and hepatocytes synergizing paracrine mechanisms are more likely to significantly 
contribute to hepatotrophic and antiapoptotic effects of MSCs co-culture, underlying which MSCs 
co-culture may down- and upregulate apoptosis- and antiapoptosis-associated gene expressions of 
hepatocytes primarily by non-paracrine mechanisms.  
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CHAPTER 4 HYPOXIC PRECONDITIONING POTENTIATES 
HEPATOTROPHIC EFFECTS OF MSCS CO-CULTURE 
4.1 Introduction 
4.1.1 Hepatotrophic effect of MSCs co-culture 
A number of previous studies demonstrated that MSCs co-culture improved survival, cellular 
activity, and liver-specific metabolism, such as albumin secretion, urea synthesis, and CYP450 
activity, of hepatocytes. MSCs support co-cultured hepatocytes through soluble factors, ECM, and 
cell-cell crosstalk in a three-dimensional architecture, which synergistically mimics a physiological 
microenvironment for hepatocytes in vitro. The work in Chapter 2 further validated that MSCs co-
culture had hepatotrophic effects and also applied to steatotic hepatocytes and cryopreserved 
hepatocytes, both of which are frequently encountered in HCT practice. Moreover, MSCs also 
inhibited spontaneous and chemically-induced apoptotic death of co-cultured hepatocytes, which 
might be a major contributive factor of MSCs. 
In the previous chapter, effort was made to optimise MSCs/hepatocyte co-culture system by 
testing three types of MSCs, namely, AT-, BM-, and UC-MSCs at an empirical seeding ratio of 1:2.5 
(MSC:hepatocyte). This finding suggested that even a very small number of MSCs were sufficient to 
maintain and improved co-cultured hepatocyte metabolism. There is a knowledge gap existing in 
current literature how to further potentiate MSCs hepatotrophic effect, which is expected to be 
technically less complex, biologically effective, and, more importantly, subject to no safety concern.  
4.1.2 Preconditioning of MSCs 
MSCs have been widely investigated for cellular replacement therapy and regenerative 
medicine. These multipotent cells can be driven to differentiate into a variety of cell types, including 
osteoblasts, chondrocytes, and adipocytes in the presence of specific extrinsic and intrinsic cues 
(Khan and Hardingham, 2012). MSCs also promote repair and regeneration of the injured cells and 
tissues, such as fibrotic liver (Tsai et al., 2009) and infarcted myocardium (Carvalho et al., 2013), 
through paracrine and nonparacrine mechanisms. However, it remains undetermined whether MSCs 
can maintain their biological and physiological activities after consecutive expansion in vitro and 
transplantation in vivo. Human MSCs will become replicatively senescent and (epi)genetically 
unstable through passages and consequently have their proliferation and differentiation potential 
impaired. An increasing number of chemically-defined culture media have been tested on in vitro 
priming of MSCs to ensure reliable engraftment and long-term therapeutic effect after 
transplantation (Tonti and Mannello, 2008). MSCs are frequently preconditioned using 
pharmacological (Wisel et al., 2009), biochemical and molecular (Khan et al., 2011), and physical 
techniques (Rosová et al., 2008) to optimise cellular functionality and improve cell graft survival, 
especially for transplantation to an inflammatory microenvironment (Herrmann et al., 2010). 
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4.1.2.1 Pharmacological preconditioning 
Lipopolysaccharide (LPS), the major component of the outer membrane of the Gram-negative 
bacteria, acts as an endotoxin and can elicit potent immune and inflammatory responses in humans 
and animals. Human BM-MSCs subjected to LPS secrete significantly higher levels of VEGF, FGF2, 
HGF, and IGF-1 in vitro by an NFκB- but not JNK-dependent mechanism (Crisostomo et al., 2008). 
LPS-preconditioned MSCs exhibit an enhanced survival after engraftment into the myocardium by 
upregulating VEGF expression, which consequently improve in vivo neovascularisation and cardiac 
function (Yao et al., 2009). LPS preconditioning can also protect MSCs from induced apoptosis. 
Wang et al. (2013) reported that low-dose LPS preconditioning preserved the mitochondrial 
transmembrane potential and inhibited Cyc-c release in rat BM-MSCs subjected to hypoxia and 
serum deprivation. Moreover, LPS preconditioning regulates MSCs immunomodulative effect. Mei 
et al. (2013) reported that LPS challenge significantly upregulated expression of inflammatory 
cytokines such as IL-1α, -1β, -6, and -8, and inhibitory immune mediators, such as indoleamine 2,3-
dioxygenase 1, cyclooxygenase 2, interferon β, and MMP-2, but downregulation of MMP-9, in 
human UC matrix-derived MSCs, mediated by the toll-like receptor. However, the use of LPS-
preconditioned MSCs for HCT is inevitably subject to the safety concern as endotoxin 
contamination is a major hazard to human subjects receiving cellular replacement therapy (Ra et al., 
2011).  
4.1.2.2 Biochemical and molecular preconditioning 
MSCs can be preconditioned with extrinsic cytokines and growth factors. MSCs exert the 
therapeutic effect by engrafting into the injured tissue possibly transdifferentiating into parenchymal 
cells and endothelial cells and/or secreting cytokines and growth factors. These soluble factors 
reciprocally act on MSCs to improve MSCs survival, mediate cellular functionality, and enhancing 
neoangiogenesis. Stromal-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12, is a 
chemokine protein that recruits immune and endothelial cells and regulates angiogenesis. SDF-1 
preconditioning significantly suppresses apoptosis in rat BM-MSCs subjected to hypoxia and serum 
deprivation (Chen et al., 2009). Preconditioning with diazoxide, a mitochondrial ATP-sensitive 
potassium channel agonist, can improve the survival rate of transplanted rat BM-MSCs by 
upregulating expression of bFGF and HGF, which reduces the myocardial infarction area and 
improves left ventricular function in rat myocardial infarction model (Cui et al., 2010). TGF-α 
upregulates rodent BM-MSCs secretion of VEGF, which can be further potentiated by the synergistic 
effect of TNF-α; TGF-α-preconditioned MSCs show a better therapeutic effect on rat 
ischaemia/reperfusion myocardium as mediated by downregulation of IL-1β, TNF-α, and caspase-3 
signalling pathways (Herrmann et al., 2010).  Moreover, MSCs isolated from a diseased donor may 
exhibit an impaired functionality due to the underlying biochemical insufficiency or genetic defect, 
which can be compensated or repaired by growth factor preconditioning. BM-MSCs isolated from 
streptozotocin-induced diabetic mice were preconditioned with IGF-1 and concomitant FGF-2; these 
preconditioned MSCs exhibited a significantly higher superoxide dismutase activity, less cellular 
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apoptosis, stronger in vitro tube-forming ability, and improved chemotactic mobility (Khan et al., 
2011). 
More importantly, preconditioning with soluble molecules was reported to potentiate the trophic 
and resuscitation capacity of MSCs; human AT-MSCs preconditioned with a combination of 
hyaluronic, butyric, and retinoic acids optimised islet cell graft revascularisation after intrahepatic 
co-transplantation, as mediated by VEGF, kinase insert domain receptor, and HGF signalling 
pathways, and  improved glycaemic control in diabetic rats (Cavallari et al., 2012). However, 
preconditioning with cytokines and growth factors, which has been validated to be effective on the 
bench, is not feasible and cost-effective for the purpose of bedside transplantation requiring a large 
number of MSCs to be preconditioned. Additionally it remains unknown whether preconditioning 
effect of these cytokines and growth factors can maintain in the long term after transplantation in 
vivo. Genetic engineering targeting at these favourable molecules, such as VEGF (Shevchenko et al., 
2013), HGF (Yu et al., 2007; Wang et al., 2013), and TGF-β (Guo et al., 2006; Xue et al., 2013), 
may be a solution to this uncertainty, while gene modification itself is technically complex and 
subject to some safety risks. 
4.1.2.3 Hypoxic preconditioning 
MSCs normally reside in a physiologically hypoxic niche, such as AT, BM, and UC. Hypoxia 
plays an important role in the fine equilibrium between proliferative and differentiation potentials of 
MSCs as mediated by a number of extrinsic and intrinsic signals. A long-term low-oxygen tension 
culture environment maintains MSCs in an undifferentiated, multipotent status. Human BM-MSCs 
cultured under 1%-O2 hypoxia showed a significantly increased proliferative ability and migration 
capability, underlying which were upregulated expression of stemness genes, such as OCT4, 
NANOG, SALL4, and KLF4 (Weijers et al., 2011; Hung et al., 2012). Hypoxic culture condition also 
determines the differentiation fate of MSCs towards osteoblasts, chondrocytes, and adipocytes. 
Hypoxia does not alter the immunophenotype or compromise the multi-lineage differentiation 
potential of BM-MSCs; however, hypoxia inhibits the transdifferentiation of MSCs into osteoblasts 
signalled by MAPK/ERK 1/2 (Wang et al., 2012), hypoxia-induced factor-1α (HIF-1α; Hsu et al., 
2013), and Notch1 (Xu et al., 2013). In contrast, MSCs exposed to chondrogenic growth factors and 
a 2% O2 hypoxic environment express significantly greater collagen type II and proteoglygan, two 
major components of cartilage (Kanichai et al., J Cell Physiol, 2008). Moreover, hypoxia mobilises 
MSCs into the circulating bloodstream in a way similar to HSCs (Rochefort et al., 2006), and 
promotes the domiciliation of MSCs to the injured site (Rochefort et al., 2005).  
Hypoxic preconditioning (HPc), namely, in vitro hypoxic culture followed by normoxic culture 
or transplantation in vivo, has been widely applied to optimise MSCs for uses of regenerative 
medicine and tissue engineering. HPc can protect MSCs from hypoxia/reoxygenation-induced 
apoptosis by stabilising mitochondrial membrane potential, upregulating Bcl-2 and VEGF signalling, 
and promoting phosphorylation of ERK and Akt (Wang et al., 2008). HPc significantly increases 
expression of pro-survival and pro-angiogenic factors, such as HIF-1α; angiopoietin 1, VEGF and 
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VEGF receptor, erythropoietin, Bcl-2, and Bcl-xL, and also significantly decreases that of caspase-3 
initiating cellular apoptosis in mouse BM-MSCs; HPc-MSCs improve angiogenesis in myocardium 
and enhance morphological and functional recovery (Hu et al., 2008). This potentiated therapeutic 
effect of transplanting HPc-MSCs has also been validated in experimental limb, cerebral, renal, and 
spinal cord ischaemia. HPc can rejuvenilise aged AT-MSCs by upregulating gene expression of pro-
angiogenic factors, including VEGF, placental growth factor, and HGF but downregulating that of 
TGF-β (Efimenko et al., 2011). Due to its technical simplicity and superior cost-effectiveness, HPc 
is a promising physical technique for optimising MSCs for cellular replacement therapy. However, it 
is rarely reported in literature whether HPc can potentiate the trophic and protective effects of MSCs 
on co-cultured or co-transplanted seed cells.  
4.1.3 ROS: a signalling factor pivoting HPc 
ROS refer to a collection of chemically reactive, oxygen-containing molecules, including 
radical, superoxide anion, hydrogen peroxide, and singlet oxygen. Production of ROS can occur in 
both physiological and pathological conditions, mainly in response to oxidative stress but also to 
exogenous sources, such as ionizing radiation. As a natural by-product of normal oxygen metabolism, 
excessive ROS may cause damage to cells by disrupting DNA and oxidising fatty acids, amino acids, 
and specific enzymes. However, ROS plays a crucial role in regulating cellular signalling and 
maintaining homeostasis. ROS are controversially thought to be involved in ageing, and also 
extensively studied in the scenario of cancer, including carcinogenesis, uncontrolled proliferation, 
escape from apoptosis, tumor cell invasion, neoangiogenesis and metastasis, and chronic 
inflammation bridging cancer.  
Exogenous ROS induce marked apoptosis of MSCs in a dose- and time-dependent manner 
through the endoplasmic reticulum and mitochondrial pathways, including p38 MAPK signalling at 
an early time point and c-Jun N-terminal kinase signalling at a late time point (Wei et al., 2010). 
MSCs, however, are well known to be resistant to the detrimental effect of excessive ROS by 
possession of a potent ROS scavenging facility (Valle-Prieto and Conget, 2010). Conversely HPc is 
known to significantly increase intracellular ROS activity and improve MSCs survival and motility. 
ROS plays a crucial role in maintaining undifferentiated status of human MSCs: decreased 
intracellular ROS activity accompanies transdifferentiation of MSCs into osteoblasts, while 
exogenous hydrogen peroxide prevents osteogenic differentiation (Chen et al., 2008). In contrast, 
increased intracellular ROS from upregulated expression of NAD(P)H oxidase 4 facilitates 
adipocyte differentiation of mouse embryonic MSCs by activating the transcription of cAMP 
response element-binding protein (Kanda et al., 2011). ROS controls the cell growth cycle and life 
span of human MSCs in vitro as mediated by upregulation of p38 MAPK signalling. ROS is also 
reported to regulate migration and tube formation (in vitro angiogenesis) of MSCs as mediated by 
placental growth factor signalling (Shyu et al., 2008). Increase of intracellular ROS results in 
significant downregulation of focal adhesion-related molecules, such as phospho-FAK (focal 
adhesion kinase) and phospho-Src, and integrin-related adhesion molecules, such as integrin 5α and 
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β1, suggesting the involvement of ROS in MSCs mobilisation and migration (Song et al., 2010). It is  
possible that intracellular ROS might mediate the hypothesised HPc-induced potentiation of MSCs 
hepatotrophic and antiapoptotic effects on co-cultured hepatocytes. 
4.1.4 Chapter objectives 
 Effects of HPc on MSCs 
To investigate the effects of HPc on AT-MSCs in vitro, with respect to cellular mitochondrial 
dehydrogenase activity, attachment, DNA/protein synthesis, and intracellular ROS activity. 
 Optimisation of time length of HPc 
To compare potentiative effect of 8-, 24-, 48-, and 72-h HPc on MSCs co-culture hepatotrophic 
effect, with respect to cellular viability, cell attachment, and liver-specific metabolism. 
 Potentiation of MSCs co-culture paracrine mechanisms by HPc  
To investigate whether HPc potentiates MSCs co-culture hepatotrophic effect by enhancing 
paracrine mechanisms. 
 Potentiation of MSCs co-culture antiapoptotic effect 
To investigate whether MSCs can protect co-cultured hepatocytes from chemically-induced cell 
apoptosis. 
 Dependence of HPc-induced potentiative effects on intra-MSCs ROS activity 
To investigate whether HPc induces potentiation of MSCs co-culture hepatotrophic and 
antiapoptotic effects in an intra-MSCs ROS activity dependent manner.  
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4.2 Materials and methods 
4.2.1 Subculture and immunophenotyping of AT-MSCs 
Human AT-MSCs were subcultured as described in Section 2.2, Subculture of MSCs. P6–8 
MSCs were characterised using flow cytometry with a human MSC phenotyping kit (Miltenyi 
Biotec Ltd., Surrey, UK). These MSCs were stained positive for CD73, CD90, and CD105, and 
negative for CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR surface antigens 
(Dominici et al., 2006). 
4.2.2 Isolation of human hepatocytes 
Human donor liver tissues were processed as described in Section 2.3, Primary Harvest of 
Human Hepatocytes. The total number and viability of fresh hepatocytes were determined using a 
hematocytometer and the trypan blue exclusion technique with a light microscope. Red blood cells 
in hepatocyte pellet were lysed using sterile water for injection for 1 min at room temperature, 
followed by centrifugation. The batch of hepatocytes with a viability of over 60% on trypan blue 
exclusion was used for further experiments. 
4.2.3 Optimisation of HPc 
P6–8 MSCs were subjected to hypoxia (HPc-MSCs) using an air-tight and moistened hypoxia 
incubator chamber (StemCell Technologies SARL, Sirocco, France; Figure 4.1), at 37°C for 8 h, 24 
h, 48 h, and 72 h, respectively. The chamber was purged with a mixture of 95% N2/5% CO2 (BOC 
Special Gases, Surrey, UK) for 3 min, and the flow rate was set at 20 L/min using a single flow 
meter (Billups-Rothenberg Inc., Del Mar, CA, USA) as recommended by the manufacturer. The 
intra-chamber oxygen saturation measured 2% (hypoxia) using a GasBadge® Plus single-gas 
monitor (Industrial Scientific, Arras, France) upon the completion of purge. MSCs that were cultured 
at an atmosphere of 95% air/5% CO2 served as control (NPc-MSCs), and the intra-incubator oxygen 
saturation measured 20% (normoxia) using the same protocol. MSCs morphology was examined 
using a standard light microscope. The experiments were performed in duplicate and repeated in 
triplicate independently. The optimal time length of HPc that exhibited the greatest potentiative 
effect on MSCs co-culture hepatotrophic effect was used in further experiments. 
4.2.4 Hepatocyte co-culture protocols 
4.2.4.1 Direct co-culture of hepatocytes with MSCs 
Fresh hepatocytes were co-cultured with HPc- versus NPc-MSCs as described in Section 2.4, 
Hepatocyte Mono-culture and Co-culture. The seeding density of MSCs was 20,000 viable cells 
per cm2, and that of hepatocytes was 50,000 viable cells per cm2, at a MSC:hepatocyte ratio of 1:2.5.  
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Figure 4.1 Hypoxia incubator chamber (left panel) and single flow meter (right panel). Air-
tight and moistened hypoxia incubator chamber was purged with a mixture of 95% N2/5% CO2 at a flow 
rate of 20 L/min to produce a hypoxic environment at an intra-incubator oxygen saturation measuring 20% 
(adapted from www.stemcell.com). 
Hepatocytes co-cultured with NPc-MSCs were used as control, and mono-cultured HPc- and NPc-
MSCs were used as blank controls. 
4.2.4.2 Indirect co-culture of hepatocytes with MSCs 
Indirect co-culture using Transwell Hepatocytes were indirectly co-cultured with HPc- versus 
NPc-MSCs using Transwell® Permeable Supports, as described in Section 3.2.5.5, Indirect co-
culture of hepatocytes with MSCs, to investigate whether HPc could potentiate contribution of 
MSCs-derived soluble factors to MSCs co-culture hepatotrophic effect.  
MSCs co-culture CM AT-MSCs were plated onto T75 culture flasks at a density of 
20,000 viable cells per cm2, and fed with hepatocyte culture media for 24-hour pre-culture at 37°C. 
Mono-cultured MSCs were subjected to 2%-O2 HPc and 20%-O2 NPc for 24 h, respectively. Fresh 
hepatocytes were cultured with HPc- versus NPc-MSCs co-culture CM as described in Section 
3.2.5.5, Indirect co-culture of hepatocytes with MSCs, to investigate whether HPc could potentiate 
paracrine contribution of MSCs co-culture to hepatotrophic effect. 
The culture media were refreshed on days 1, 3, 5, and 7, respectively. The cell morphology was 
examined using a standard inverted light microscope equipped with a digital SLR camera. Culture 
supernatants were collected into sterile 1.5-mL centrifuge tubes and cryopreserved at −80°C for 
further experiments. Cell cultures were rinsed with one-wash PBS at room temperature for further 
experiments. All experiments were performed in duplicate and repeated in triplicate independently. 
4.2.5 Characterisation of HPc effects on MSCs 
4.2.5.1 General cellular activity 
P6–8 AT-MSCs at 80% confluency were subjected to 2%-O2 hypoxia or 20%-O2 normoxia for 
24 h. MTT assay was performed as described in Section 2.5, 3-(4,5-Dimethylthiazol-2-yl)- 2,5-
diphenyltetrazolium Bromide Colorimetric Assay to determine MSCs mitochondrial dehydrogenase 
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activity. SRB assay was performed as described in Section 2.6, Sulforhodamine B Colorimetric 
Assay to determine overall MSCs attachment. All experiments were performed in duplicate and 
repeated in triplicate independently. 
4.2.5.2 3H-thymidine and 14C-leucine incorporation assays 
3H-thymidine and 14C-leucine incorporation assays were used to examine effects of HPc versus 
NPc on MSCs DNA and protein syntheses. P6–8 MSCs at 80% confluency were fed with MSCs 
culture media containing 3H-labled thymidine and 14C-labled leucine (Amersham International, 
Amersham, UK), at a concentration of 20 Ci/mL and 1 Ci/mL, respectively. These MSCs were 
further subjected to 24-hour hypoxia or normoxia. Upon the completion of preconditioning, 
radioisotope-labelled cells were harvested onto glass fibre membranes using a Packard FilterMate 
(Packard Instrument Co., Ltd., Caversham, UK), and the filters were dried at 60°C for 1 h. The 
radioactivities were counted using a Packard Matrix 9600 β-counter (Packard Instrument Co., Ltd., 
Caversham, UK), and expressed as count per min per well (cpm/well). MSCs incubated in 
radioisotope-free culture media were used as blank control. All experiments were performed in 
duplicate and repeated in triplicate independently. 
4.2.5.3 Quantitation of intra-MSCs ROS activity 
Intracellular ROS activity was measured using flow cytometry with dichloro-
dihydrofluorescein diacetate acetyl ester (DCFDA) staining as previously described by Eruslanov 
and Kusmartsev (2010). DCFDA, a cell-permeant fluorogenic dye, is deacetylated by cellular 
esterases to non-fluorescent 2',7'-dichlorofluorescin (DCFDH), which is subsequently oxidised by 
intracellular hydroxyl, peroxyl and other forms of ROS into cell-impermeant 2'-7'-
dichlorofluorescein (DCF). DCF can be detected by fluorescence spectroscopy at the maximum 
excitation and emission spectra of 495 nm and 527 nm, respectively. 
Briefly, P6–8 AT-MSCs were plated onto non-tissue-culture-treated 6-well plates. On 80% 
confluency, MSCs were subjected to 24-hour HPc versus NPc and rinsed with one wash of PBS, 1 
mL per well. Cell cultures were incubated with PBS, 0.5 mL per well, containing 2.5-μM 5,6-
chloromethyl-2',7'-DCFDA (Molecular Probes, Inc., Eugene, OR, USA) specifically designated for 
liver cell staining, at 37°C for 30 min. HPc-MSCs incubated with plain PBS were used as blank 
control, and NPc-MSCs deprived of serum 24 h prior to labelling were used as positive control. Cells 
were rinsed with one wash of PBS, 1 mL  per well, and detached from the plates using EDTA-
chelated trypsin (TrypLE™ Select; Invitrogen Ltd, Paisley, UK), 0.5 mL per well. Dissociation was 
terminated by adding PBS containing 10% FCS, 1 mL per well. Cell suspension was centrifuged at 
4°C and 1,500 rpm for 5 min. Cell pellets were resuspended in 0.5-mL plain PBS at a density of 
100,000 cells per mL, and kept on ice and in the dark for further flow cytometry. 
An 8-channel BD FACS Canto II flow meter (BD Biosciences, San Jose, CA, USA) was used 
to quantitate intra-MSCs ROS activity. Briefly, 10,000 events were recorded and analysed, and the 
side scatter (SSC) axis was plotted against the forward scatter (FSC) axis to produce the scatter 
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graph and  gate the cell population (at least 90% of the total events). Unlabelled cells were analysed 
to polygon gate the positive population (labelled cells). Intracellular ROS activity was measured 
using the Alex Fluor® 488 fluorescein isothiocyanate (FITC) channel, and the SSC-axis was plotted 
against the FITC-axis. The flow cytometry analysis software FlowJo 10.0.6 for Windows (Tree Star, 
Inc., Ashland, OR, USA) was used to determine median fluorescence intensity (FI) for each sample. 
Median FIs of HPc-, and serum-deprived NPc-MSCs were normalised to those of NPc-MSCs (Du et 
al., J Biol Chem, 2006). All experiments were performed in duplicate and repeated in triplicate 
independently. 
4.2.6 NAC antagonisation experiment 
4.2.6.1 Optimisation of NAC concentration 
P6–8 AT-MSCs were plated onto non-tissue culture-treated 6-well plates. On 80% confluency, 
MSCs were and rinsed with one wash of PBS, and subjected to 24-hour HPc versus NPc and rinsed 
with one wash of PBS, 1 mL per well. HPc-MSCs were pretreated with 0-, 5-, 10-, and 20-mM NAC 
(PLIVA Pharma, Ltd., Hampshire, UK), respectively. Intra-MSCs ROS activity was measured as 
described in Section 4.2.5.3, Quantitation of intra-MSCs ROS activity, and the least concentration of 
NAC that resulted in significantly lower ROS activity in HPc-MSCs than that in NPc-MSCs was 
used for further antagonisation experiments. All experiments were performed in duplicate and 
repeated in triplicate independently. 
4.2.6.2 Co-culture of hepatocytes with non-pretreated and NAC-pretreated HPc-MSCs 
P6–8 AT-MSCs were plated onto collagen-coated 24-well plates and subjected to 24-hour HPc; 
HPc-MSCs were pretreated with the optimal concentration of NAC and without NAC, respectively. 
MSCs cultures were rinsed with one wash of PBS, and fresh hepatocytes were co-cultured with HPc-
MSCs as described in Section 4.2.4.1, Direct co-culture of hepatocytes with MSC. The culture media 
were refreshed on days 1, 3, 5, and 7, respectively. Culture supernatants were collected into sterile 
1.5-mL centrifuge tubes and cryopreserved at −80°C for further albumin, urea, CCK18, and CK18 
assays. All experiments were performed in duplicate and repeated in triplicate independently. 
4.2.7 General cellular activity and liver-specific metabolic function assays 
MTT assay was performed as described in Section 2.5, 3-(4,5-Dimethylthiazol-2-yl)- 2,5-
diphenyltetrazolium Bromide Colorimetric Assay to determine hepatocyte overall viability. SRB 
assay was performed as described in Section 2.6, Sulforhodamine B Colorimetric Assay to 
determine overall hepatocyte attachment. Albumin ELISA was performed as described in Section 2.7, 
Albumin Enzyme-linked Immunoabsorbent Assay to determine protein synthesis of hepatocytes. 
Urea colorimetric assay was performed as described in Section 2.8, Urea Colorimetry to determine 




4.2.8 Staurosporine cytotoxicity assay 
Fresh hepatocytes were pre-treated with 1-μM staurosporine (Sigma-Aldrich, St. Louis, MO, 
USA) and co-cultured with non-NAC- and NAC-pretreated HPc-MSCs for 24 h, as controlled by 
staurosporine-treated hepatocytes co-cultured with NPc-MSCs. Cell culture supernatants were 
collected for CCK18 and CK18 assays as described in Section 2.9, Caspase-cleaved CK18 Assay 
and Section 2.10, CK18 Assay. All experiments were performed in duplicate and repeated in 
triplicate independently. 
4.2.9 Hepatocyte apoptosis and total death assays 
CCK18 assay was performed as described in Section 2.9, Caspase-cleaved CK18 Assay to 
determine caspase-mediated hepatocyte apoptosis. CK18 assay was performed as described in 
Section 2.10, CK18 Assay to determine total hepatocyte death. The ratio of CCK18 to CK18 was 
also produced to determine the death mode of hepatocytes in vitro; a ratio of over 0.40 indicated that 
hepatocytes underwent apoptosis mainly, and necrosis vice versa. All experiments were performed in 




4.3.1 Morphology of HPc- vs. NPc- MSCs mono- and co-cultures 
4.3.1.1 Morphology of HPc-MSCs 
HPc did not result in cell detachment, necrosis, or morphological distortion of MSCs. HPc-
MSCs (Fig. 4.2A)  exhibited a spindle-shaped fibroblast-like phenotype similar to NPc-MSCs (Fig. 
4.2B) and reached 80% confluency within 7 d. On confluency HPc-MSCs were also polarised, with 
a small cell body and multiple slim projections in a homogenous manner. HPc-MSCs showed 
viability over 99% on trypan blue exclusion after trypsinisation.  
4.3.1.2 Morphology of HPc-MSCs co-culture 
The great majority of freshly isolated human hepatocytes attached to the MSCs monolayer 
within 2–4 hours, and only a few hepatocytes were detached from culture vessel surface at the time 
of culture media replacement Hepatocytes co-cultured with HPc-MSCs exhibited a morphology 
similar to those in co-culture with NPc-MSCs (Figure 4.2C), but a little more hepatocytes aggregated 




Figure 4.2 Morphology of NPc-MSCs (A), HPc-MSCs (B), and hepatocytes co-cultured with 
NPc- (C) and HPc-MSCs (D) (200×): HPc-MSCs (A) exhibited a spindle-shaped fibroblast-like 
phenotype similar to NPc-MSCs (B); compared to hepatocytes co-cultured with NPc-MSCs (C), a little 





4.3.2 Effects of HPc on MSCs 
4.3.2.1 HPc has no cytotoxic effect on MSCs 
As is shown in Figure 4.3A, HPc-MSCs showed a significant decrease in mitochondrial 
dehydrogenase activity as compared to NPc-MSCs (HPc vs. NPc, 1.18 ± 0.11 vs. 1.36 ± 0.09 OD 
units; P <0.05). However, HPc resulted in a significant increase in SRB cell attachment  as compared 
to NPc (1.88 ± 0.11 vs. 1.66 ± 0.11 OD units; P <0.01). Addition of 10-mM NAC significantly 
reduced MTT activity (HPc+NAC, 0.95 ± 0.09 OD units; P <0.01 vs. HPc) and reversed cellular 
attachment increase (1.53 ± 0.14 OD units; P <0.01) in HPc-MSCs. 
4.3.2.2 HPc increases MSCs DNA synthesis 
As is shown in Figure 4.3B, HPc significantly increased DNA synthesis in MSCs as compared 
to NPc (3,121 ± 295 vs. 1,815 ± 334 cpm/well; P <0.01). However, HPc resulted in a significant 
reduction in MSCs protein synthesis as compared to NPc (567 ± 60 vs. 715 ± 118 cpm/well; P < 
0.05). Addition of 10-mM NAC significantly reversed DNA synthesis increase (1,314 ± 54 cpm/well; 
P <0.01) and further reduced protein synthesis (263 ± 17 cpm/well; P < 0.01) in HPc-MSCs. 
Figure 4.3 Effects of HPc and NAC pretreatment on MTT and SRB activities (A) and 3H-
thymidine and 14C-leucine incorporation (B) of MSCs. HPc significantly decreased MSCs 
mitochondrial dehydrogenase activity but significantly increased cellular attachment, while NAC 
pretreatment significantly reduced MTT and SRB activities in HPc-MSCs (A); HPc also significantly 
increased DNA synthesis but significantly decreased protein synthesis, while NAC pretreatment  
significantly reduced DNA and protein syntheses in HPc-MSCs (B). All data were expressed as mean ± 
SD (error bar); *P <0.05 and **P <0.01 versus NPc-MSCs; ^^P <0.01 versus HPc-MSCs (n = 6). NPc, 
normoxia-preconditioned; HPc, hypoxia-preconditioned; NAC, N-acetylcysteine. 
4.3.3 Potentiative effect of HPc on MSCs co-culture hepatotrophic effect 
4.3.3.1 HPc potentiates MSCs co-culture hepatotrophic effect 
Mitochondrial dehydrogenase activity HPc at all time lengths exhibited a limited 
potentiative effect on MSCs hepatotrophic effect, with respect to hepatocyte mitochondrial 
dehydrogenase activity, as compared to control NPc (Figure 4.4A). HPc co-culture did not 




with HPc(8h)-, HPc(48h)-, and HPc(72h)-MSCs had a significantly higher MTT activity than those 
co-cultured with control NPc-MSCs on day 3 (NPc vs. HPc(8h) vs. HPc(24h) vs. HPc(48h) vs. 
HPc(72h), 1.45 ± 0.12 vs. 1.69 ± 0.17 vs. 1.62 ± 0.20 vs. 1.77 ± 0.14 vs. 1.65 ± 0.17 OD units; P 
<0.01), and hepatocytes co-cultured with HPc(24h)-MSCs had a significantly higher MTT activity 
than control NPc co-culture on day 7 (2.60 ± 0.25 vs. 2.75 ± 0.25 vs. 3.09 ± 0.33 vs. 2.79 ± 0.33 vs. 
2.92 ± 0.30 OD units; P <0.05). 
Cell attachment HPc at all time lengths exhibited a limited potentiative effect on MSCs 
hepatotrophic effect, with respect to hepatocyte cellular attachment, as compared to control NPc 
(Figure 4.4B). HPc-MSCs co-culture did not significantly improve hepatocyte SRB activity on days 
1, 3, and 5; however, hepatocytes co-cultured with HPc(24h)- and HPc(48h)-MSCs had a 
significantly higher SRB activity than those co-cultured with control NPc-MSCs on day 7 (3.58 ± 
0.42 vs. 3.93 ± 0.27 vs. 4.14 ± 0.29 vs. 4.26 ± 0.29 vs. 4.03 ± 0.28 OD units; P <0.05). 
Albumin secretion No albumin secretion was detected in NPc- and HPc-MSCs mono-culture. 
HPc at 24, 48, and 72 h significantly potentiated MSCs hepatotrophic effect, with respect to albumin 
secretion, as compared to control NPc, although 8-h HPc did not show any potentiative effect 
throughout 7 days of co-culture (Figure 4.4C). HPc co-culture did not significantly improve 
hepatocyte secretion of albumin on day 1; however, hepatocytes co-cultured with HPc(24h)-, 
HPc(48h)-, and HPc(72h)-MSCs had a significantly higher albumin secretion, to a similar extent, 
than those co-cultured with control NPc-MSCs from day 3 (2.4 ± 0.3 vs. 2.4 ± 0.3 vs. 3.7 ± 0.4 vs. 
3.6 ± 0.4 vs. 3.9 ± 0.4 μg/106 hepatocytes; P <0.01) until day 7 (4.6 ± 0.4 vs. 4.3 ± 0.3 vs. 5.4 ± 0.3 
vs. 5.2 ± 0.3 vs. 5.4 ± 0.3 μg/106 hepatocytes; P <0.01). 
Urea synthesis HPc at 24, 48, and 72 h significantly potentiated MSCs hepatotrophic 
effect, with respect to urea synthesis, as compared to control NPc, although 8-h HPc did not show 
any potentiative effect throughout 7 days of co-culture (Figure 4.4D). HPc co-culture did not 
significantly improve hepatocyte synthesis of urea on day 1; however, hepatocytes co-cultured with 
HPc(24h)-, HPc(48h)-, and HPc(72h)-MSCs had a significantly higher urea synthesis, to a similar 
extent, than those co-cultured with control NPc-MSCs from day 3 (23.4 ± 2.2 vs. 23.3 ± 2.3 vs. 32.8 
± 3.1 vs. 32.4 ± 2.4 vs. 33.2 ± 3.1 μg/106 hepatocytes; P <0.01) until day 7 (35.9 ± 3.0 vs. 33.5 ± 3.1 
vs. 40.8 ± 3.6 vs. 40.4 ± 3.3 vs. 41.4 ± 3.5 μg/106 hepatocytes; P <0.01). 
Overall 24-, 48-, and 72-h rather than 8-h HPc significantly potentiated MSCs co-culture 
hepatotrophic effect, to a similar extent, as compared to control 24-h NPc. Therefore, 24 h was 
determined to be the optimal time length of HPc used in further hepatocyte co-culture experiments.
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Figure 4.4 MTT activity (A), SRB cell attachment (B), albumin secretion (C), and urea synthesis (D) of hepatocytes co-cultured with HPc(8h)-, HPc(24h)-, HPc(48h)-, 
and HPc(72h)- MSCs versus hepatocytes co-cultured with NPc(24h)-MSCs at a MSC:hepatocyte seeding ratio of 2.5:1. HPc for 24, 48, and 72 h significantly potentiated 
MSCs co-culture hepatotrophic effect from day 3 until day 7. All data were expressed as mean ± SD; *P <0.05 and **P <0.01 versus control NPc co-culture (n = 6). NPc, normoxia-





4.3.3.2 HPc does not potentiate MSCs paracrine contribution to co-culture hepatotrophic effect 
HPc-MSCs indirect co-culture using Transwell plates exhibited no significantly potentiated 
hepatotrophic effect, with respect to hepatocyte mitochondrial dehydrogenase activity and cellular 
attachment (Table 4.1), as well as albumin secretion and urea synthesis (Table 4.2), as compared to 
control NPc-MSCs indirect co-culture, throughout 7 days of culture. 
Table 4.1 MTT activity and SRB cell attachment (mean ± SD) of hepatocytes indirectly co-
cultured on Transwell plates with HPc-MSCs versus with NPc-MSCs 
 MTT (OD unit) SRB (OD unit) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
HPc-iCo 1.58 ± 0.18 1.43 ± 0.21 1.35 ± 0.25 1.44 ± 0.20 3.03 ± 0.22 3.21 ± 0.24 3.10 ± 0.19 3.18 ± 0.25 
NPc-iCo 1.60 ± 0.16 1.30 ± 0.10 1.25 ± 0.10 1.31± 0.09 2.88 ± 0.20 3.10 ± 0.20 3.01 ± 0.16 3.05 ± 0.21 
HPc, hypoxia-preconditioned; NPc, normoxia-preconditioned; iCo-, indirect co-culture. 
Table 4.2 Albumin secretion and urea synthesis (mean ± SD) of hepatocytes indirectly co-
cultured on Transwell plates with HPc-MSCs versus with NPc-MSCs 
 Albumin (μg/106 hepatocytes) Urea (μg/106 hepatocytes) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
HPc-iCo 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 18.6 ± 2.4 16.9 ± 2.5 17.1 ± 2.4 15.6 ± 2.0 
NPc-iCo 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 18.6 ± 2.4 16.9 ± 2.5 17.1 ± 2.4 15.6 ± 2.0 
HPc, hypoxia-preconditioned; NPc, normoxia-preconditioned; iCo-, indirect co-culture. 
HPc-MSCs co-culture CM improved hepatocyte mitochondrial dehydrogenase activity on day 3 
only (HPc vs. NPc, 2.11 ± 0.25 vs. 1.21 ± 0.19 OD units; P <0.01), but did not significantly increase 
hepatocyte attachment throughout 7 days of culture as compared to control NPc-MSCs co-culture 
CM (Table 4.3). HPc-MSCs co-culture CM also significantly increased hepatocyte secretion of 
albumin only day 7 only (1.4 ± 0.1 vs. 1.2 ± 0.1 μg/106 hepatocytes; P <0.01), but did not 
significantly improve urea synthesis throughout 7 days of culture as compared to control NPc-MSCs 
co-culture CM (Table 4.4). 
Table 4.3 MTT activity and SRB cell attachment (mean ± SD) of hepatocytes cultured with 
HPc-MSCs co-culture CM versus with NPc-MSCs co-culture CM 
 MTT (OD unit) SRB (OD unit) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
HPc- 1.54 ± 0.17 2.11 ± 0.25** 1.42 ± 0.23 1.38 ± 0.19 2.63 ± 0.19 2.90 ± 0.24 2.99 ± 0.20 2.98 ± 0.23 
NPc- 1.58 ± 0.15 1.21 ± 0.19 1.25 ± 0.10 1.29 ± 0.17 2.71 ± 0.26 2.91 ± 0.24 2.93 ± 0.26 2.97 ± 0.24 
HPc, hypoxia-preconditioned; NPc, normoxia-preconditioned; **P< 0.01 versus NPc. 
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Table 4.4 Albumin secretion and urea synthesis (mean ± SD) of hepatocytes cultured with 
HPc-MSCs co-culture CM versus with NPc-MSCs co-culture CM 
 Albumin (μg/106 hepatocytes) Urea (μg/106 hepatocytes) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
HPc- 1.1 ± 0.1 1.1 ± 0.3 1.1 ± 0.2 1.4 ± 0.1** 18.0 ± 3.6 17.6 ± 2.6 17.2 ± 2.2 17.0 ± 2.2 
NPc- 1.0 ± 0.1 1.0 ± 0.3 1.1 ± 0.2 1.2 ± 0.1 19.0 ± 2.6 15.6 ± 2.6 16.4 ± 2.3 15.6 ± 2.6 
HPc, hypoxia-preconditioned; NPc, normoxia-preconditioned; **P< 0.01 versus NPc. 
4.3.4 Potentiative effect of HPc depends on intra-MSCs ROS activity 
4.3.4.1 NAC pretreatment antagonises HPc-induced intra-MSCs ROS activity increase 
As is shown in Figure 4.5, serum deprivation and HPc significantly increased intra-MSCs ROS 
activity to a similar extent as compared to NPc (normalised median FI: NPc vs. NPc+SF vs. HPc, 
100.0% vs. 133.8% ± 16.4% vs. 141.1% ± 17.1%, P <0.01). Pretreatment with 5-mM NAC did not 
completely eliminate HPc-induced increase in ROS activity (HPc+NAC, 113.1% ± 11.2%, P <0.05 
vs. NPc); however, addition of 10- (74.3% ± 7.2%, P <0.01) and 20-mM NAC (63.1% ± 3.9%, P 
<0.01) significantly antagonised HPc-induced ROS activity increase in HPc-MSCs. Therefore, 10-
mM NAC was used in further antagonisation experiments. 
4.3.4.2 HPc-potentiated co-culture hepatotrophic effect depends on intra-MSCs ROS activity 
Figure 4.6 shows that 10-mM NAC pretreatment significantly antagonised HPc-induced 
potentiation of liver-specific metabolic function of hepatocytes co-cultured with HPc-MSCs. 
Hepatocytes co-cultured with NAC-pretreated HPc-MSCs secreted significantly less albumin, as 
compared to those with non-NAC-pretreated HPc-MSCs, from day 1 (HPc-Co vs. HPc+NAC-Co, 
1.2 ± 0.3 vs. 0.9 ± 0.1 μg/106 hepatocytes; P <0.05) until day 7 (5.4 ± 0.3 vs. 4.5 ± 0.3 μg/106 
hepatocytes; P <0.01). Moreover, hepatocytes co-cultured with NAC-pretreated HPc-MSCs 
synthesised significantly less urea, as compared to those with non-NAC-pretreated HPc-MSCs, from 
day 3 (32.8 ± 3.1 vs. 22.8 ± 2.2 μg/106 hepatocytes; P <0.05) until day 7 (40.8 ± 3.6 vs. 35.3 ± 3.3 




Figure 4.5 Effect of HPc and NAC pretreatment on intra-MSCs ROS activity as measured by 
flow cytometry with DCFDA: representative SSC-versus-DCFDA (intracellular ROS) FI scatter plots of 
unlabelled (A), NPc- (B), HPc- (C), and HPc+10-mM-NAC-pretreated (D) MSCs, and bar charts of 
normalised median FI (E) of intra-MSCs ROS activity. Serum deprivation and HPc significantly 
increased intra-MSCs activity as compared to NPc, while 10- and 20-mM NAC pretreatment significantly 
eliminated HPc-induced intra-MSCs ROS increase. All data were expressed as mean ± SD; *P <0.05 and 
**P <0.01 versus NPc-MSCs (n = 6). SSC, side scattered; NPc, normoxia-preconditioned; SF, serum-free; 
HPc, hypoxia-preconditioned; NAC, N-acetylcysteine; nMean FI, normalised mean; nMedian, normalised 






Figure 4.6 Albumin secretion (A) and urea synthesis (B) of hepatocytes co-cultured with HPc-, 
non-NAC-pretreated MSCs versus with HPc-, 10-mM NAC-pretreated MSCs. NAC pretreatment 
significantly antagonised HPc-induced potentiation of hepatotrophic effect on liver-specific metabolic 
function. All data were expressed as mean ± SD (error bar); *P <0.05 and **P <0.01 versus HPc co-
culture (n = 6). HPc, hypoxia-preconditioned; NAC, N-acetylcysteine; Co, co-culture. 
4.3.5 Potentiative effect of HPc on MSCs co-culture antiapoptotic effect 
4.3.5.1 HPc-potentiated co-culture antiapoptotic effect depends on intra-MSCs ROS activity 
No CCK18 or CK18 release was detected in HPc-MSCs mono-culture. Direct co-culture with 
HPc-MSCs significantly further reduced CCK18 release from hepatocytes as compared to control 
NPc-MSCs co-culture (Figure 4.7A). Soluble CCK18 level remained significantly lower in 
hepatocytes co-cultured with HPc-MSCs than that in hepatocytes co-cultured with NPc-MSCs from 
day 1 (HPc-Co vs. NPc-Co, 14.5 ± 1.6 vs. 18.0 ± 1.4 U/106 hepatocytes; P <0.01) until day 5 (6.4 ± 
0.9 vs. 9.2 ± 1.1 U/106 hepatocytes; P <0.01); however, 10-mM NAC pretreatment eliminated HPc-
induced potentiation of MSCs antiapoptotic effect on co-cultured hepatocytes from day 1 
(HPc+NAC-Co, 18.3 ± 1.4 U/106 hepatocytes; P <0.01) until day 5 (9.0 ± 10 U/106 hepatocytes; P 
<0.01). 
 Direct co-culture with HPc-MSCs also significantly further reduced CK18 release from 
hepatocytes, as compared to that with NPc-MSCs (Figure 4.7B), from day 1 (61.6 ± 4.8 vs. 91.2 ± 
8.2 U/106 hepatocytes; P<0.01) until day 5 (61.8 ± 5.2 vs. 100.9 ± 8.1 U/106 hepatocytes; P <0.01); 
however, NAC pretreatment eliminated HPc-induced potentiation of MSCs prosurvival effect on co-
cultured hepatocytes from day 3 (176.0 ± 16.8 U/106 hepatocytes; P <0.01) until day 5 (99.0 ± 8.6 
U/106 hepatocytes; P <0.01). 
As is shown in Figure 4.7C, CCK18/CK18 ratio remained similar between hepatocytes co-
cultured with HPc-MSCs and hepatocytes co-cultured with NPc-MSC from day 1 (23.6% ± 2.6% vs. 
20.2% ± 3.0%; P >0.05) until day 7 (1.7% ± 0.1% vs. 1.5% ± 0.1%; P >0.05). It was noted that NAC 
pretreatment of HPc-MSCs switched death mode of co-cultured hepatocytes from necrosis to 






Figure 4.7 CCK18 release (A), CK18 release (B), and CCK18/CK18 ratio (C) of hepatocytes 
co-cultured with NPc-MSCs versus with non-NAC-pretreated HPc-MSCs versus NAC-pretreated 
HPc-MSCs. HPc-MSCs co-culture significantly further reduced caspase-mediated apoptosis and total 
death of hepatocytes, and NAC pretreatment eliminated HP-potentiated MSCs co-culture antiapoptotic 
and prosurvival effects. All data were expressed as mean ± SD; **P <0.01 versus NPc-Co; ^^P <0.01 
versus HPc-Co (n = 6). NPc, normoxia-preconditioned; HPc, hypoxia-preconditioned; Co, co-culture; 






4.3.5.2 HPc does not potentiate MSCs paracrine contribution to co-culture antiapoptotic effect 
MSCs indirect co-culture using Transwell plates Indirect co-culture with HPc-MSCs had 
no significant effect on hepatocyte CCK18 or CK18 release as compared to control NPc-MSCs 
indirect co-culture (Table 4.5). Soluble CCK18 level remained similar between hepatocytes 
indirectly co-cultured with HPc-MSCs and with NPc-MSCs from day 1 until day 7. Soluble CK18 
level also remained similar between hepatocytes indirectly co-cultured with HPc-MSCs and with 
NPc-MSCs from day 1 until day 7. CCK18/CK18 ratio remained similar between hepatocytes 
indirectly co-cultured HPc-MSCs and with NPc-MSCs from day 1 until day 7. 
MSCs co-culture CM  HPc-MSCs co-culture CM had no significant effect on 
hepatocyte CCK18 or CK18 release from hepatocytes as compared to control NPc-MSCs co-culture 
CM (Table 4.6). Soluble CCK18 level remained similar between hepatocytes cultured with HPc- and 
NPc-MSCs co-culture CM from day 1 until day 7. Soluble CK18 level also remained similar 
between hepatocytes cultured with HPc- and NPc-MSCs co-culture CM from day 1 until day 7. 
CCK18/CK18 ratio remained similar between hepatocytes cultured with HPc- and NPc-MSCs co-
culture CM  from day 1 until day 7. 
4.3.5.3 HPc potentiates MSCs co-culture hepatoprotective effect against staurosporine-induced 
cytotoxicity 
Co-culture with HPc-MSCs significantly further reduced staurosporine-induced hepatocyte 
apoptosis (soluble CCK18 level) as compared to co-culture with NPc-MSCs (HPc vs. NPc, 21.6 ± 
2.8 vs. 26.5 ± 2.5 U/106 hepatocytes, P <0.01; Figure 4.8A). However, HPc-MSCs co-culture had no 
significant effect on staurosporine-induced total cell death of hepatocytes as compared to NPc-MSCs 
co-culture (Figure 4.8B). However, HPc-MSCs co-culture reversed staurosporine-induced necrosis-
to-apoptosis switch of hepatocyte death mode to a similar extent as compared to NPc-MSCs co-





Table 4.5  CCK18 release, CK18 release, and CCK18/CK18 ratio (mean ± SD) of hepatocytes indirectly co-cultured with HPc-MSCs versus with NPc-MSCs 
 CCK18 (U/106 hepatocytes) CK18 (U/106 hepatocytes) CCK18/CK18 ratio (%) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
HPc-iCo 21.2 ± 2.6 22.7 ± 2.5 14.1 ± 1.8 1.4 ± 0.3 99.8 ± 11.7 375.0 ± 30.4 255.6 ± 28.9 45.9 ± 4.3 21.2 ± 2.4 6.1 ± 1.2 5.5 ± 1.1 3.1 ± 0.2 
NPc-iCo 20.8 ± 2.4 23.2 ± 2.3 15.9 ± 1.7 1.6 ± 0.2 108.8 ± 12.4 390.0 ± 35.0 276.0 ± 33.0 50.4 ± 4.6 19.1 ± 2.8 5.9 ± 1.1 5.8 ± 1.3 3.2 ± 0.1 
HPc, hypoxia-conditioned; NPc, normoxia-preconditioned; iCo-, indirect co-culture. 
 
 
Table 4.6 CCK18 release, CK18 release, and CCK18/CK18 ratio (mean ± SD) of hepatocytes cultured with HPc- versus NPc-MSCs co-culture CM 
 CCK18 (U/106 hepatocytes) CK18 (U/106 hepatocytes) CCK18/CK18 ratio (%) 
 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 Day 1 Day 3 Day 5 Day 7 
HPc- 22.1 ± 2.2 23.2 ± 2.1 17.1 ± 1.9 2.1 ± 0.3 112.2 ± 12.2 358.0 ± 31.1 290.0 ± 35.5 52.5 ± 4.5 19.7 ± 2.4 6.5 ± 1.2 5.9 ± 1.1 4.0 ± 0.3 
NPc- 20.3 ± 2.1 22.5 ± 2.0 16.3 ± 1.8 2.0 ± 0.4 110.5 ± 12.5 360.0 ± 33.3 286.0 ± 31.7 54.1 ± 4.0 18.4 ± 2.0 6.3 ± 1.1 5.7 ± 1.0 3.7 ± 0.2 






Figure 4.8 CCK18 release (A), CK18 release (B), and CCK18/CK18 ratio (C) of hepatocytes 
subjected to 1-μM staurosporine and co-cultured with HPc-MSCs versus with NPc-MSCs. HPc-
MSCs co-culture significantly further reduced staurosporine-induced hepatocyte apoptosis and had no 
significant effect on total death of hepatocytes; HPc-MSCs co-culture reversed staurosporine-induced 
necrosis-to-apoptosis death mode switch to a similar extent  as compared to NPc-MSCs co-culture. All 
data were expressed as mean ± SD; **P <0.01versus control NPc-MSCs co-culture (n = 6). HPc, 







4.4.1 Effects of HPc on MSCs 
MSCs are known to be highly sensitive to oxygen tension in the culture environment. Previous 
reports were controversial regarding hypoxic effects on MSCs, probably due to the variations in 
MSCs sources as well as hypoxic conditioning protocols. The variation in hypoxic effect on MSCs is 
most striking in cellular apoptosis: hypoxic conditioning was reported to be pro-apoptotic 
(Rasmussen et al., 2011), anti-apoptotic (Zhang et al., 2009), or without effect (Efimenko et al., 
2011). Severe hypoxia will distort the morphology and ultrastructure of MSCs, especially the 
mitochondria and nucleus; however, moderate hypoxic atmosphere favours human MSCs expansion 
in vitro. Hypoxia normally results in a smaller size of MSCs containing a less number of 
mitochondria, but hypoxia alone does not induce apoptosis in MSCs, but serum or glucose 
deprivation will cause marked apoptotic death in MSCs. In the present work, 24-hour 2% O2 
hypoxia had no cytotoxic effect on human AT-MSCs as shown by the morphological results 
consistent with a previous report (Fu et al., 2011). It is generally accepted that HPc-MSCs exhibit a 
higher survival rate when subsequently subjected to hypoxia or hypoxia-reoxygenation, mainly by 
attenuating apoptosis in MSCs. Low-dose oxidative preconditioning can protect MSCs from cellular 
apoptosis induced by high-dose oxidative stress (Li et al., 2009). 
Hypoxia, as a major cause of mitochondrial oxidative stress, has a negative effect on 
mitochondrial metabolism. Hypoxia (1% O2) decreases human BM-MSCs mitochondrial activity by 
inhibiting expression of respiratory enzymes and oxygen consumption; under a hypoxic condition, 
MSCs depends mainly on anaerobic glycolysis for energy supply, accompanied by upregulated 
expression of glycolytic enzymes and increased production of lactate acid. Hypoxia also activates 
cell-matrix contact of MSCs. Hypoxia under 2% O2 upregulates expression of integrin subunits, 
including α1, α3, α5, α6, α11, β1, and β3,  in human BM-MSCs (Saller et al., 2012). The HPc 
protocol used in the present work did inhibit mitochondrial dehydrogenase activity as evidenced by 
decreased MTT activity but improved cellular attachment as shown by the increased SRB activity. 
HPc is reported to positively affect the colony-forming potential and proliferation of BM- and 
UC-MSCs (Martin-Rendon et al., 2007; Pilgaard  et al., 2009), while hypoxia-mimetic agents can 
inhibit the hypoxic effect on MSCs proliferation by inducing a G1-phase cell cycle arrest (Zeng et al., 
2011). BM-MSCs cultured under 2% O2 exhibit an advanced  exponential growth phase and greater 
cell division kinetics (Dos Santos et al., 2010). Physiological hypoxia (1%–3% O2) enhances rat 
BM-MSCs proliferation, which manifests as increases in the ratio of S-phase cells, 
bromodeoxyuridine incorporation, and proliferating cell nuclear antigen expression, by upregulating 
phosphorylation of p38 MAPK and nuclear translocation of HIF-1α (Wang et al., 2013). Hypoxic 
condition also enhances the propagation ability of human BM-MSCs possibly by maintaining 
telomere length (Tsai et al., 2011). The 3H-thymidine incorporation assay in the present work 
demonstrated that 24-hour of 2%-O2 hypoxia promoted DNA synthesis in MSCs. The effect of 
hypoxia on overall protein synthesis was less reported in previous studies, although expression of 
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specific proteins was inhibited or activated in hypoxic MSCs (Abdollahi et al., 2011). The 14C-
leucine incorporation assay in the present work showed that hypoxia slightly decreased overall 
protein synthesis. It is expected that MSCs synthesis of protein is inhibited under a hypoxic micro-
environment as hypoxia switches the energy metabolism from oxidation phosphorylation to 
glycolysis; however, it is known that translation of protein generally requires a large amount of 
energy supply. It is likely that the stimulatory effect of hypoxia on MSCs protein synthesis will 
become evident after a longer time as reported in previous studies (Sengupta et al., 2010). 
4.4.2 HPc potentiates trophic and protective effects of MSCs co-culture on 
hepatocytes by non-paracrine, ROS-dependent mechanisms 
Enhanced angiogenesis of HPc-MSCs has been well documented in literature, especially in the 
setting of myocardial, limb and cerebral ischaemia. HPc upregulates expression of various pro-
survival and pro-angiogenic factors, especially angiopoietin-1, erythropoietin, and VEGF in MSCs, 
transplantation of which consequently enhances angiogenesis as well as morphological and 
functional restoration of the infarcted myocardium (Hu et al., 2008). HPc also helps BM-MSCs to 
more effectively restore the blood flow in an experimental rat hind limb ischaemia model by 
improving revascularisation through activating HGF signalling (Rosová et al., 2008). Moreover, HPc 
AT-MSCs also significantly increased the viability and decreased apoptotic death of co-cultured or 
co-transplanted neural stem cells by downregulating Bax signalling in an experimental rat spinal 
cord ischaemia model (Oh et al., 2010). The present work demonstrated for the first time that HPc 
potentiated the hepatotrophic effect of MSCs on co-cultured hepatocytes with respect to liver-
specific metabolic function in vitro.  
Putative paracrine mechanisms are thought to primarily contribute to the potentiative effect of 
HPc on MSCs. HPc was reported to significantly upregulate expression of a large number of soluble 
cytokines and growth factors, such as HGF, VEGF, FGF2, IGF-1, and IL-6 in MSCs (Lam et al., 
2010). HGF and VEGF are two candidate factors that have been most frequently studied. HPc 
significantly increases the secretion of both HGF and VEGF from human BM-MSCs into the culture 
medium; concentrated HPc-MSCs conditioned medium favours the regeneration of neurons in vivo 
by limiting neuronal apoptosis resulting from experimental traumatic brain injury in rats, and further 
improves motor and cognitive function of the rat model (Chang et al., 2013). Hsiao et al. (2013) 
reported that HPc enhanced paracrine angiogenic activity of human AT-MSCs through VEGF-A and 
angiogenin signalling pathways. HPc also increases human AT-MSCs secretion of VEGF and bFGF 
to the culture medium, and HPc-MSCs conditioned medium improves vitality and reduces apoptosis 
in human umbilical vein endothelial cells with enhanced tube formation in vitro (Liu et al., 2013). 
Yu et al. (2013) recently reported an interesting study regarding BM-MSCs therapy for an 
experimental rat extensive hepatectomy model. NPc-MSCs did improve hepatocyte proliferation in 
vivo but not liver regeneration or animal survival, while HPc-MSCs significantly enhanced liver 
regeneration and animal survival. Activation of VEGF signalling in HPc-MSCs was thought to be 
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the underlying mechanism as expression of VEGF signalling was significantly upregulated and the 
improved therapeutic effects could be diminished by VEGF neutralisation antibody. However, the 
present work showed that HPc minimally potentiate paracrine contribution to trophic and 
antiapoptotic effects of MSCs on co-cultured human hepatocytes. It was possible that isolated human 
hepatocytes became unresponsive to HPc-potentiated MSCs release of soluble trophic and 
antiapoptotic factors. Therefore, HPc-induced potentiation of MSCs co-culture hepatotrophic and 
antiapoptotic effects may result primary from enhanced ECM construction and heterotypic MSC-
hepatocyte communication. 
Intracellular ROS is known to finely modulate biological activities of MSCs. Exposure to 
moderate hypoxia is known to immediately increase intracellular ROS production in human BM-
MSCs (Busletta et al., 2011), while pretreatment with NAC significantly inhibits increased ROS 
production and ameliorates oxidative stress associated cellular damages in hypoxic MSCs (Fan et al., 
2011). NAC pretreatment improves the antioxidant capacity of human MSCs to restore the 
reduction-oxidation balance by eliminating intracellular ROS, elevating intracellular glutathione 
level, and enhancing cellular adhesion when exposed to in vitro oxidative stress (Wang et al., 2013). 
Oxidative stress resulting from low-level broadband visible light illumination was also found to 
stimulate the proliferative potential of BM-MSCs, in which production of ROS increased (Lipovsky 
et al., 2013). These findings demonstrate that ROS is a major factor mediating the effects of 
oxidative stress, such as hypoxia and ion radiation, on cellular proliferation, survival/apoptosis, and 
attachment of MSCs in vitro.  
The present work showed that scavenge of increased ROS reversed HPc-induced increases in 
synthesis of DNA and membrane proteins of human AT-MSCs, implying that ROS are involved in 
regulating DNA synthesis and cellular attachment. However, the paradox that addition of NAC 
further significantly reduced mitochondrial dehydrogenase activity and protein synthesis suggested 
the possibility that a pre-existing, relatively higher intracellular ROS level facilitates MSCs recovery 
from moderate hypoxia and resistance to subsequent hypoxia/reoxygenation-induced inhibitive 
effect on mitochondrial activity and protein synthesis of MSCs (Wang et al., 2008). This also 
indicated the involvement of non-ROS-dependent mechanisms, such as HIF-1α, in HPc of MSCs. 
Upregulation of HIF-1α expression occurs at a late phase of HPc and mediates the cascades of 
hypoxic response (Busletta et al., 2011). Overexpression of HIF-1α enhances the survivability, 
attachment, migration, ECM synthesis, osteogenic differentiation and energy metabolism of MSCs 
(Palomäki et al., 2013).  
The present work showed that HPc potentiated hepatotrophic and antiapoptotic effects of MSCs 
on co-cultured hepatocytes and NAC pretreatment diminished HPc-induced potentiative effects as 
evidenced by liver-specific metabolism and caspase-mediated hepatocyte apoptosis assays. Induction 
of ROS production accompanies phosphorylation of EGF receptor in human BM-MSCs, which can 
be antagonised by NAC treatment (Park et al., 2013). Aged AT-MSCs show a relatively limited 
angiogenic capacity associated with significant downregulation of VEGF, placental growth factor, 
and HGF, while HPc significantly upregulated expression of these pro-angiogenic factors and 
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restored angiogenesis of aged AT-MSCs (Efimenko et al., 2011). De Barros et al. (2013) also 
reported that aged human AT-MSCs had a relatively lower ROS level, while HPc could improve 
angiogenic capacity of aged MSCs; conversely NAC treatment eliminated HPc-induced potentiation 
of MSCs angiogenesis both in vitro and in vivo. It remains less investigated whether ROS also 
regulate ECM activity involved in trophic and antiapoptotic effects of MSCs on co-cultured 
hepatocytes. Chemically-induced oxidative stress was reported to upregulate expression of bone 
morphogenetic protein 2 and FGF2 in human AT-MSCs in an intra-MSCs ROS dependent manner 
(Moriyama et al., 2012). These two cytokines are well known to actively participate in ECM 
formation and modification of bone and cartilages (Krawczak et al., 2009). 
4.4.3 Conclusions 
In conclusion, as compared to NPc, HPc potentiated trophic effect of MSCs on co-cultured 
hepatocytes with respect to liver-specific metabolic function. HPc also enhanced antiapoptotic and 
protective effects of MSCs co-culture in an ROS-dependent manner as pretreatment with 
antioxidative NAC diminished HPc-induced potentiative effects. However, This potentiative effect 
might not result primarily from enhanced paracrine activities of MSCs regardless of the presence or 
absence of MSC-hepatocyte direct contact. It remains to be investigated whether HPc-induced 
potentiative effect on MSCs co-culture results from nonparacrine contribution of soluble factors and 
ECM secreted by MSCs by an ROS-dependent mechanism. Signalling pathways involved in 
apoptosis and survival of hepatocytes, such as caspases and BAX/BCL-2, will also be addressed in 
the next chapter.  
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CHAPTER 5 MECHANIMS OF MSCS CO-CULTURE HEPATOTROPHIC 
EFFECT AND HPC-INDUCED POTENTIATIVE EFFECT 
5.1 Introduction 
5.1.1 Contributive factors to hepatotrophic effect of MSCs co-culture 
Trophic and protective effects of MSCs on co-cultured hepatocytes in vitro have been well 
documented in the present work and in previous studies. MSCs also have pronounced effects on 
hepatocyte proliferation, repair, and regeneration in physiological and pathological conditions in vivo 
(Esrefoglu, 2013). MSCs transplantation (Meier et al., 2013) and co-transplantation with hepatocytes 
(Joshi et al., 2012) are expected to be therapeutically effective for acute and chronic liver diseases. 
Putative mechanistic factors contributing to the hepatotrophic effects of MSCs co-culture in vitro 
mimic supportive factors for hepatocytes in vivo. These factors consist mainly of paracrine factors 
(soluble cytokines and growth factors), ECM, and heterotypic MSC-to-hepatocyte interaction 
(Figure 5.1; Gómez-Aristizábal et al., 2009). 
 
Figure 5.1 Putative mechanisms of trophic effect of MSCs on co-cultured hepatocytes, 
including soluble cytokines, ECM, and direct cell contact (Gómez-Aristizábal et al., Mol Ther, 2009). 
5.1.1.1 Soluble factors in MSCs co-culture 
Soluble factors contributing to the trophic effect of MSCs on co-cultured epithelial cells and 
other cell lines, such as cardiomyocytes, hepatocytes, and islet cells, have been relatively well 
studied in the current literature. Injection with CM from Akt-overexpressing MSCs enriched with 
VEGF, FGF-2, HGF, IGF-I, and TB4 significantly shrank infarction size and improved ventricular 
function (Gnecchi et al., 2006). Gu and his colleagues (2009a) reported that MSCs co-culture with 
hepatocytes significantly increased secretion of IL-6 rather than TGF-α or TNF-α; conversely IL-6 
neutralisation significantly diminished the trophic effects of MSCs co-culture CM on liver-specific 
metabolism. Moreover, MSCs-derived soluble factors have supportive effect on transplanted cells 
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after transplantation in vivo. Park et al. (2010) demonstrated that HGF, IL-6, TGF-β, and VEGF-A 
were the trophic molecules of human BM- and UC-MSCs enhancing survival, function, and 
angiogenesis of isolated islets after transplantation. Overexpression of VEGF and HGF in MSCs 
significantly increased cardiomyocytes survival and peri-infarct vessel density in the border zone of 
acute myocardial infarction (Deuse et al., 2009). MSCs CM also protects hepatocytes from CCl4-
induced apoptosis as mediated by IL-6 signalling and consequent activation of fibroblast-like-protein 
1 (Xagorari et al., 2013). Preliminary analysis of MSCs secretome using the proteomics technique 
showed out of all chemokines only heparin-bound eluent was effective for treating fulminant hepatic 
failure (Parekkadan et al., 2007). Interestingly, trophic factors may have an autocrine regulative 
effect on MSCs. Ex vivo treatment of human BM-MSCs with ischaemic rat brain extract containing 
high levels of brain-derived neurotrophic factor, VEGF, and HGF results in a further increase in 
production of these growth factors (Choi et al., 2010). The physiological activities of lipid 
microvesicles released from MSCs have been recently discovered but not well understood. Generally 
these microvesicles play a sophisticated role in transporting proteins, lipids, and RNAs to 
neighbouring cells (Baglio et al., 2012). 
5.1.1.2 ECM in MSCs co-culture 
ECM is historically known to play an essential role in maintaining and regulating hepatocyte 
survival, proliferation, maturation, regeneration, and metabolism (Depreter et al., 2000). ECM 
supports hepatocyte directly through cell-to-ECM interaction or indirectly through modulating 
release of growth factors, such as HGF (Schuppan et al., 1998) and bFGF (Sakakura et al., 1999). 
Minimal self-deposition of ECM may result in deterioration of cell survival and metabolic function 
in hepatocyte mono-culture due to the absence of cell-to-matrix interaction (Thomas et al., 2005); 
interruption of cellular attachment to ECM, such as laminin, fibronectin, and collagen type I and V 
by neutralising β1-integrin results in marked apoptosis of hepatocytes (Pinkse et al., 2004). 
Engineered bioscaffolds containing synthetic ECM, such as xyloglucan (Seo et al., 2005) have been 
developed to maintain and support hepatocytes both in vitro and in vivo. Co-culture of rabbit 
chondrocytes with allogeneic BM-MSCs at an optimal ratio (chondrocytes:MSC, 2:1) improves 
expression of type II collagen and aggrecan, two major components of cartilaginous ECM (Qing et 
al., 2011). MSCs co-encapsulation was also reported to synergistically enhance insulin secretion of 
pancreatic islets with ECM by upregulating expression of insulin I/II, glucagon, somatostatin, and 
pancreatic and duodenal HOX 1, and downregulating expression of CK19 and vimentin (Davis et al., 
2012). Gu and his colleague (2009c) reported that mono-cultured hepatocytes deposited minimal 
ECM, such as fibronectin, laminin, and collagen type I, III, and V, while MSCs co-culture secreted 
fibronectin and collagen type I, as well as some laminin and collagen type V; further siRNA 
knockdown experiments validated that inhibition of fibronectin, laminin, and collagen type I and V 
compromised the hepatotrophic effect of MSCs on co-cultured hepatocytes with respect to liver-
specific metabolic function. Interaction between MSCs and ECM also modulates capillary 
morphogenesis of vascular endothelial cells both in vitro and in vivo, suggesting the role of MSCs in 
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neoangiogenesis in addition to paracrine activity (Kniazeva et al., 2011). It is noted that MSCs have 
a biphasic modulatory effect on ECM formation of the liver (Zhao et al., 2012). Li et al. (2013) 
reported that BM-MSCs transplantation significantly decreased hydroxyproline content and collagen 
accumulation in an experimental liver fibrosis model, accompanied by upregulated expression of 
HGF, IL-10, VEGF, and MMP-9.  
5.1.1.3 Cell-to-cell contact in MSCs co-culture 
Epithelial-to-mesenchymal interaction (EMI) plays a paramount role in reciprocal regulation of 
biological activities involved in development and regeneration of the liver. Moreover, liver MSCs 
also promotes differentiation and maturation of hepatic progenitor cells by direct cell-to-cell contact 
(Hoppo et al., 2004; Ito et al., 2013). The contribution of cell-to-cell contact to trophic effect of 
MSCs co-culture is evidenced by the fact that direct contact co-culture is superior to indirect non-
contact co-culture and MSCs-derived CM in the present work and previous studies. Jung et al. (2011) 
reported that contact between MSCs and islet cells was a major factor favouring survival, 
morphology maintenance, and insulin release of pancreatic islets in the presence of synergic 
regulation of inflammatory cytokine production. Gómez-Aristizábal and Davies (2012) also reported 
that human UC perivascular cells contact co-culture significantly improved ureagenesis of human 
hepatocytes as compared to non-contact co-culture. EMI is modulated by multiple growth factors, 
such as EGF, TGF-α, HGF, TGF-β, bFGF, platelet-derived growth factor β, and IGF-1; out of these 
factors IGF-1 is the key to EMI during gastric mucosal healing (Watanabe et al., 2000). This 
interaction is also modulated by membrane-associated ligand/receptor. The Notch signalling 
pathway is a highly conservative cellular signalling system regulating cell-to-cell contact and 
involved in remodelling liver progenitor cell niche in the setting of liver  fibrosis (Spee et al., 2010). 
Human BM-MSCs expresses a high level of Notch ligand on contact with rat neural stem cells, 
which highly express the receptor NOTCH1 (Robinson et al., 2011). Moreover, human UC 
perivascular cells in co-culture with rat hepatocytes exhibited marked upregulation of HGF and 
Jagged1 (a ligand of NOTCH1 receptor) expression, suggesting the role of Notch-Jagged1 
interaction in maintaining functional polarity of hepatocytes (Gómez-Aristizábal and Davies, 2013). 
Liver-regulating protein, which is widely expressed by BM-MSCs, hepatocytes, and liver NPCs, is 
thought to partially contribute to hepatotrophic effect of MSCs co-culture; blocking antibody against 
LRP will diminish the trophic effect of MSCs on co-cultured hepatocytes (Corlu et al., 1997). 
Conversely direct contact with distinct differentiated cells also plays a critical role in determining 
MSCs fate. Wang et al. (2006) reported that direct contact co-culture with rat cardiomyocytes rather 
than indirect non-contact co-culture or culture with CM drove rat BM-MSCs differentiation into 
cardiomyocytes or smooth muscle cells.  
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5.1.2 HPc-induced potentiative effect 
5.1.2.1 HPc potentiates paracrine activity 
MSCs exhibit a potentiated paracrine activity in response to hypoxia (Das et al., 2010), and 
HPc-potentiated paracrine effect of MSCs can improve the therapeutic benefit of MSCs 
transplantation (Cheng and Yau, 2008). Hypoxia triggers activation of Akt signalling pathway and 
consequently upregulates expression of genes encoding VEGF, FGF-2, HGF, IGF-1, and thymosin 
β4, enriched with which MSCs CM results in marked reduction of cardiomyocytes apoptosis 
(Gnecchi et al., 2006). Hypoxic challenge was reported to upregulate expression of MSC VEGF, 
FGF2, HGF, and IGF-1 by an ERK- and JNK-independent, NFκB-dependent, mechanism 
(Crisostomo et al., 2008). Hypoxic exposure also significantly increased secretion of VEGF, HGF, 
and bFGF, which depends on HIF, a pivotal signalling factor in hypoxic response (Tamama et al., 
2011). After HPc, rat BM-MSCs exhibit significantly upregulated expression of pro-survival and 
pro-angiogenic factors, such as HIF-1, angiopoietin-1, VEGF and its receptor, Flk-1, and 
erythropoietin (Hu et al., 2008). HPc-MSCs CM shows a significantly greater protective effect on 
cardiomyocytes deprived of serum under 1%-O2 hypoxia as compared to NPc counterpart (Fidelis-
de-Oliveira et al., 2012). HPc-MSCs enhanced skeletal muscle regeneration, to a greater extent as 
compared to NPc-MSCs, by improving blood flow and vascular formation in an experimental rat 
hind limb ischaemia model; the putative mechanism might be activation of Wnt4 gene (Leroux et al., 
2010), encoding a secreted protein regulating myogenic proliferation. HPc also potentiates 
neurotrophic effects of rat BM-MSCs by upregulating expression of a series of trophic and growth 
factors, including brain- and glial cell-derived neurotrophic factor, VEGF and its receptor, 
erythropoietin and its receptor, SDF-1, and CXC chemokine receptor 4 (Wei et al., 2012). These 
HPc-potentiated paracrine mechanisms are likely to offer additional benefits with respect to 
neovascularisation and progenitor cell recruitment if transplanted in vivo. HPc increases secretion of 
angiogenic VEGF and bFGF from AT-MSCs, by which HPc-MSCs CM improves survival and tube 
formation of human umbilical vein endothelial cells (Liu et al., 2013). HPc stimulates secretion of 
proangiogenic and mitogenic factors and improved MSCs chemotaxis; upregulation of SFDF-1α 
expression in the ischaemic tissue selectively recruited HPc- rather than NPc-MSCs by a CXC 
receptor (CXCR) 7-independent, CXCR4-dependent manner (Liu et al., 2012).  
5.1.2.2 HPc enhances formation and organisation of ECM 
Microenvironmental oxygen tension finely modulates chondrogenesis and osteogenesis of 
MSCs by switching on and off MSCs formation of ECM. Hypoxic conditions stimulate MSCs to 
deposit multiple components of ECM and adhesion molecules. A previous genomic study 
demonstrated that HPc had a late-phase upregulative effect on expression of genes involved in ECM 
by up to 60 folds (Basciano et al., 2011). Hypoxia (5% O2) rather than normoxia (21% O2) in 
combination with TGF-β3 can induce chondrogenic differentiation of foetal synovium-derived 
MSCs in a serum free culture (Li et al., 2011). Expression of MMP-2, collagen type II and XI, 
aggrecan, and integrins α2 and β3 is significantly upregulated in rat MSCs subjected to TGF-β1 and 
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2%-O2 hypoxia along with phosphorylation of MAPK/ERK1/2 signalling pathway (Risbud et al., 
2004). IL-1β has an inhibitory effect on chondrogenesis, while hypoxic condition can reverse the 
inhibitory effects of IL-1β on BM-MSCs deposition of ECM (Felka et al., 2009). Stimulatory effect 
of hypoxia on MSCs deposition of ECM can also be maintained after transplantation in vivo. Feng et 
al. (2011) reported that HPc in combination with TGF-β1 drove rabbit MSCs differentiation towards 
a nucleus pulposus-like phenotype in vitro, as evidenced by significantly upregulated expression of 
aggrecan, collagen type II, Sox-9, glycosaminoglycan, and HIF-1α; subcutaneous implantation 
experiment showed that HPc facilitated MSCs-scaffold construct to maintain chondrial morphology 
and prevent secondary calcification. Oxygen tension tunes MMPs and tissue inhibitor of MMPs in a 
differential manner; low oxygen tension inhibits expression of MMP-13 and tissue inhibitor of 
MMP-1 involved in ECM remodelling and vascular invasion, but has significant effects on 
expression of MMP-2, an enzyme involved in cell migration, in human MSCs (Raheja et al., 2010). 
More interestingly, MSCs have a beneficial regulative effect on ECM remodelling in response to 
hypoxia. NPc- or HPc-MSCs co-culture downregulates expression of MMP and upregulates 
expression of tissue inhibitor of MMP-1 in cardiac fibroblasts subject to severe hypoxia (0.5% O2) 
mediated by erythropoietin and its receptor as well as ERK1/2 signalling pathway (Wang et al., 
2011). 
5.1.2.3 HPc potentially augments cell-to-cell contact 
Effect of hypoxia on interaction inbetween MSCs and between MSCs and other cell lines is 
rarely reported in literature. Connexins are a family of structurally related transmembrane proteins 
that assemble the gap junction and serve as the electrical coupling in the neuromuscular tissue. 
Long-term hypoxic culture of human MSCs significantly upregulates expression of connexin 43 
(Cx43), a connexin family member mainly found in myocardium, along with enhanced ECM 
formation. The biological role of Cx43 is not well understood; knockdown of Cx43 will reduce 
cardiomyocyte survival and diminish protective effect of IGF-1 on HSCs (Lu et al., 2009). 
Overexpression of Cx43 significantly upregulates expression of Bcl-2, downregulates expression of 
Bax, increases phosphorylation of Akt signalling pathway in MSCs; Cx43-overexpressing MSCs 
shows an enhanced survival in infarcted myocardium (Wang et al., 2010). Enhanced expression of 
Cx43 in response to hypoxia accompanies expression of prosurvival and proangiogenic factors in 
MSCs (Chacko et al., 2010). Integrins are another collection of transmembrane receptors mediating 
adhesion between a cell and the neighbouring cells or  ECM and transducing signals that regulate a 
number of biological activities, such as cellular survival, division, growth, differentiation, and 
apoptosis (Docheva et al., 2007). Overexpression of integrin-linked kinase enhances attachment of 
hypoxic MSCs to ischaemic myocardium (Song et al., 2009). It remains to be investigated whether 
hypoxia augments heterotypical interaction of MSCs with epithelial and other cells and how this 
augmented interaction improves supportive effect of MSCs. 
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5.1.3 Chapter objectives 
 Contribution of TNF-α and TGF-β1  
To investigate whether autocrine TNF-α activity of hepatocytes and autocrine TGF-β1 activity 
of MSCs mediate hepatotrophic effect of MSCs and potentiative effect of HPc induction. 
 Contribution of collagen 
To investigate whether extracellular collagen mediates hepatotrophic effect of MSCs and 
potentiative effect of HPc induction. 
 Pro- and antiapoptosis-associated gene expression analysis 
To characterise expression profiles of pro- and antiapoptosis-associated genes, such as caspase 
and BAX/BCL-2 signalling pathways, in MSCs co-culture and HPc co-culture as compared to those 
in mono-cultured hepatocytes.  
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5.2 Materials and methods 
5.2.1 Cell culture protocols 
5.2.1.1 Subculture and HPc of AT-MSCs and isolation of hepatocytes  
Human AT-MSCs were subcultured as described in Section 2.2, Subculture of MSCs. P6–8 
MSCs were subjected to 2%-O2 hypoxia (HPc-MSCs) or  20%-O2 normoxia (NPc-MSCs) for 24 h 
as described in Section 4.2.3, Optimisation of HPc. Non-steatotic donor liver tissues were processed 
as described in Section 2.3, Primary Harvest of Human Hepatocytes. Batches of hepatocytes with a 
viability of over 60% on trypan blue exclusion were used for experiments.  
5.2.1.2 Direct co-culture of hepatocytes with MSCs 
Fresh hepatocytes were co-cultured with HPc- versus NPc-MSCs as described in Section 
4.2.4.1, Direct co-culture of hepatocytes with MSC. The seeding density of MSCs was 20,000 viable 
cells per cm2, and that of hepatocytes was 50,000 viable cells per cm2, at a MSC:hepatocyte ratio of 
1:2.5. Mono-cultured hepatocytes were used as control, and mono-cultured HPc-/NPc-MSCs were 
used as blank controls. 
5.2.1.3 Indirect co-culture of hepatocytes with MSCs 
Hepatocytes were indirectly co-cultured with HPc- versus NPc-MSCs using Transwell® 
Permeable Supports, as described in Section 4.2.4.2, Indirect co-culture of hepatocytes with MSCs, 
to investigate soluble factors underlying the hepatotrophic effects of MSCs co-culture and 
potentiative effect of HPc induction. 
The culture media were collected 24 h after culture. Culture supernatants were collected into 
sterile 1.5-mL centrifuge tubes and cryopreserved at −80°C for assays. Cell cultures were rinsed with 
one-wash PBS and cryopreserved at −80°C for further experiments. All experiments were performed 
in duplicate and repeated in triplicate independently. 
5.2.2 Pretreatment experiments 
5.2.2.1 NAC antagonisation experiment 
HPc-MSCs were pretreated with 10-mM NAC as described in Section 4.2.6.1, Optimisation of 
N-acetylcysteine concentration. MSCs cultures were rinsed with one wash of PBS, and fresh 
hepatocytes were co-cultured with NAC-treated versus non-treated HPc-MSCs as described in 
Section 4.2.4.1, Direct co-culture of hepatocytes with MSC.  
5.2.2.2 Staurosporine cytotoxicity experiment 
Fresh hepatocytes were pre-treated with 1-μM staurosporine and co-cultured with NPc-, HPc-, 




5.2.2.3 TNF-α ELISA and neutralisation experiment 
TNF-α ELISA The Quantikine® human TNF-α ELISA immunoassay kit (R&D Systems 
Europe, Ltd., Abingdon, UK) with the solid-phase sandwich enzyme immunoassay technique was 
used to quantitate soluble TNF-α level in cell cultures. The 96-well (12 strips of 8 wells) polystyrene 
microplate is pre-coated with a mouse monoclonal antibody against human TNF-α. All reagents were 
brought to room temperature 20 min prior to use. TNF-α standard was reconstituted with deionised 
water to prepare a stock solution of 10,000 pg/mL 15 min prior to dilution, and was serially diluted 
with the diluted calibrator diluent RD6-35 (animal serum) to give the standards 1,000, 500, 250, 125, 
62.5, 31.2, 15.6 pg/mL, whilst the calibrator diluent was used as the zero standard (0 pg/mL). Cell 
culture supernates were thawed at room temperature and centrifuged at 1,500 rpm for 1 min to pellet 
any cell debris or particulates. The assay diluent RD1F (buffered protein base), 50 μL per well, was 
added, and the standards, samples, and controls were incubated in the assigned wells, 200 μL per 
well, at room temperature for 2 h. The wells were rinsed with four washes of detergent buffer. The 
bound TNF-α was detected by TNF-α conjugate (polyclonal antibody against TNF-α conjugated to 
HRP),  100 μL per well, at room temperature for 60 min. The HRP detection antibody was removed, 
and the wells were rinsed with four washes of detergent buffer. The substrate solution containing 
stabilised hydrogen peroxide and stabilised chromogen TMB in an equal volume, 200 μL per well, 
was added, and the plate was incubated in the dark and at room temperature for 20 min. The 
enzymatic colour reaction was stopped by adding 2 N sulphuric acid, 50 μL per well. The OD was 
measured at 450 nm using the microplate reader. The TNF-α concentration (pg/mL) in each sample 
was determined using the TNF-α standard curve, and the reading of background hepatocyte culture 
medium (blank control) was subtracted from that of mono- or co-cultured hepatocytes or MSCs to 
obtain the colorimetric OD of hepatocyte or MSCs culture per se.  
TNF-α neutralisation experiment TNF-α neutralisation experiment was performed to 
investigate proapoptotic effect of  TNF-α on mono-cultured hepatocytes. Human TNF-α affinity 
purified polyclonal antibody was purchased from R&D Systems Europe Ltd. (Abingdon, United 
Kingdom) and reconstituted at 1 mg/mL in sterile PBS. Freshly isolated primary human hepatocytes 
were seeded onto collagen-precoated 96-well plates at a density of 50,000 viable cells per cm2 for a 
24-h pre-incubation. The culture media were replaced by fresh hepatocyte culture media containing 
0× (control), 1× (10 μg/mL), 2.5×, 5×, 10×, and 20× TNF-α neutralisation antibody for further 24-h 
mono-culture. 
5.2.2.4 TGF-β ELISA and neutralisation experiment 
TGF-β1 ELISA The Quantikine® human TGF-β1 ELISA immunoassay kit (R&D Systems 
Europe, Ltd., Abingdon, UK) with the solid-phase sandwich enzyme immunoassay technique was 
used to quantitate soluble TGF-β1 level in cell cultures. The 96-well (12 strips of 8 wells) 
polystyrene microplate is pre-coated with a mouse monoclonal antibody against human TGF-β1. All 
reagents were brought to room temperature 20 min prior to use. TGF-β1 standard was reconstituted 
with deionised water to prepare a stock solution of 2,000 pg/mL 15 min prior to dilution, and was 
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serially diluted with the diluted calibrator diluent RD5-53 (buffered protein base) to give the 
standards 1,000, 500, 250, 125, 62.5, 31.2, 15.6 pg/mL, whilst the calibrator diluent was used as the 
zero standard (0 pg/mL). Cell culture supernates were thawed at room temperature and centrifuged 
at 1,500 rpm for 1 min to pellet any cell debris or particulates. TGF-β1 is generally secreted as a 
latent form to the cell culture medium and becomes immunoreactive following acid activation and 
neutralisation. Briefly, the cell culture supernate (100 μL) was incubated with 1-N hydrochloride 
acid (20 μL; Sigma-Aldrich, St Louis, MO, USA) at room temperature for 10 min, and the acidified 
sample was neutralised by adding 1.2-N hydroxyl peroxide (20 μL; Sigma-Aldrich, St Louis, MO, 
USA) containing 0.5-M HEPES to a pH value of 7.2−7.6. The assay diluent RD1-21 (buffered 
protein solution), 50 μL per well, was added, and the standards, activated samples (diluted in 1.4 
folds), and controls were incubated in the assigned wells, 50 μL per well, at room temperature for 2 
h. The wells were rinsed with four washes of detergent buffer. The bound TGF-β1 was detected by 
TGF-β1 conjugate (polyclonal antibody against TGF-β1 conjugated to HRP),  100 μL per well, at 
room temperature for 2 h. The HRP detection antibody was removed, and the wells were washed 
with were rinsed with four washes of detergent buffer. The substrate solution containing stabilised 
hydrogen peroxide and stabilised chromogen TMB in an equal volume, 100 μL per well, was added, 
and the plate was incubated in the dark and at room temperature for 30 min. The enzymatic colour 
reaction was stopped by adding hydrochloride acid solution, 100 μL per well. The OD was measured 
at 450 nm using the microplate reader. The TGF-β1 concentration (pg/mL) in each sample was 
determined using the TGF-β1 standard curve, and the reading of background hepatocyte culture 
medium (blank control) was subtracted from that of mono- or co-cultured hepatocytes or MSCs to 
obtain the colorimetric OD of hepatocyte or MSCs culture per se.  
TGF-β neutralisation experiment TGF-β1 neutralisation experiment was performed to 
investigate whether soluble TGF-β1 secreted by MSCs contributed to the hepatotrophic effects of 
MSCs co-culture and potentiative effect of HPc induction. Human TGF-β1 affinity purified 
polyclonal antibody was purchased from R&D Systems Europe Ltd. (Abingdon, United Kingdom) 
and reconstituted at 1 mg/mL in sterile PBS. P4−6 human AT-MSCs were seeded onto collagen-
precoated 96-well plates at a density of 20,000 viable cells per cm2 for a 24-h pre-incubation. The 
culture media were replaced by fresh hepatocyte culture media containing 0× (control), 1× (1 
μg/mL), 2.5×, 5×, 10×, and 20× TGF-β1 neutralisation antibody. Mono-cultured MSCs were further 
subjected to HPc versus NPc for 24 h, and fresh hepatocytes were co-cultured with HPc- and NPc-
MSCs for additional 24 h as described in Section 4.2.4.1, Direct co-culture of hepatocytes with MSC. 
5.2.2.5 Collagen assay and inhibition experiment 
Cellular collagen assay Cellular collagen was semi-quantitated using the colorimetric 
assay with picro-sirius red (PSR) staining. PSR specifically binds to hydroxyproline residuals 
enriched in collagen (up to 14% by weight). PSR was gifted by Dr Qihe Xu (Department of Renal 
Medicine, King’s College London) and reconstituted at 0.1% in saturated aqueous solution of picric 
acid (Sigma-Aldrich, St Louis, MO, USA). Cell cultures in chamber slides (Thermo Scientific Nunc, 
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Loughborough, UK) or 96-well plates were fixed in methanol (Sigma-Aldrich, St Louis, MO, USA) 
at -20°C overnight, and rinsed with two washes of PBS for 5 min. Cell cultures were stained in 0.1% 
PSR solution at room temperature for 4 h. The staining solution was discarded, and cell cultures 
were rinsed with three washes of 0.1% acetic acid for 5 min. PSR-stained cell cultures in chamber 
slides were dehydrated in three washes of absolute ethanol for 5 min, permeabilised in three washes 
of xylene for 10 min, and mounted with coverslips for light photomicrography. PSR-stained cell 
cultures in 96-well plates were eluted in 0.1 N sodium hydroxide (Sigma-Aldrich, St Louis, MO, 
USA), 200 μL per well, for 1 h for spectrophotometry. The OD was measured at 540 nm using the 
microplate reader.  
Soluble and extracellular collagen assays Soluble and extracellular collagen was 
quantitated using the colorimetric assay with the Sircol™ soluble collagen assay kit (Biocolor, 
Carrickfergus, UK). Fresh (blank control) and thawed culture media, 1 mL per vial, were transferred 
into 1.5-mL low-protein-binding Eppendorf tubes (Eppendorf UK Limited, Stevenage, UK). The ice-
cold isolation and concentration reagent containing Tris-HCl buffered polyethylene glycol (pH = 7.6) 
was added, 200 μL per vial, for an overnight incubation at 4°C. The tubes were centrifuged to pellet 
hydrated collagen at 12,000 rpm for 10 min, and the supernatant was removed using a 1-mL 
micropipette. The Sircol dye reagent containing PSR was added, 1 mL per vial, and the tubes were 
gently shaken for 30 min. The tubes were centrifuged to pellet the collagen-dye complex at  12,000 
rpm for 10 min, and the supernatant was removed using a 1-mL micropipette. The ice-cold acid-salt 
wash reagent containing acetic acid, sodium chloride, and surfactants was gently layered on the 
collagen-dye pellet, 750 μL per vial, to remove unbound dye. The tubes were centrifuged to pellet 
the bound collagen-dye complex at 12,000 rpm for 10 min, and the supernatant was removed using a 
1-mL micropipette. The alkali reagent containing 0.5-M sodium hydroxide was added, 250 μL per 
vial, to release the bound collagen-dye into the solution for 5 min. Samples were transferred to 
assigned wells of a clear-bottom 96-well plate, 200 μL per well. Extracellular collagen was 
solubilised by overnight incubation with 0.1 mg/mL pepsin (Sigma-Aldrich, St Louis, MO, USA) in 
0.5-M acetic acid at 4°C. The acid extracts were neutralised by adding the acid neutralising reagent, 
1 mL per vial, containing Tris-HCl buffered sodium hydroxide. Extracellular collagen was further 
stained using the same protocol, and collagen standards 0, 5, 10, and 15 μg reconstituted in 100-μL, 
0.5-M acetic acid were also stained using the same protocol to produce the standard curve. The OD 
was measured at 540 nm using the microplate reader. The collagen content in each sample was 
determined using the collagen standard curve, and the reading of background hepatocyte culture 
medium (blank control) was subtracted from that of mono- or co-cultured hepatocytes or MSCs to 
obtain the colorimetric OD of hepatocyte or MSCs culture per se. The collagen content was 
normalised to that (mg) of 1 million hepatocytes or MSCs.  
Collagen inhibition experiment N-(methylamino)isobutyric acid  (MaIBA) is a 
competitive inhibitor of the neutral amino acid transport A system in collagen synthesis. HPc- and 
NPc-MSCs were subjected to 0-, 0.1-, 0.5-, 1-, 2.5-, 5-, 10-, 20-mM MaIBA (Sigma-Aldrich, St 
Louis, MO, USA) for 24 h. Cytotoxic effect of MaIBA on MSCs was evaluated using MTT and SRB 
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attachment assays as described in MTT assay was performed as described in Section 2.5, 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Colorimetric Assay and Section 2.6, 
Sulforhodamine B Colorimetric Assay. Extracellular collagen deposit of MaIBA-treated HPc- and 
NPc-MSCs was determined using the Sircol™ soluble collagen assay kit as described above. The 
least concentration of MaIBA that resulted in significant reduction in extracellular collagen deposit 
of HPc- and NPc-MSCs was used for further inhibition experiment. MaIBA-treated versus non-
treated HPc- and NPc-MSCs were co-cultured with hepatocytes for 24 h as described in Section 
5.2.1.2, Direct co-culture of hepatocytes with MSCs. 
The culture media were collected 24 h after culture. Culture supernatants were collected into 
sterile 1.5-mL centrifuge tubes and cryopreserved at −80°C for further assays. Cell cultures were 
rinsed with one-wash PBS and cryopreserved at −80°C for further experiments. All experiments 
were performed in duplicate and repeated in triplicate independently. 
5.2.3 Hepatocyte apoptosis and total death assays 
CCK18 assay was performed as described in Section 2.9, Caspase-cleaved CK18 Assay to 
determine caspase-mediated hepatocyte apoptosis. CK18 assay was performed as described in 
Section 2.10, CK18 Assay to determine total hepatocyte death. The ratio of CCK18 to CK18 was 
also produced to determine the death mode of hepatocytes in vitro; a ratio of over 0.40 indicated that 
hepatocytes underwent apoptosis mainly, and necrosis vice versa. All experiments were performed in 
duplicate and repeated in triplicate independently. 
5.2.4 Two-step, semi-quantitative, real-time polymerase-chained reaction assay 
5.2.4.1 Total RNA extraction 
The Direct-zol™ RNA MiniPrep kit (Zymo Research Corporation, Irvine, CA, USA) was used 
to isolate and purify RNA samples. Fresh cell cultures in 6-well plate were lysed by adding the 
TRIzol® reagent (Life Technologies Ltd., Paisley, UK), 1 mL per well. Cell sample homogenates 
were centrifuged at 12,000 × g for 1 min to remove any particulates and transferred into RNase-free 
Eppendorf tubes. One volume of absolute ethanol, molecular biology grade (Sigma-Aldrich, St 
Louis, MO, USA), was added into one volume of sample homogenate (1:1). The mixture was loaded 
into a Zymo-Spin™ IIC Column2 and centrifuged in a collection tube at 12,000 × g for 1 min. The 
flow-through was discarded, and the Zymo-Spin™ column was transferred into a new collection 
tube. The concentrated (5 ×) RNA wash buffer was diluted with absolute ethanol and loaded into the 
Zymo-Spin™ column. The column was centrifuged 12,000 × g for 1 min, and the flow-through was 
discarded. The in-column DNase I digestion was performed using the DNase I cocktail (Promega, 




Table 5.1 In-column DNase I digestion cocktail recipe 
Constituents Volume per column (μL) 
Lyophilised DNase I (1 U/μL) 5 
10× RNase-free DNase I reaction buffer 8 
DNase/RNase-free water 3 
RNA wash buffer 64 
Total 80 
The cocktail was well mixed in an RNase-free Eppendorf tube by gentle inversion. The cocktail 
was directly loaded into the column matrix, 80 μL per column, and incubated on a heat block at 
37°C for 15 min. The column was centrifuged at 12,000 × g for 30 sec.  The Direct-zol™ RNA 
PreWash (5 ×, diluted in absolute ethanol) was loaded onto the column, 400 μL per column. The 
column was centrifuged at 12,000 × g for 1 min, and the flow-through was discarded. The step of 
prewash was repeated once. The RNA wash buffer was loaded onto the column, 700 μL per column, 
and the column was centrifuged at 12,000 × g for 1 min. The flow-through was discarded, and the 
column was centrifuged for additional 2 min. The column was transferred to an RNase-free 
Eppendorf tube. DNase/RNase-free water, 25 μL per column, was directly loaded into the column 
matrix, and the column was centrifuged at the maximum speed for 1 min. Additional 25-μL 
DNase/RNase-free water was added to further elute RNA sample. The quantity and purity of the 
eluted RNA sample were determined using a NanoDrop 1000 spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA). RNA samples were reconstituted, at 1 μg for mono- or co-cultured 
hepatocytes and 0.5 per μg for mono-cultured MSCs per 26-μL final stock solution, in 0.2-mL PCR-
clean Eppendorf tubes. An RNA sample with a ratio of the absorbance at 260 and 280 nm (A260/280) 
above 2.0 was determined to be pure RNA (Okamoto and Okabe, Int J Mol Med, 2000). The 
reconstituted stock solutions were stored at -20°C for further experiments. 
5.2.4.2 cDNA synthesis 
RNA samples were thawed on ice and reversely transcribed into complement DNA (cDNA) 
using the Omniscript® Reverse Transcriptase kit (Qiagen, West Sussex, UK). The reverse 
transcription (RT) cocktail was prepared using the following recipe (Table 5.2). 
Table 5.2 Reverse transcription cocktail recipe 
Constituents Volume per sample (μL) 
10× RT buffer 4 
dNTP mix 4 
Oligo dT primer 2 
RNase out 0.5 
Reverse transcriptase 2 






RNA samples were preheated at 65°C using a PCR thermal cycler (Thermo Scientific, 
Wilmington, DE, USA) for 5min, and snap chilled on ice. The RT cocktail, 14 μL per vial, was 
added into the RNA sample, and the mixture was incubated at 37°C using the PCR thermal cycler 
for 60 min. The resultant cDNA samples were stored at -20°C for further experiments. 
5.2.4.3 Semi-quantitative, real-time polymerase-chained reaction assay (qRT-PCR) 
cDNA samples were thawed on ice and amplified using the TaqMan® PreAmp master mix kit 
(Applied Biosystems, Foster City, CA, USA). The qPCR Master Mix was prepared using the 
following recipe (Table 5.3).  
Table 5.3 qPCR Master Mix recipe 
Constituents Volume per column (μL) 
TaqMan® gene expression MasterMix 10 
Primers 1 
DNase/RNase-free water 7 
Total 18 
The qPCR Master Mix was added into a chilled MicroAmp® fast optical 96-well reaction plate 
Applied Biosystems, Foster City, CA, USA), 18 μL per well. The following proprietary primers 
(Table 5.4) for human gene expression assays were used and synthesised by Invitrogen (Paisley, UK). 
cDNA samples were added to the assigned wells, 2 μL per well, and well mixed by gentle pipetting. 
Table 5.4 qPCR primer identification 
Gene Symbol Assay ID Dye Label 
B2M (reference gene) Hs00984230_m1 VIC 
CASP3 Hs00234385_m1 FAM 
CASP8 Hs01018151_m1 FAM 
CASP9 Hs00154261_m1 FAM 
CASP14 Hs00201637_m1 FAM 
BAX Hs00180269_m1 FAM 
BCL-2 Hs00236808_s1 FAM 
BID Hs00609632_m1  FAM 
BLK Hs00176441_m1 FAM 
Semi qRT-PCR assay was performed using the ABI PRISM® 7000 sequence detection system 
(Applied Biosystems, Foster City, CA, USA). The thermal cycling conditions were as follows: 
uracil-DNA glycosylase was activated at 50°C for 2 min; AmpliTaq® gold enzyme was activated at 
50°C for 2 min; and cDNA template was denatured at 95°C for 15 sec and annealed/extended at 
60°C for 1 min, for a total of 40 cycles. Cycle threshold (Ct) was produced with an automatic 
threshold using the Sequence Detection Software version 1.2.3 with 7000 System SDS Software RQ 
Study Application (Applied Biosystems, Foster City, CA, USA). 
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The qPCR results were analysed using the semi-quantitative 2-ΔΔCt method (Livak and 
Schmittgen, Methods, 2001) with the following formulae [ΔΔCt = ΔCt(treated) − ΔCt(control), where 
ΔCt(treated/control) = Ct(target gene) − Ct(reference gene)], and expressed as mRNA expression level (fold) 
relative to the control (mono-cultured hepatocytes). A 2-ΔΔCt value higher than 1 fold indicates 
upregulated expression of the target gene, and vice versa. All experiments were performed in 




5.3.1 Contribution of TNF-α and TGF-β to MSCs co-culture and HPc-induced 
potentiation 
5.3.1.1 TNF-α secretion and neutralisation 
Mono-cultured hepatocytes secreted a high level of TNF-α, while NPc-, HPc-, and NAC-
pretreated HPc-MSCs secreted no detectable (below the lower assay limit) TNF-α (Figure 5.2A). 
Direct co-culture with NPc-MSCs significantly decreased hepatocyte secretion of TNF-α as 
compared to hepatocyte mono-culture, while indirect co-culture decreased TNF-α secretion to a 
significantly lesser extent (mono- vs. direct co- vs. indirect co-culture, 154.5 ± 12.6 vs.10.6 ± 1.3 vs. 
134.1 ± 12.6 pg/mL, P <0.01). Co-culture with HPc-MSCs significantly further reduced hepatocyte 
secretion of TNF-α as compared to that with NPc-MSCs, while co-culture with NAC-pretreated 
HPc-MSCs significantly increased TNF-α secretion (NPc- vs. HPc- vs. NAC-treated HPc-MSCs co-
culture, 10.6 ± 1.3 vs. undetectable vs. 10.3 ± 1.6 pg/mL, P <0.01). 
TNF-α neutralisation even at the lowest dose (1×, 10 μg/mL) significantly inhibited CCK18 
release from mono-cultured hepatocytes (0× vs. 1×, 64.6 ± 6.4 vs. 40.4 ± 6.2 U/106 hepatocytes, P 
<0.01), while TNF-α neutralisation at higher doses did not significantly further inhibit apoptosis of 
mono-cultured hepatocytes (Figure 5.2B). Similarly, TNF-α neutralisation at 2.5× significantly 
suppressed total death of hepatocytes, although that at 1× showed no significant effect (0× vs. 1× vs. 
2.5×, 114.5 ± 7.2 vs. 105.9 ± 8.1 vs. 99.2 ± 7.3 U/106 hepatocytes, P <0.01; Figure 5.2C).  TNF-α 
neutralisation switched the death mode of mono-cultured hepatocytes from apoptosis to necrosis (0× 
vs. 1× vs. 2.5×, 56.4% ± 4.5% vs. 38.1% ± 5.9% vs. 38.7% ± 4.8%, P <0.01; Figure 5.2D). 
5.3.1.2 TGF-β1 secretion and neutralisation 
Mono-cultured hepatocytes and MSCs secreted high levels of TGF-β1. HPc significantly 
increased MSCs secretion of TGF-β1, while NAC pretreatment significantly decreased TGF-β1 
secretion (NPc vs. HPc vs. HPc+NAC, 172.5 ± 15.1 vs. 784.0 ± 35.0 vs. 596.9 ± 46.0 pg/mL, P 
<0.01; Figure 5.3A). Direct co-culture with NPc-MSCs significantly increased TGF-β1 secretion as 
compared to hepatocyte or MSCs mono-culture, while indirect co-culture increased TGF-β1 
secretion to a significantly lesser extent (mono- vs. direct co- vs. indirect co-culture, 369.5 ± 19.6 vs. 
871.0± 44.6 vs. 370.3 ± 22.4 pg/mL, P <0.01). Co-culture with HPc-MSCs further increased TGF-β1 
secretion as compared to that with NPc-MSCs, while co-culture with NAC-pretreated HPc-MSCs 
significantly decreased TGF-β1 secretion (NPc- vs. HPc- vs. NAC-treated HPc-MSCs co-culture, 
871.0± 44.6 vs. 1,370.8 ± 101.0 vs. 1,017.7 ± 64.1 pg/mL, P <0.01). 
TGF-β1 neutralisation starting from 5× (1× = 1 μg/mL) significantly diminished antiapoptotic 
effect of NPc- and HPc-MSCs co-culture (0× vs. 5×, NPc: 35.2 ± 2.4 vs. 45.0 ± 1.8 U/106 
hepatocytes, P <0.01; HPc: 32.0 ± 2.2 vs. 40.4 ± 2.8 U/106 hepatocytes, P <0.01; Figure 5.3B).  






Figure 5.2 TNF-α ELISA and neutralisation experiments. TNF-α secretion of mono-/co-cultured hepatocytes (A); effects of autocrine TNF-α neutralisation on apoptosis 
(B), total death (C), and death mode (D) of mono-cultured hepatocytes. All data were expressed as mean ± SD; **P <0.01 versus control mono-/co-culture; ^^P <0.01 versus non-








Figure 5.3 TGF-β1 ELISA and neutralisation experiments. TGF-β1 secretion of mono-/co-cultured hepatocytes and NPc-/HPc-MSCs (A); effects of MSCs TGF-β1 
neutralisation on apoptosis (B), total death (C), and death mode (D) of co-cultured hepatocytes. All data were expressed as mean ± SD; *P <0.05 and **P <0.01 versus control mono- 
or co-culture; ^^P <0.01 versus non-NAC treated; ##P <0.01 versus control mono-culture; ++P <0.01 versus direct co-culture. Hx, mono-cultured hepatocytes; UD, undetectable; iCo, 





MSCs co-culture (0× vs. 5×, NPc: 89.5 ± 8.2 vs. 96.3 ± 9.9 U/106 hepatocytes, P <0.05; HPc: 80.5 ± 
7.1 vs. 91.2 ± 7.4 U/106 hepatocytes, P <0.05; Figure 5.3C). TGF-β1 neutralisation resulted in a 
necrosis-to-apoptosis switch in death mode of hepatocytes co-cultured with NPc-MSCs starting from 
1× (0× vs. 1×, 39.3% ± 3.3% vs. 44.7% ± 3.6%, P <0.05) and with HPc-MSCs from 10× (0× vs. 10×, 
39.8% ± 4.1% vs. 46.6% ± 3.4%, P <0.05; Figure 5.3D). 
5.3.2 Contribution of cellular and extracellular collagen  
5.3.2.1 Cellular and extracellular collagen content 
Hepatocytes expressed some cellular rather than extracellular collagen in mono- (data not 
shown) and co-culture (Figure 5.4A), while MSCs secreted massive cellular and extracellular 
collagen in both mono- (Figure 5.4B) and co-culture (Figure 5.4A). 
Figure 5.4 PSR collagen staining (200×) of hepatocytes in co-culture with MSCs (A) and 
MSCs in mono-culture (B). Intracellular collagen was found in hepatocytes and MSCs, and extracellular 
collagen was mainly located in proximity to MSCs. 
HPc significantly increased MSCs expression of cellular collagen, while NAC pretreatment 
significantly decreased cellular collagen expression (NPc vs. HPc vs. HPc+NAC, 0.19 ± 0.04 vs. 
0.31 ± 0.06 vs. 0.24 ± 0.04 OD units, P <0.01; Figure 5.5A). Direct co-culture with NPc-MSCs 
significantly increased cellular collagen expression as compared to hepatocyte or MSCs mono-
culture, while indirect co-culture increased cellular collagen expression to a significantly lesser 
extent (mono- vs. direct co- vs. indirect co-culture, 0.07 ± 0.01 vs. 0.30 ± 0.06 vs. 0.22 ± 0.03 OD 
units, P <0.01). Co-culture with HPc-MSCs further increased cellular collagen expression as 
compared to that with NPc-MSCs, while co-culture with NAC-pretreated HPc-MSCs significantly 
decreased cellular collagen expression (NPc- vs. HPc- vs. NAC-treated HPc-MSCs co-culture, 0.30 
± 0.06 vs. 0.55 ± 0.04 vs. 0.33 ± 0.04 OD units, P <0.01). 
Mono-cultured hepatocytes secreted minimal extracellular collagen (below the lower assay 
limit), while MSCs deposited extracellular collagen (Figure 5.5B). HPc significantly increased 




extracellular collagen deposition (NPc vs. HPc vs. HPc+NAC, 0.39 ± 0.04 vs. 0.56 ± 0.06 vs. 0.40 ± 
0.02 mg/106 cells, P <0.01). Direct co-culture with NPc-MSCs significantly increased extracellular 
collagen deposition as compared to hepatocyte or MSCs mono-culture, while indirect co-culture 
increased extracellular collagen deposition to a significantly lesser extent (mono- vs. direct co- vs. 
indirect co-culture, 0.39 ± 0.04 vs. 2.89 ± 0.26 vs. 0.41 ± 0.02 mg/106 cells, P <0.01). Co-culture 
with HPc-MSCs further increased cellular collagen expression as compared to that with NPc-MSCs, 
while co-culture with NAC-pretreated HPc-MSCs significantly decreased cellular collagen 
expression (NPc- vs. HPc- vs. NAC-treated HPc-MSCs co-culture, 2.89 ± 0.26 vs. 5.97 ± 0.53 vs. 
3.30 ± 0.30 mg/106 cells, P <0.01). 
5.3.2.2 Effects of MaIBA on NPc- and HPc-MSCs co-culture 
MaIBA at a dose range from 0.1 to 20 mM had no toxic effect on MSCs with respect to 
mitochondrial dehydrogenase activity and cellular attachment (Table 5.5). MaIBA pretreatment at 5, 
10, and 20 mM significantly inhibited extracellular collagen deposition of NPc- and HPc-MSCs (0 
mM vs. 5 mM vs. 10 mM vs. 20 mM, NPc: 0.39 ± 0.04 vs. 0.33 ± 0.03 vs. 0.32 ± 0.03 vs. 0.30 ± 0.02 
mg/106 cells, P <0.01, Figure 5.5C; HPc: 0.56 ± 0.06 vs. 0.45 ± 0.05 vs. 0.44 ± 0.04 vs. 0.42 ± 0.04 
mg/106 cells, P <0.01; Figure 5.5D); therefore, 5-mM MaIBA was used for further collagen 
inhibition experiment. 







0 0.35 ± 0.03 0.53 ± 0.05 
0.1 0.33 ± 0.02 0.51 ± 0.04 
0.5 0.33 ± 0.03 0.51 ± 0.06 
1 0.33 ± 0.02 0.50 ± 0.03 
2.5 0.32 ± 0.03 0.53 ± 0.03 
5 0.32 ± 0.03 0.49 ± 0.03 
10 0.31 ± 0.03 0.51 ± 0.06 
20 0.33 ± 0.03 0.50 ± 0.03 
Pretreatment of 5-mM MaIBA significantly inhibited extracellular collagen deposition of 
hepatocytes co-cultured with NPc- and HPc-MSCs (0 mM vs. 5 mM, NPc: 2.89 ± 0.26 vs. 2.03 ± 
0.28 mg/106 cells, P <0.01; HPc: 5.97 ± 0.23 vs. 4.47 ± 0.29 mg/106 cells, P <0.01; Figure 5.6A). 
MaIBA pretreatment significantly diminished antiapoptotic effect of MSCs co-culture (0 mM vs. 5 
mM, 18.5 ± 2.4 vs. 25.5 ± 2.5 U/106 hepatocytes, P <0.01) and potentiative effect of HPc induction 
(14.5 ± 2.3 vs. 20.8 ± 2.1 U/106 hepatocytes, P <0.01; Figure 5.6B). However, MaIBA pretreatment 
had no significant prosurvival effect of MSCs co-culture and potentiative effect of HPc induction 
(Figure 5.6C). MaIBA pretreatment resulted in a necrosis-to-apoptosis switch in hepatocytes co-
cultured with NPc-MSCs (30.2% ± 3.2% vs. 38.9% ± 4.5%, P <0.01) and with HPc-MSCs (28.1% ± 





Figure 5.5 Cellular and extracellular collagen assays and collagen inhibition experiment. Cellular (A) and extracellular collagen (B) content of mono-/co-cultured 
hepatocytes and NPc-/HPc-MSCs; inhibitory effect of 0- to 20-mM MaIBA on extracellular collagen deposit of NPc- (C) and HPc-MSCs (D). All data were expressed as mean ± SD; 
*P <0.05 and **P <0.01 versus control mono- or co-culture; ^^P <0.01 versus non-NAC treated; ##P <0.01 versus control mono-culture; ++P  <0.01 versus direct co-culture. Hx, 






Figure 5.6 Effects of 5-mM MaIBA pretreatment on extracellular collagen deposit (A), 
cellular apoptosis (B), total death (C), and death mode (D) of hepatocytes co-cultured with NPc-
versus HPc-MSCs. All data were expressed as mean ± SD; **P <0.01 versus NPc-Co. Co, co-culture. 
5.3.3 Pro- and antiapoptosis-associated gene expressions 
5.3.3.1 CASP9 
Expression of CASP3, CASP8, and CASP14 mRNA was undetectable in mono- or co-cultured 
hepatocytes. MSCs co-culture significantly downregulated expression of CASP9 mRNA (0.72 ± 0.07 
fold, P <0.01), while indirect co-culture slightly downregulated CASP9 mRNA expression (0.90 ± 
0.07 fold, P >0.0; Figure 5.7A). HPc further downregulated CASP9 mRNA expression in MSCs co-
culture (0.55 ± 0.05 fold, P <0.01), while NAC pretreatment diminished HPc-induced further 
downregulation (0.71 ± 0.07 fold, P <0.01). Additionally, staurosporine pretreatment significantly 
upregulated expression of CASP9 mRNA in mono-cultured hepatocytes (1.44 ± 0.12 folds, P <0.01), 
while MSCs co-culture significantly decreased staurosporine-induced upregulation of CASP9 mRNA 
expression (0.90 ± 0.07 fold, P <0.01). 
5.3.3.2 BAX, BCL-2, BAX/BCL-2 ratio, and BID 
MSCs co-culture significantly downregulated expression of BAX mRNA (0.39 ± 0.11 fold, P 
<0.01), while indirect co-culture slightly downregulated BAX mRNA expression (0.83 ± 0.17 fold, 
P >0.05; Figure 5.7B). HPc further downregulated BAX mRNA expression in MSCs co-culture (0.12 
± 0.03 fold, P <0.01), while NAC pretreatment diminished HPc-induced further downregulation 






expression of BAX mRNA in mono-cultured hepatocytes (1.37 ± 0.24 folds, P <0.01), while MSCs 
co-culture significantly decreased staurosporine-induced upregulation of BAX mRNA expression 
(0.65 ± 0.17 fold, P <0.01). 
MSCs co-culture significantly upregulated expression of BCL-2 mRNA (1.28 ± 0.17 fold, P 
<0.01), while indirect co-culture slightly downregulated BCL-2  mRNA expression (0.95 ± 0.10 fold, 
P >0.05; Figure 5.7C). HPc further upregulated BCL-2 mRNA expression in MSCs co-culture (1.86 
± 0.26 folds, P <0.01), while NAC pretreatment diminished HPc-induced further upregulation (1.34 
± 0.09 folds, P <0.01). Additionally, staurosporine pretreatment significantly downregulated 
expression of BCL-2 mRNA in mono-cultured hepatocytes (0.58 ± 0.17 fold, P <0.01), while MSCs 
co-culture significantly increased staurosporine-induced downregulation of BCL-2 mRNA 
expression (0.86 ± 0.10 fold, P <0.01). 
MSCs co-culture significantly decreased BAX/BCL-2 ratio (0.30 ± 0.07 fold, P <0.01), while 
indirect co-culture slightly decreased BAX/BCL-2 ratio (0.88 ± 0.12 fold, P >0.05; Figure 5.7D). HPc 
further decreased BAX/BCL-2 ratio in MSCs co-culture (0.06 ± 0.01 fold, P <0.01), while NAC 
pretreatment diminished HPc-induced further decrease (0.20 ± 0.07 fold, P <0.01). Additionally, 
staurosporine pretreatment significantly increased BAX/BCL-2 ratio in mono-cultured hepatocytes 
(2.36 ± 0.22 folds, P <0.01), while MSCs co-culture significantly decreased staurosporine-induced 





Figure 5.7 Relative mRNA expression levels of pro- and antiapoptosis-associated genes in mono- and co-cultured hepatocytes: CASP9 (A), BAX (B), BCL-2 (C), 
BAX/BCL-2 ratio (D), BID (E), and BLK (F). All data were expressed as mean ± SD; **P <0.01 versus control hepatocyte mono-culture; §§P <0.01 versus direct co-culture; ^^P <0.01 
versus SS-treated, mono-cultured hepatocytes; ##P  <0.01 versus NPc co-culture; +P < 0.05 and ++P <0.01 versus non-NAC-treated HPc co-culture. Hx, mono-cultured hepatocytes; 
SS, staurosporine; Co, co-culture; iCo, indirect co-culture. 
§§ 
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MSCs co-culture significantly downregulated expression of BID mRNA (0.25 ± 0.13 fold, P 
<0.01), and indirect co-culture also significantly downregulated BID mRNA expression to a 
significantly lesser extent (0.65 ± 0.12 fold, P <0.01; Figure 5.7E). HPc further downregulated BID 
mRNA expression in MSCs co-culture (0.10 ± 0.04 fold, P <0.01), while NAC pretreatment 
diminished HPc-induced further downregulation (0.15 ± 0.02 fold, P <0.01). Additionally, 
staurosporine pretreatment significantly upregulated expression of BID mRNA in mono-cultured 
hepatocytes (1.46 ± 0.17 folds, P <0.01), while MSCs co-culture significantly decreased 
staurosporine-induced upregulation of BID mRNA expression (0.53 ± 0.12 fold, P <0.01). 
5.3.3.3 BLK 
MSCs co-culture significantly downregulated expression of BLK mRNA (0.48 ± 0.05 fold, P 
<0.01), and indirect co-culture also significantly downregulated BLK mRNA expression to a 
significantly lesser extent (0.63 ± 0.05 fold, P <0.01; Figure 5.7F). HPc further downregulated BLK 
mRNA expression in MSCs co-culture (0.32 ± 0.06 fold, P <0.01), while NAC pretreatment 
diminished HPc-induced further downregulation (0.44 ± 0.12 fold, P <0.01). Additionally, 
staurosporine pretreatment significantly upregulated expression of BLK mRNA in mono-cultured 
hepatocytes (1.69 ± 0.24 folds, P <0.01), while MSCs co-culture significantly decreased 
staurosporine-induced upregulation of BLK mRNA expression (0.61 ± 0.05 fold, P <0.01). 
5.3.3.4 Summary of gene expression assays 
Direct MSCs co-culture significantly downregulated expression of proapoptotic CASP9, BAX, 
and BID mRNA and significantly upregulated expression of antiapoptotic BCL-2 mRNA. In contrast, 
indirect MSCs co-culture significantly downregulated expression of BID and BLK mRNA to a 
significantly lesser extent only. HPc further significantly downregulated expression of CASP9, BAX, 
BID, and BLK mRNA and significantly upregulated expression of BCL-2 mRNA in MSCs co-culture; 
however, NAC pretreatment diminished HPc-induced down- and upregulation of the respective 
genes. Additionally, staurosporine pretreatment culture significantly upregulated expression of 
CASP9, BAX, BID, and BLK mRNA and significantly downregulated expression of BCL-2 mRNA, 





5.4.1 MSCs inhibit autocrine TNF-α activity of co-cultured hepatocytes 
TNF-α is a pleiotropic cytokine chiefly secreted by activated immune cells, and plays a central 
role in inflammation and apoptosis. TNF-α is known to mediate LPS-induced hepatocyte apoptosis, 
manifesting as DNA fragmentation and cytoplasmic translocation of alanine aminotransferase, which 
can be antagonised by pretreatment with IL-1β (Leist et al., 1995). TNF-α induced hepatocyte 
apoptosis depends on caspase signalling pathway, including activation of caspases-2 (Guicciardi et 
al., 2005), -8 (Imao et al., 2006), and -9 (Imao et al., 2006). Hepatocytes secrete a high level of 
TNF-α (600 pg/mL) within 4 h if challenged with LPS (Saad et al., 1995). However, TNF-α 
inhibitors suppress hepatocyte proliferation in response to mitogen (Kubo et al., 1996), while 
stimulatory effect of TNF-α on hepatocytes may result from liver NPCs response to TNF-α 
(Shinozuka et al., 1996). It was also reported that hepatocytes resisted TNF-α induced apoptosis by a 
mechanism dependent on pre-existing intracellular glutathione, a major effector reducing ROS (Xu 
et al., 1998). This bidirectional regulation of TNF-α on epithelial cells may be modulated by other 
extrinsic and/or intrinsic factors, such as redox (Kim et al., 2000), NF-κB (Nagaki et al., 2000), 
EGFR (Argast et al., 2004), and HGF (Grant-Tschudy and Wira, 2005). 
The present work showed that mono-cultured hepatocytes secreted a baseline level of autocrine 
TNF-α (approximately 640 pg/106 hepatocytes/24 h), and TNF-α neutralisation significantly 
decreased spontaneous apoptosis and total death of mono-cultured hepatocytes. MSCs expressed no 
TNF-α and inhibited autocrine activity of TNF-α in co-cultured hepatocytes. This finding was 
contradictory to that reported by Gu et al. (2009a), in which TNF-α was not expressed  in mono- or 
co-cultured hepatocytes. This inconsistency might derive from the differences in source of 
hepatocytes (human versus porcine) and co-culture protocol (layered versus mixed). Shi et al. (2011) 
reported that MSCs co-culture protected hepatocytes from apoptosis induced by exposure to acute-
on-chronic liver failure serum containing a high level of  TNF-α. It was also reported that TNF-α 
treatment significantly upregulated expression of VEGF, FGF2, HGF, and IGF-1 in human MSCs by 
an NF-κB-independent, JNK-independent mechanism (Crisostomo et al., 2008). The present work 
demonstrated for the first time that trophic and protective effects of MSCs on co-cultured 
hepatocytes might result from inhibition of proapoptotic TNF-α in addition to expression of trophic 
factors by MSCs. However, this finding should be cautiously explained as MSCs co-culture CM 
containing a very low level of TNF-α could not improve liver-specific metabolism or protect mono-
cultured hepatocytes from spontaneous apoptosis, suggesting the role of synergistic factors aside 
from TNF-α. The present work showed that inhibitory effect of MSCs co-culture on autocrine TNF-α 
activity of hepatocytes depended on MSC-to-hepatocyte contact as evidenced by the minimal effect 
of indirect non-contact co-culture. This inhibitory effect could also be potentiated by HPc in an intra-
MSCs ROS activity dependent manner as NAC pretreatment diminished the potentiative effect of 
HPc induction.  
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5.4.2 Hepatotrophic effect of MSCs co-culture and potentiative effect of HPc 
induction depend on autocrine TGF-β activity of MSCs 
TGF-β is a polypeptide secreted by multiple cell lines, including platelets, macrophages, 
fibroblasts, and mesenchymal stem cells, and involved in a large number of biological activities, 
such as cell growth, cell proliferation, cell differentiation, and apoptosis (Ng et al., 2008). TGF-β 
plays a crucial role in regulating MSCs differentiation and promotes chondrogenic differentiation of 
human MSCs by upregulating expression of SOX9, type II collagen, and aggrecan (Miyanishi et al., 
2006). Synergistic treatment of IL-1β and TGF-β1 can also increase MSCs secretion of VEGF and 
improve cardioprotective effect of MSCs transplantation (Luo et al., 2012). TGF-β is also believed 
to be a major trophic factor released from MSCs for the host cells. MSCs maintain phenotype and 
pluripotency of human ES cells through TGF-β and FGF receptor in response to bFGF (Montes et al., 
2009).  
Generally, TGF-β has a negative effect on biological activities of hepatocytes. TGF-β inhibits 
hepatocyte DNA synthesis, proliferation, differentiation, and liver-specific metabolism. TGF-β is 
well known as a potent stimulant that induces EMT. TGF-β treatment in vitro can induce EMT in 
human foetal hepatocytes accompanied by upregulation of Snail signalling (mesenchymal cell 
marker) and downregulation of E-cadherin (epithelial cell marker) expression (Caja et al., 2011). 
Abnormal TGF-β expression is believed to be a major etiology of liver fibrosis (Dooley et al., 2008; 
Ciuclan et al., 2010).  However, TGF-β1 was reported to be required for functional enhancement in 
hepatocytes co-cultured with NIH/3T3 cells as this functional enhancement could be eliminated by 
TGF-β1 depletion and restored by TGF-β1 reconstitution (Chia et al., 2005). This paradox might 
result from the complex interplays between soluble factors and MSCs/hepatocytes.  
The present work showed that both hepatocytes and MSCs secreted a baseline level of TGF-β1, 
while co-culture of hepatocytes with MSCs exhibited an additive or synergistic effect with respect to 
TGF-β1 production. This additive or synergistic effect depended on MSC-to-hepatocyte contact as 
indirect non-contact co-culture only secreted a similar level of TGF-β1 to direct co-culture. This 
finding was consistent with the previous report (Chia et al., 2005). HPc potentiated MSCs secretion 
of TGF-β1 in both mono- and co-culture by an intracellular ROS-dependent manner as evidenced by 
the reversal effect of NAC pretreatment. It has recently been reported that hypoxia increases MSCs 
secretion of TGF-β1 and promotes breast cancer cell progression, and the major hypoxia-regulated 
element is determined to be HIF-1 binding to the hypoxia response element of TGF-β1 promoter 
(Hung et al., 2013). The present work also demonstrated that autocrine TGF-β1 activity of MSCs 
was required for the hepatotrophic effects of MSCs co-culture and potentiative effect of HPc 
induction as evidenced by neutralisation of MSCs-derived TGF-β1. As MSCs co-culture CM 
containing high-level TGF-β1 had no significant hepatotrophic and antiapoptotic effect, autocrine 
TGF-β1 of NPc- and HPc-MSCs might not act on hepatocytes through ECM and/or cell-to-cell 
contact rather than a paracrine mechanism. TGF-β activation is reported to mediate the crosstalk 
between hepatocytes and the stromal niche in the setting of HCV infection (Benzoubir et al., 2013).  
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5.4.3 Hepatotrophic effect of MSCs co-culture and potentiative effect of HPc 
induction depend on MSCs deposition of extracellular collagen 
Collagen is the major component and the most abundant protein in ECM. The main biological 
function of collagen, especially extracellular form, is to support resident cells in the form of fibrillar 
protein. In physiological conditions, liver collagen is mainly produced by hepatic NPCs rather than 
hepatocytes, while pathological hepatocytes deposit collagen in response to profibrotic factors, such 
as TGF-β (Vadasz et al., 2005). The present work confirmed that hepatocytes secreted little 
extracellular collagen; however, hepatocytes were reported to produce some collagenous 
components, such as collagen type I, II, III, and V (Diegelmann et al., 1983). Collagen attachment is 
known to support hepatocyte with respect to metabolic function; as a result, monolayer collagen 
coating and modified collagen gel ‘‘sandwich’’ culture are widely used for hepatocyte culture and 
bioartificial liver system (Wang et al., 2004). Maintenance effect of collagen was thought to result 
from persistent phosphorylation of HGF and EGF receptors (Engl et al., 2004). Extracellular 
collagen also regulates the cell cycle of hepatocytes. Collagen facilitates the entry of hepatocytes 
into the S-phase by a cyclin D1-dependent mechanism (Hansen and Albrecht, 1999), and mediates 
aggregation of hepatocytes and intercellular contact (Moghe et al., 1997).  
Collagen regulates survival, proliferation, and differentiation of MSCs; conversely, MSCs 
deposit extracellular collagen during chondrogenesis and osteogenesis (Li et al., 2011). The present 
work demonstrated that MSCs deposition of extracellular collagen could be enhanced by direct co-
culture with hepatocytes, and extracellular collagen deposition contributed, at least partially, to 
trophic and antiapoptotic effects of MSCs on co-cultured hepatocytes as shown in the collagen 
inhibition experiments. This finding was consistent with the report by Gu et al. (2009c); extracellular 
collagen was mainly located around MSCs and knockdown of collagen type I/V expression in MSCs 
significantly reduced synthesis of albumin and urea in hepatocytes. This finding also suggested that 
enhanced MSCs deposition of extracellular collagen might result primarily from MSC-to-hepatocyte 
contact as indirect non-contact co-culture did not show any significant effect. The present work also 
showed that HPc significantly increased extracellular collagen expression in mono- and co-cultured 
MSCs in an intracellular ROS dependent manner. Low oxygen tension is known to promote 
osteochondrogenesis of MSCs. HPc significantly upregulated expression of collagen I, II, and X 
along with some other genes encoding ECM (Müller et al., 2011). Hypoxia can also optimise 
cartilaginous matrix production of articular chondrocytes co-cultured with MSCs, thereby 
minimizing the requirement on harvest and expansion of primary chondrocytes (Meretoja et al., 
2013). It was noted that increased MSCs deposition of extracellular collagen was accompanied by 
enhanced autocrine activity of TGF-β, a potent stimulant of collagen synthesis (Rodríguez et al., J 
Cell Biochem, 2000). Increased extracellular collagen deposit might result from autocrine TGF-β 
activation in MSCs. 
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5.4.4 Hepatotrophic effect of MSCs co-culture and potentiative effect of HPc 
induction result from downregulation of proapoptotic signalling and 
upregulation of antiapoptotic signalling  
Apoptotic death of hepatocytes is finely modulated by the complex interplay between 
proapoptotic factors and antiapoptotic factors. Spontaneous hepatocyte apoptosis is thought to be a 
major cause of early cellular loss and metabolic deterioration. The well documented trophic effect of 
MSCs on co-cultured hepatocytes may result from suppression of hepatocyte apoptosis. The 
antiapoptotic effect of MSCs is supposed to derive from a combination of paracrine factors, ECM, 
and cell-to-cell interaction. The results in Chapter 3 showed that MSCs significantly inhibited 
spontaneous and chemically-induced apoptosis of co-cultured hepatocytes by nonparacrine 
mechanisms, and those in Chapter 4 further confirmed that HPc potentiated antiapoptotic effect of 
MSCs co-culture by an intracellular ROS dependent mechanism. The results of gene expression 
analyses in this chapter showed that downregulation of apoptosis-associated caspases and 
BAX/BCL-2 signalling pathways underlay the antiapoptotic effect of MSCs and potentiative effect 
of HPc induction. To the best of my knowledge, the present work demonstrated apoptosis-associated 
gene expression profiles of hepatocytes co-cultured with MSCs for the first time. It was also noted 
that indirect co-culture with MSCs only downregulated expression of two genes, BID and BLK. This 
finding might explain why paracrine factors of MSCs had limited trophic and antiapoptotic effect on 
co-cultured hepatocytes. 
Caspases, also called cysteine-dependent aspartate-directed proteases, are a family of cysteine 
proteases that play an essential role in regulating cellular apoptosis, necrosis, and inflammatory 
response. Caspase signalling pathway functions to initiate and execute cellular apoptosis in a 
complex but well documented cascade manner, if activated by granzyme B for caspases-3 and -7, 
death receptors for caspases-8 and -10, and apoptosome for caspase-9. Caspase-3 plays a central role 
in the execution phase of apoptosis activated both by extrinsic (death ligand) and intrinsic 
(mitochondrial) pathways, and interacts with caspases-8 and-9. LPS-induced hepatocyte apoptosis 
was thought to result from upregulation of caspase-3 expression in the presence of activated Kupffer 
cells (Hamada et al., 1999). AT-MSCs CM was reported to protect PC12 cells from glutamate 
excitotoxicity-induced apoptosis by inhibiting caspase-3 activity through upregulation of XIAP (X-
linked inhibitor of apoptosis protein) and PI3-K (phosphatidylinositide 3-kinases)/Akt activation (Lu 
et al., 2011). Caspase-8 is the prototypical apoptosis initiator downstream of TNF superfamily death 
receptors, and activated caspase-8 can start the cascades of cellular apoptosis along with other 
effector caspases and proapoptotic Bcl-2 family members.  ROS-induced activation of caspase-8 was 
reported to promote hepatocyte apoptosis and liver fibrosis in the setting of non-alcoholic 
steatohepatitis (Hatting et al., 2013). Caspase-9 is the initiator of caspase-mediated apoptosis 
through the mitochondrial pathway; activation of JNK/SAPK (stress-activated protein kinase) 
signalling releases cytochrome from the mitochondrial into the cytoplasm and activates the 
apoptosome, which cleaves the pro-enzyme of caspase-9 into the active form (Kang  and Chae, 
2003). Caspase-14 is activated by caspases-8 and -9 and invovled in apoptosis execution and also 
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keratinocyte terminal differentiation (Walsh et al., 2005). The role of caspase-14 remains unknown 
in hepatocyte apoptosis. The present work showed that MSCs co-culture and HPc significantly 
downregulated expression of caspase-9; however, no expression of caspases-3, -8, and -14 was 
detected. This finding suggested that antiapoptotic effect of MSCs co-culture and potentiative effect 
of HPc induction mainly acted on initiation of apoptosis, consistent with reduced caspase-9 initiated 
cleavage of hepatocyte CK18 into CCK18.  
BCL-2 is a superfamily of regulator proteins, including Bax, Bcl-2, Bid, invovled in cellular 
survival and apoptosis. Bax (Bcl-2-associated X protein 4) was the first identified proapoptotic 
member of Bcl-2 protein family. Following induction of apoptosis, BAX interacts with the 
mitochondrial membrane and activate the voltage-dependent anion channel. The opening of the 
anion channel results in massive release of cytochrome c and other proapoptotic factors and further 
activates caspases. In contrast, Bcl-2 (B-cell lymphoma 2) is an antiapoptotic member, and prevents 
the activation of BAX signalled by the ‘‘death cue’’ along with Bcl-xL. The Bax/Bcl-2 balance is 
well known to regulate hepatocyte apoptosis (Hikita et al., 2011). BID (BH3 interacting-domain 
death agonist) interacts with Bax and leads to Bax insertion into the outer mitochondrial membrane 
in response to apoptotic signals. Activation of the death receptor with Fas ligand leads to activation 
of caspase-3 and -8 as mediated by Bid-dependent mitochondrial release of Smac in the apoptotic 
event of hepatocytes (Li et al., 2002). Bid is also upstream of caspase-2 activation in the setting of 
TNF-α triggered hepatocyte apoptosis (Guicciardi et al., 2005). Park et al. (2010) reported that 
MSCs co-culture upregulated expression of Bcl-xL and Bcl-2 in islet cells. Autologous 
transplantation of AT-MSCs alleviated ischaemia/reperfusion-induced hepatocyte apoptosis by 
upregulating Bcl-2 (Sun et al., 2012). The present work showed that co-culture with NPc-MSCs 
significantly decreased BAX/BCL-2 ratio and BID expression in a cell-contact dependent manner, 
while that with HPc-MSCs exhibited a significantly greater effect by an intracellular ROS-dependent 
mechanism. 
BLK (B lymphoid tyrosine kinase) is a member of SRC non-receptor tyrosine kinase subfamily  
involved in B-lymphocyte development, differentiation and signalling. BLK is mainly present in 
lymphatic tissues, pancreatic islets, and also highly expressed  in colon epithelial cells (Seidelin and 
Nielsen, 2006). BLK protein enhances islet cell synthesis and secretion of insulin in response to 
glucose and upregulates expression of pancreatic β-cell transcription factors. The biological role of 
BLK in hepatocyte biology remains to be investigated. The present work showed that staurosporine 
significantly upregulated expression of BLK, while MSCs co-culture inhibited upregulation of BLK 
expression in a partially cell-contact dependent manner. It can be postulated that BLK might be 
invovled in apoptosis and inflammatory response of hepatocytes as BLK is reported to participate in 
pre-B-cell receptor-mediated NF-κB activation (Krappmann et al., 2001), while activation of NF-κB 
is known to determine the balance between apoptosis and proliferation of hepatocytes in response to 
TNF-α during liver regeneration (Plümpe et al., 2000).  
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5.4.5 Conclusions  
In conclusion, MSCs that expressed no TNF-α themselves significantly decreased autocrine 
TNF-α activity of co-cultured hepatocytes in a cell contact dependent manner. HPc further 
potentiated the inhibitory effect of MSCs co-culture by an intracellular ROS dependent mechanism. 
Inhibited autocrine activity of TNF-α might be a negative regulating mechanism of MSCs co-culture. 
Heterotypic interaction between hepatocytes and MSCs increased TGF-β secretion in co-culture, and 
autocrine TGF-β activity of MSCs was required for the hepatotrophic effects of MSCs co-culture 
and potentiative effect of HPc induction. Cell contact and intracellular ROS dependent extracellular 
collagen deposit of MSCs also played an essential role in trophic and antiapoptotic effect of MSCs 
on co-cultured hepatocytes. The underlying molecular mechanisms included downregulation of 
caspase-9 and decreased BAX/BCL-2 ratio, while the implication of BLK in hepatocyte biology and 
MSCs co-culture remains to be investigated.  
144 
 
CHAPTER 6 CONCLUDING DISCUSSION AND FUTURE WORK 
6.1 Concluding Discussion 
6.1.1 Trophic and protective effects of MSCs on co-cultured hepatocytes 
In the present work, the well documented trophic effect of MSCs on co-cultured porcine (Gu et 
al., 2009a; Gu et al., 2009a; Gu et al., 2009c) or rodent (Shi et al., 2009) hepatocytes was reproduced 
in primary human hepatocytes. The trophic effect of MSCs also applied to steatotic and 
cryopreserved hepatocytes, both of which are frequently encountered and used in the practice of 
HCT. This trophic effect with respect to liver-specific metabolic function might result from 
improved hepatocyte survival, potentiated metabolism of surviving hepatocytes, or both. MSCs 
transplantation was reported to ameliorate hepatocyte apoptosis following ischaemia/reperfusion 
injury (Pan et al., 2012) or CCl4 exposure (Manuelpillai et al., 2010). A novel contribution of the 
present work was the finding that MSCs significantly inhibited caspase-mediated spontaneous and 
chemically-induced apoptosis of co-cultured hepatocytes. Furthermore, MSCs co-culture reversed 
staurosporine-induced necrosis-to-apoptosis switch in death mode of hepatocytes. Supportive effect 
of MSCs for co-cultured epithelial cells is deduced to be the synergistic effect of soluble factors, 
ECM, and cell-to-cell crosstalk. In contrast to previous studies reporting a positive role of paracrine 
factors in the hepatotrophic effects of MSCs (Gu et al., 2009a), the present work showed that soluble 
factors released from MSCs alone or MSCs co-cultured with hepatocytes contributed minimally to 
the trophic and protective effects of MSCs co-culture although co-culture might amplify paracrine 
activity of MSCs-derived soluble factors. This contradiction might be explained as species variation 
(human versus porcine) so that human primary hepatocytes became unresponsive to the stimuli with 
potential soluble factors. Conversely, this finding suggested that trophic and antiapoptotic effects of 
MSCs co-culture might result primarily from additive or synergistic effects of ECM and cell-to-cell 
interaction. Deprivation of ECM (Sérandour et al., 2005) and cell-to-cell contact (Gómez-Aristizábal 
and Davies, 2012) has an adverse effect on hepatocyte proliferation and metabolism. 
The present work also demonstrated that the extent of the hepatotrophic effect of co-culture 
remained similar among AT-, BM-, and UC-MSCs. Co-culture with any type of MSCs improved 
liver-specific metabolic function of hepatocytes to a significantly greater extent as compared to that 
with ADFs. Moreover, AT-MSCs even at a low seeding ratio to hepatocytes still exhibited a 
significant hepatotrophic effect comparable to those at a high seeding ratio. This finding suggested 
that MSCs contributed to hepatotrophic effect of co-culture by a stem cell-specific mechanism in 
addition to providing hepatocytes with an attachment matrix. 
It will be worthwhile investigating the possibility of using autologous liver-derived MSCs for 
co-culture with hepatocytes. Liver-derived MSCs is a potential progenitor reservoir of hepatocytes 
through transdifferentiation in addition to a supportive cell population for hepatocytes (Najimi et al., 
2007). The advantages of using liver-derived MSCs are the synergistic effect of hepatocytes and 
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MSCs isolated from a single donor liver and potentially better cellular engraftment into the liver 
(Moreno et al., 2012). The present work showed that co-culture with a small number of hepatic 
NPCs possibly containing liver MSCs significantly improved viability and liver-specific metabolism 
of hepatocytes as evidenced by the preliminary results. The major limitation of the experiments with 
hepatic NPCs was poor reproducibility and  propagatability. Further effort should be made to 
produce a constant, reliable hepatic NPC line, and this cell population should be fractioned and 
characterised to identify the underlying stem cell subpopulation. Steatotic liver may be a suitable 
source for isolating liver NPCs including MSCs and hepatic progenitor cells (Tolosa et al., 2011); 
however, use of steatotic liver-derived NPCs carries a potential profibrogenic risk as NF-κB 
activation in liver NPCs mediates inflammatory response and bridges steatohepatitis and liver 
fibrosis (Beraza et al., 2008). It will be of great significance to investigate how co-culture with 
hepatocytes modulates the biological behaviour of MSCs. It was reported that co-culture with human 
liver cells drove differentiation of rat MSCs into hepatocyte-like cells in a spheroid architecture in 
the presence of HGF (Qihao et al., 2007). Lange et al. (World J Gastroenterol, 2005b; World J 
Gastroenterol, 2006) detected hepatocytic differentiation of rat MSCs co-cultured with adult rat or 
foetal liver cells, as evidenced by expression of hepatocyte-specific markers, in the absence of 
chemically-defined culture medium. Hepatotrophic effect of MSCs co-culture may also partially 
result from hepatogenic transdifferentiation of MSCs especially after transplantation and 
engraftment into the liver. 
6.1.2 HPc potentiates hepatotrophic and antiapoptotic effects of MSCs co-culture by 
an intracellular ROS dependent mechanism 
The present work showed that HPc potentiated trophic and antiapoptotic effect of MSCs on 
hepatocytes as compared to NPc. Potentiative effect of HPc on MSCs themselves has been 
extensively investigated, and HPc-primed MSCs exhibit an enhanced supportive and protective 
effect on the host cells, such as hepatocytes (Yu et al., 2013), cardiomyocytes (He et al., 2009), and 
neural  cells (Wei et al., 2012). Potentiated paracrine activity is thought to be a major contributive 
factor of HPc-induced potentiative effect; however, the present work showed indirect noncontact co-
culture with HPc-MSCs did not significantly improved cellular viability and metabolic function of 
hepatocytes. The probable explanation was that freshly isolated hepatocytes still remained 
unresponsive even in the presence of potentiated extrinsic cues due to mechanical and enzymatic 
stress from isolation. Conversely, the absence of potentiative effect in HPc indirect co-culture 
implied that HPc potentiated MSCs mainly by an mechanism involving ECM and/or cell-to-cell 
interplay.  
NAC pretreatment diminished the increase of intracellular ROS activity in MSCs and reduced 
HPc-potentiated trophic and antiapoptotic effects of MSCs on co-cultured MSCs. This finding was 
consistent with that reported by De Barros et al. (2013), in which HPc counteracted ageing-related 
impairment of angiogenic potential in human AT-MSCs. The improved angiogenesis might be the 
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synergetic effect of MSCs transdifferentiation into endothelial cells, enhanced expression of 
proangiogenic and prosurvival factors, and oxidative stress. The major signal was determined to be 
intracellular ROS as NAC pretreatment reversed HPc-induced improvement. A second potential 
candidate factor responsible for HPc-induced potentiative effect is HIF, a family of transcription 
factors sensitive to oxygen tension in the microenvironment. Activation of HIF participates in the 
inhibitory effect of hypoxia on MSCs differentiation (Haque et al., 2013) but improves angiogenesis 
(Hu et al., 2008) and migration (Liu et al., 2011) of MSCs. It will also be important to investigate 
what beneficial mechanisms, especially those invovled in ECM formation and cell-to-cell crosstalk 
are activated by oxygen-sensoring factors, such as ROS and HIF, and how these mechanisms 
potentiate trophic and protective effect of MSCs on co-cultured hepatocytes.  
6.1.3 Molecules underlying hepatotrophic effect of MSCs co-culture and 
potentiative effect of HPc induction  
The trophic and protective effects of MSCs on co-cultured hepatocytes are attributed to 
synergistic effects of soluble factors, ECM, and heterotypic cellular interaction. As a result, it is 
likely that HPc potentiated the hepatotrophic and antiapoptotic effects of MSCs by enhancing these 
mechanistic factors. TNF-α is thought to play an essential role in mediating hepatocyte apoptosis in 
the setting of inflammatory response (Zang et al., 2000; Biburger and Tiegs, 2005). The present 
work showed that hepatocytes secreted a relatively high level of baseline TNF-α and neutralisation 
of baseline TNF-α reduced apoptosis and total death of hepatocytes. In addition, hepatocyte 
secretion of TNF-α was significantly inhibited by co-culture with MSCs and by HPc-MSCs to a 
significantly greater extent. This inhibitory effect of MSCs on co-cultured hepatocytes also depended 
on  MSC-to-hepatocyte contact as evidenced by the minimal inhibitory effect seen in the indirect 
non-contact co-culture. Therefore, MSCs co-culture might suppress autocrine TNF-α activity of 
hepatocytes by a cell-to-cell contact dependent mechanism. The possibility that decreased autocrine 
TNF-α activity resulted in inhibition of hepatocyte apoptosis remains an open question as MSCs co-
culture CM contained a low level of TNF-α but had no effect on hepatocyte apoptosis. It is possible 
that reduced autocrine TNF-α activity is a prerequisite rather than sufficient condition for 
antiapoptotic effect of MSCs co-culture. It remains to be investigated by which mechanism MSCs 
co-culture and HPc induction inhibited autocrine TNF-α activity of hepatocytes. A possibility is that 
TNF-α synergistically coordinates with other proapoptotic factors by a positive feedback mechanism 
in hepatocytes undergoing spontaneous apoptosis (Schlatter et al., 2011). Interruption of this positive 
feedback will reduce hepatocyte apoptosis and consequently inhibit autocrine TNF-α activity.  
TGF-β is known to be involved in liver fibrosis by promoting collagen deposition (Gabriel et 
al., 2008); however, TGF-β positively regulates osteochondrogenesis of MSCs (Mehlhorn et al., 
2006). Contact of MSCs with T-lymphocytes also upregulates expression of IL-10 and TGF-β, both 
of which mediates T-cell tolerance (Nasef et al., 2007). The present work showed that MSCs-to-
hepatocytes contact and HPc increased TGF-β1 secretion in co-culture and by MSCs, respectively. 
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Neutralising autocrine activity of TGF-β1 in both NPc- and HPc-MSCs led to a significant reduction 
of MSCs co-culture antiapoptotic effect. As MSCs co-culture CM containing high-level TGF-β1 had 
no significant effect on hepatocyte apoptosis, enhanced TGF-β1 expression in co-culture and HPc-
MSCs contributed to the antiapoptotic effect of MSCs co-culture by an MSC-autocrine rather 
hepatocyte-paracrine mechanism. This contact co-culture induced enhancement might result from 
activation of latent TGF-β1 rather than upregulation of TGF-β1 transcriptional and translational 
expression (Chia et al., 2005). It is an open question how activation of autocrine TGF-β1 in MSCs 
inhibits apoptosis of co-cultured hepatocytes. Mediation of ECM and cell-to-cell interplay may be 
the candidate mechanism. TGF-β1 is reported to modulate MSCs attachment to collagen type I by an 
integrin-mediated mechanism (Warstat et al., 2010). 
The primary effect of collagen on hepatocytes is provision of an attachment matrix and also 
regulation of hepatocyte cell cycle progression and differentiation (Hansen et al., 2006). Under 
physiological conditions, liver collagen is mainly produced by NPCs rather than hepatocytes; 
however, collagen deprivation will be detrimental for hepatocytes cultured in vitro. The present work 
demonstrated that extracellular collagen, the active form of collagen, was mainly deposited by MSCs 
rather than hepatocytes. Cell contact and HPc also enhanced extracellular collagen deposit of MSCs 
co-culture and MSCs, respectively. Antagonisation experiments showed that inhibition of 
extracellular collagen deposit by MSCs diminished the hepatotrophic effects of MSCs co-culture and 
potentiative effect of HPc induction. Conventional hepatocyte mono-culture only allows hepatocyte 
monolayer collagen attachment, while MSCs co-culture supports hepatocytes in a three-dimensional 
architecture (Gu et al., 2009b). Three-dimensional hepatocyte culture in sandwich collagen gel is 
thought to mimic the microenvironment and shows a supportive effect superior to conventional 
monolayer collagen architecture (Wang et al., 2004). Collagen may also regulate responsiveness of 
hepatocytes to soluble factors and intercellular interaction (Berthiaume et al., 1996). It will be 
academically significant to investigate what subtype(s) of collagen is increased in MSCs co-culture 
and after HPc induction as biological activities of collagen vary significantly among subtypes. It is 
also interesting to delineate by which mechanism, such as modification of collagen topography, shift 
of collagen isoforms, and amplification of soluble factors and cellular interplay, enhanced collagen 
deposition results in the hepatotrophic effects of MSCs co-culture and potentiative effect of HPc 
induction.  
Apoptotic death of hepatocytes is a biological event finely modulated by a complex network of 
proapoptotic and antiapoptotic factors. The results of Chapter 3 showed that MSCs co-culture 
significantly inhibited caspase-mediated CK18 cleavage, an early-stage event in the process of 
cellular apoptosis, as evidenced by downregulated expression of caspase-9 in MSCs co-culture. This 
finding suggested that MSCs co-culture mainly inhibited initiation of hepatocyte apoptosis mediated 
by the mitochondrial pathway. Additionally, decreased BAX/BCL-2 ratio indicated that MSCs co-
culture suppressed the death receptor-associated apoptosis pathway. The present work also 
demonstrated for the first time that MSCs co-culture downregulated expression of BLK, biological 
activities of which are rarely reported in hepatocytes, at the transcriptional level by a cell contact, 
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intracellular ROS-dependent mechanism. It remains unknown how the potential contributive factors 
of MSCs co-culture, such as hepatocyte-autocrine TNF-α, MSC-autocrine TGF-β1, and extracellular 
collagen, modulate the balance between proapoptosis and antiapoptosis in hepatocytes by a cell 
contact, intracellular ROS-dependent  mechanism. It is impossible for a single factor or mechanism 
to fully explain the hepatotrophic effects of MSCs co-culture and potentiative effect of HPc 
induction. It will also be informative to investigate the reciprocal interaction between hepatocytes 
and MSCs using genomic microarray techniques. 
6.2 Conclusions 
In conclusion, MSCs have trophic, antiapoptotic, prosurvival, and protective effects on co-
cultured hepatocytes. These favourable effects can also be reproduced in functionally impaired 
steatotic and cryopreserved hepatocytes. The paracrine contribution of soluble factors to 
hepatotrophic effect of MSCs co-culture that has been well documented in animal-derived 
hepatocytes could not be reproduced in the present work possibly due to the unresponsiveness of 
human hepatocytes to extrinsic cues in the absence of ECM and intercellular crosstalk. HPc 
significantly potentiated the hepatotrophic effects of MSCs co-culture by an intracellular ROS-
dependent mechanism, while this potentiative effect also depended on heterotypic cellular 
interaction as evidenced by the minimal effect of HPc indirect noncontact co-culture. Potential 
contributive factors to the hepatotrophic effects of MSCs co-culture and potentiative effect of HPc 
induction were decreased hepatocyte autocrine activity of TNF-α, increased MSC autocrine activity 
of TGF-β1, and enhanced extracellular collagen deposit by MSCs, as evidenced by the reversal 
effects of neutralisation or inhibition experiments. These potential contributive factors may 
synergistically switch the balance from proapoptosis to antiapoptosis in hepatocytes co-cultured with 
MSCs. 
With respect to the bench-to-bedside translation of the present work, co-transplantation with 
MSCs is expected to improve therapeutic efficacy of current HCT facing two major hurdles, limited 
donor tissue availability and  marginal cell quality. Co-transplantation of MSCs may offer additional 
benefits, such as transdifferentiation into hepatocytes, repair of the injured host hepatocytes, 
improvement of neovascularisation in vivo, and modulation of immune response. HPc may also 
potentiate these therapeutic effects of MSCs in vivo like hepatotrophic and antiapoptotic effects of 
MSCs co-culture in vitro observed in the present work. However, the effectiveness and safety of 
MSCs co-transplantation and HPc modification needs to be validated in preclinical liver failure 
models. A major safety concern arising from incorporation of MSCs to HCT is that MSCs carry a 
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